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ABSTRACT OF DISSERTATION

NICOTINIC RECEPTOR MODULATION OF DOPAMINE TRANSPORTERS
The current project examined the ability of nicotine to modulate dopamine
transporter (DAT) function. Initial experiments determined the dose-response for
nicotine to modulate dopamine (DA) clearance in rat striatum and medial
prefrontal cortex (MPFC) using in vivo voltammetry and determined if this effect
was mediated by nicotinic receptors (nAChRs). In both striatum and MPFC,
nicotine increased DA clearance in a mecamylamine-sensitive manner, indicating
nAChR-mediation. The effect of acute nornicotine on DAT function was also
determined. In contrast to nicotine, nornicotine in a dose-related manner
decreased striatal DA clearance in a mecamylamine-sensitive manner, indicating
nAChR mediation. To determine if tolerance developed to the nicotine effect
nicotine, separate groups of rats were injected once daily for 5 days with nicotine
or saline. DA clearance in striatum and MPFC was determined 24 hrs after the
last injection. Nicotine increased DA clearance only 10-15% in the group
repeatedly administered nicotine, demonstrating that tolerance developed. To
determine if nicotine altered striatal DAT efficiency, following nicotine injection,

DAT density and maximal velocity of [3H]DA uptake was determined using
[3H]GBR12935 binding and saturation analysis of [3H]DA uptake in rat striatum,
respectively. Nicotine did not alter the Bmax or Kd of maximal binding of
[3H]GBR12935 binding. However, an increase in Vmax was observed at 10 and
40 min following nicotine injection, suggesting that nicotine increases DAT
efficiency. To determine if systemic nicotine enhanced DAT function via an
action at nAChRs on striatal DA terminals, [3H]DA uptake was determined in
striatum in vitro in the absence or presence of nicotine in the buffer. Nicotine did
not alter the Vmax for [3H]DA uptake in vitro, suggesting that the nicotine-induced
increase in DAT function observed in vivo is mediated by nAChRs on DA cell
bodies or another site which indirectly alters DAT function. To determine if the
increase in DAT efficiency was due to increased surface expression of striatal
DAT, biotinylation and Western blot analyses were performed. Nicotine did not
alter striatal DAT, suggesting that the nicotine-induced increase in DA clearance
in vivo and DAT efficiency in vitro is not the result of increased trafficking of this
protein to the cell surface.
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Chapter One
Introduction and Background
I. Drug Abuse and Reward
The brain is a complex organ made up of various structures that interact
with each other through neuronal networks. Drugs of abuse have many different
effects on neuronal circuitry and can modulate how information is carried
throughout the brain. Psychostimulants, such as nicotine, cocaine and
amphetamine, modulate two primary circuitry pathways, the mesolimbic and
nigrostriatal pathways. Figure 1 represents a sagittal section through a rat brain.
The mesolimbic system has cell bodies in the ventral tegmental area (VTA) and
sends projections to the nucleus accumbens and the medial prefrontal cortex
(MPFC). The nigrostriatal pathway has cell bodies in the substantia nigra (SN)
and sends projections to the striatum. The mesolimbic and nigrostriatal
pathways are dopaminergic pathways, i.e., dopamine (DA) is the
neurotransmitter contained in the neurons in this pathway.

Previous research on the neurobiology of reward and drug addiction has
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the
role of the nucleus accumbens, MPFC and striatum. The accumbens shell,
which is innervated by dopaminergic projections from the VTA, and its associated
neurocircuitry are believed to encode primary appetitive stimuli associated with
unconditioned drug reward (Wise and Bozarth, 1987; Robbins and Everitt, 1996;
Bardo, 1998; Koob, 1999; Di Chiara, 2000; Kelley and Berridge, 2002), including
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reward produced by nicotine (Fibiger and Phillips, 1987; Corrigall et al., 1992,
1994; Balfour and Benwell, 1993; Mansvelder and McGehee, 2002; Mathieu-Kia
et al., 2002). More recently, focus has been placed on the involvement of the
striatum and MPFC in reward and reinforcement. The MPFC, which includes the
anterior cingulate cortex and is innervated by dopaminergic projections from the
VTA, is believed to encode secondary conditioned stimuli associated with
environmental cues paired with drug, leading to reward expectancy, which is
recognized as important to the process of addiction and relapse to drug use
(Berridge and Robinson, 1998; Shima and Tanji, 1998; Kelley, 1999; Di Chiara,
2000; Kelley and Berridge, 2002; Peoples, 2002; Cohen et al., 2004; Di Chiara et
al., 2004; Rose and Behm, 2004; Brody et al., 2004). Integration of the
motivational information from the MPFC occurs at least in part in striatal
cholinergic neurons, which are innervated by dopaminergic projections from the
substantia nigra, leading to the initiation and execution of movement in reward
expectancy and detection of reward (Martin-Soelch et al., 2001).

Ia. Animal Models of Reward
According to the DSM-IV, drug abuse is defined as an individual who uses
a drug despite the knowledge that that drug may be harmful to them. Abuse is
different from drug dependence/addiction in that an addicted individual has an
obsessive preoccupation with a drug, i.e., the drug is the most important
relationship the individual has. Animal models have been developed to examine
the abusive or rewarding properties of drugs. Conditioned place preference is a
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paradigm in which an environmental stimuli is paired with a reward such as food
or drug. This results in a preference of the animal for the environment that was
paired with the reward, even in the absence of the reward. Therefore, one can
determine the rewarding properties of a drug by evaluating the animal’s
preference for the environment associated with reward. Drug self-administration
is the “gold-standard” for measuring the rewarding properties of a drug. In this
paradigm, animals are trained to press a lever to receive a drug reward. Fixedratio (FR) self-administration is a reinforcement schedule that will vary the
number of lever presses required to receive a reward. For example, an FR1
means that one lever press will result in one infusion of drug whereas an FR5
schedule requires 5 lever presses to receive one infusion of drug. The number of
lever presses can be increased within a session (progressive ratio schedule)
which will require the animal to work harder to receive the reward. The point at
which an animal will no longer increase the number of bar presses to receive
drug is known as the break point, indicating that the level that the animal will
work for the drug, indicating the amount of reward associated with it.

II. Diseases and Disorders
Tobacco smoking and depressive disorders are highly comorbid
(Glassman et al., 1993; Covey et al., 1997; Covey, 1999; Pomerleau et al., 2000;
Cardenas et al., 2002). Nicotine has been reported to have antidepressant
properties in depressed individuals (Glassman, 1993; Salin-Pascual and
Drucker-Colin, 1998; Balfour and Ridley, 2000; Picciotto et al., 2002) and in
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animal models of depression (Tizabi et al., 1999; Vazquez-Palacios et al., 2004).
Such evidence has led to the self-medication hypothesis of nicotine dependence,
such that individuals may use tobacco, at least in part, to ameliorate depression
(Markou et al., 1998; Balfour and Ridley, 2000; Hughes et al., 2003; Popik et al.,
2003). The self-medication hypothesis is further strengthened by the observation
that antidepressants, bupropion and perhaps others, serve as an efficacious
smoking cessation pharmacotherapies (Hurt et al., 1997; Jorenby et al., 1999;
Cryan et al., 2003a,b; Ferry and Johnston, 2003; Haustein, 2003; Richmond and
Zwar, 2003; Hall et al., 2004), although the mechanism of action in this regard is
not clear. Clinical depression is generally accepted as associated with
dysfunction of monoaminergic neurotransmitter systems. Most effective
antidepressants inhibit monoamine transporter function, increasing the
extracellular concentrations of DA, norepinephrine and/or serotonin. Many
antidepressants, including bupropion (Wellbutrin®), inhibit monoamine
transporters, but also act as nicotinic receptor antagonists (Richelson and
Pfenning; 1984; Nomikos et al., 1989; Ascher et al., 1995; Fryer and Lukas,
1999; Slemmer et al., 2000; Li et al., 2002; Miller et al., 2002a,b; Gumilar et al.,
2003; Damaj et al., 2004). Smokers treated with bupropion while trying to quit
smoking have been shown to have a decrease in symptoms of depression
(Lerman et al., 2004).

The use of nicotine replacement as a cessation therapy is based on
activation of nicotinic receptors resulting in DA release, and potentially nicotine’s
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ability to modulate DAT function. Treatment of smokers with a transdermal
nicotine patch has been shown to increase positive affect, whereas nicotine
administration by a nasal spray did not have any impact on affect (Strasser et al.,
2005), which demonstrates the importance of not only type of treatment but route
of administration. Furthermore, the presence of a DAT polymorphism (SLC6A3),
in cigarette smokers, has been associated with an increase in stress-induced
craving associated with smoking (Erblich et al., 2004). That is exposure to a
stressor results in an increased craving for a cigarette, and the stress-induced
craving is higher in smokers with the SLC6A3 DAT polymorphism. One
possibility is that both transporters and nicotinic receptors contribute to
antidepressant alleviation of depression as well as to smoking cessation.
Understanding functional interactions between DAT and nicotinic receptors may
provide a mechanistic basis and more thorough comprehension of the
relationship between depression and nicotine dependence.

A number of neurological diseases result in an alteration in the number of
nicotinic receptors in striatum and SN, e.g., Parkinson’s disease and
schizophrenia. In Parkinson’s disease, there is a selective loss of nigrostriatal
DA neurons with a concomitant loss of presynaptic nicotinic receptors on DA
nerve terminals in striatum (Wonnacott et al., 1997). In post mortem striatal
tissue from Parkinson’s patients, there is a decrease in the number of
[3H]nicotine binding sites (Court et al., 2000; Guan et al., 2002). Furthermore, a
decrease in the number of α3/α6 nicotinic receptors in monkey brain has been
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shown after nigrostriatal damage (McCallum et al., 2005), as well as a loss of
nicotine binding in the substantia nigra (Perry et al., 1995). Following chronic
tobacco use in humans, there is an increase in the number of nicotine binding
sites in the brain (Perry et al., 1999). Furthermore, people who smoke tobacco
are reported to have a lower incidence of Parkinson’s disease (Morens et al.,
1995; Baron, 1986; Gorell et al., 1999; Quik and Kulak, 2002). Both tobacco
smoke and nicotine have been shown to be protective against MPTP
neurotoxicity, which is an animal model for Parkinson’s (Parain et al., 2003).
Therefore, therapies that increase the number of nicotine binding sites or
nicotinic receptors may be beneficial in the treatment of Parkinson’s disease.

Schizophrenic patients have a higher incidence of tobacco smoking
compared to the general population (Hughes et al., 1986; Lohr and Flynn, 1992;
Dalack et al., 1998; Esterberg and Compton, 2005). A lack of sensory gating is
observed in schizophrenics and this may involve desensitization of nicotinic
receptors (Griffith et al., 1998). In striatum, nicotine binding sites are increased
in schizophrenic patients (Court et al., 2000). Interestingly, hypoactivity is
observed in the dopaminergic neurons in prefrontal cortex in schizophrenic
patients (Davis et al., 1991), suggesting that different brain regions and
potentially different nicotinic receptor subtypes in these brain regions may be
involved in schizophrenia. In schizophrenic smokers, nicotine administration
improved delayed recognition memory, visuospatial working memory and
continuous performance test scores (Myers et al., 2004; Sacco et al., 2005).
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More recently, schizophrenic patients with a 113 base pair allele of the α7
nicotinic receptor gene were found to be more likely to smoke and smoke heavily
(De Luca et al., 2004). In addition, a polymorphism in the α7 nicotinic receptor
gene (CHRNA7) was found to be linked to the auditory gating deficit common in
the schizophrenic patient population (Freedman et al., 1997). Consistent with its
proposed involvement in sensory gating, selective α7 nicotinic receptor agonists
and partial agonists such as tropisetron have been shown to restore auditory
gating deficits in rodent models of schizophrenia (Stevens et al., 1998; O'Neill et
al., 2003; Hajós et al., 2005; Koike et al., 2005; Siegel et al., 2005). Not only
nicotinic receptors, but also inhibition of monoamine transporters by bupropion
has been shown to improve the auditory gating deficits in a mouse model of
schizophrenia (Siegel et al., 2005).

III. Dopamine
Dopamine (Figure 2) is a neurotransmitter in the central nervous system.
Figure 3 shows a schematic representation of a DA nerve terminal. The first step
in the synthesis of DA is the conversion of tyrosine to 3, 4dihydroxyphenylalanine (DOPA) in the DA nerve terminal by the enzyme tyrosine
hydroxylase. Tyrosine is an amino acid that is transported across the blood brain
barrier and then into DA neurons by amino acid transporters. DOPA is then
converted to DA by DOPA decarboxylase in the nerve terminal. Tyrosine
hydroxylase is the rate-limiting enzyme of DA synthesis. Once DA is
synthesized, it can be stored in synaptic vesicles in preparation for release from
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the terminal into the synapse. Following stimulation and depolarization of the
nerve terminal, synaptic vesicles fuse to the synaptic membrane and release DA
into the synaptic cleft by a process called exocytosis. After release, DA can be
metabolized by catechol-O-methyl transferase or monoamine oxidase in the
synapse, bind to presynaptic D2 DA autoreceptors located presynaptically,
activate postsynaptic D1 and D2 DA receptors, or be transported back into the
terminal by the DA transporter (DAT; Cooper et al., 2003). D1 and D2 DA
receptors are the most abundant DA receptors in striatum. The D1 DA receptor
has one known subtype, D5, which acts similarly to D1 in that it stimulates
adenylate cyclase activity, but D5 has a 10-fold higher affinity for DA than does
D1. D1 is located throughout the brain including striatum and cortex. However,
D1 is more abundant in striatum than cortex. D5 is also only located in
hippocampus, thalamus and hypothalamus. The D2 DA receptor family also has
two receptor subtypes, D3 and D4. Similar to D2 receptors, D3 and D4 both
inhibit adenylate cyclase activity. However, D3 has a 100-fold higher affinity for
the DA receptor agonist quinpirol, and D4 has an order of magnitude higher
affinity for the atypical antipsychotics such as clozapine. D2 is located in both
striatum and cortex and is also more abundant in striatum than cortex. Both D3
and D4 receptors have very little expression in the striatum or MPFC. Once back
inside the terminal, DA can be re-stored in vesicles or metabolized by
monoamine oxidase located in the cytoplasm to provide the metabolite
dihydroxyphenyacetic acid (DOPAC).
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In smokers, nicotine dose-dependently increases neuronal activity in
cingulate cortex, MPFC, striatum and accumbens assessed using functional
magnetic resonance imaging (fMRI) and positron emission tomography (PET)
(Stein et al., 1998; Barrett et al., 2004). Recently, in an fMRI study examining
decision-making and monetary reward, activity in the striatum was correlated with
short-term reward (Haruno et al., 2004). These data suggest that the striatum is
heavily involved in reward-based behavioral learning. Changes in striatal neural
activity and blood flow have been observed following rewarding experiences in
studies using humans (Delgado et al., 2000; Knutson et al., 2000; Elliot et al.,
2003; O’Doherty et al., 2004; Tanaka et al., 2004; Tricomi et al., 2004), monkeys
(Kawagoe et al., 2003; Watanabe et al., 2003; Yamada et al., 2004), and rats
(Schmitzer-Torbert and Redish, 2004). The changes in neural activity may be
related to the magnitude of reward that is received (Cromwell and Schultz, 2003).
Recently, injection of a kappa-opioid antagonist into mouse striatum was shown
to result in a decrease in cocaine-induced conditioned place preference, also
indicating the involvement of the striatum in the rewarding properties of cocaine
(Zhang et al., 2004).

IV. The Dopamine Transporter (DAT)
Brain monoamine transporters are expressed almost exclusively in
neurons that contain their cognate transmitter. Immunolocalization studies reveal
the presence of DAT, the norepinephrine transporter and the serotonin
transporter on their respective cell bodies, axons and terminals (Nirenberg et al.,
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1996; Hersch et al. 1997; Hoffman et al., 1998; Sesack et al. 1998; Schroeter et
al., 2000; Mengual and Pickel, 2004). As shown in Figure 4, DAT is a twelve
transmembrane protein with both the carboxy and amino termini located
intracellularly. Translocation of DA by DAT across the membrane is coupled with
the cotransport of two Na+ ions and one Cl- ion down their electrochemical
gradients, generating a small inward current (Kanner and Schuldiner, 1987;
Rudnick and Clark, 1993). Moreover, the DA neuron membrane potential
influences DAT function, such that hyperpolarization increases the velocity of DA
transport by DAT and depolarization decreases DA transport velocity (Sonders et
al., 1997). DA is also removed from the extracellular space by metabolism and
diffusion, the latter factor playing a larger role in brain regions with sparse
dopaminergic innervation and lower DAT density, such as the MPFC (Sesack et
al., 1998). These transporter proteins are located presynaptically and may be in
close apposition to nicotinic receptors, suggesting the potential for their functional
interaction. Psychostimulants and antidepressants interact with these
transporters (Barker and Blakely, 1996). For example, amphetamine reverses
monoamines transporters evoking monoamine release, whereas cocaine and
antidepressants inhibit transporter function. Since nicotine is a psychostimulant
with antidepressant properties, it is reasonable to hypothesize that nicotine may
interact with or modulate transporter function.

DAT is a major pharmacological target for psychostimulant action.
Psychostimulants inhibit DAT function and increase synaptic DA concentrations
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(Horn 1990). Cocaine and amphetamine alter the expression of cell surface DAT
protein (Saunders et al. 2000; Daws et al. 2002; Little et al. 2002). In cell
expression systems, cocaine increases cell surface expression of DAT, whereas
amphetamine decreases DAT localization on the cell surface. The ability of
nicotine to modulate the cell-surface expression of DAT has not been examined.
As many psychostimulants alter DAT localization as their mechanism of action,
studies examining the ability of nicotine to modulate DAT localization are
warranted. DAT is regulated by activation of protein kinase C, which decreases
the maximal velocity (Vmax) of DA uptake and decreases DAT cell surface
expression in cell expression systems and in brain (Melikian et al. 1994;
Copeland et al. 1996; Melikian et al. 1996; Huff et al. 1997; Vaughan et al. 1997;
Zhang et al. 1997; Pristupa et al. 1998; Daniels and Amara 1999; Melikian and
Buckley 1999; Chi and Reith 2003). Little is known about the effect of nicotine on
transporter function and trafficking, as well as the underlying cellular mechanisms
regulating these processes.

IVa.

DAT Regulation through Trafficking

Studies suggest that monoamine transporters are regulated by several
mechanisms, including constitutive internalization and recycling (i.e., trafficking),
involving transporter phosphorylation and protein-protein interactions (Zahniser
and Doolen, 2001; Kahlig and Galli, 2003; Loder and Melikian, 2003; Torres et
al., 2003; Melikian, 2004). Psychostimulants and second messengers alter
phosphorylation, function and trafficking of these transporters (Gnegy et al.,
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2004; Kahlig et al., 2004). For example, DAT surface expression in cell lines is
acutely sensitive to amphetamine and cocaine, which decrease and increase
DAT surface levels, respectively (Saunders et al., 2000; Daws et al., 2002; Little
et al., 2002; Zahniser and Sorkin 2004). Protein kinase C activation in native
preparations and cell systems decreases surface distribution of DAT (Vaughan et
al., 1997; Zhang et al., 1997; Zhu et al., 1997; Daniels and Amara, 1999;
Melikian and Buckley, 1999; Loder and Melikian, 2003), whereas protein kinase
A and calcium-calmodulin kinase II activation results in upregulation of DAT at
the cell surface (Page et al., 2004). Transporters undergo internalization and
recycling, which may involve dynamin-clathrin mediated pathways and multiple
protein-protein interactions, such as interaction with syntaxin-1A, PP2A, PICK1,
ERK and synuclein (Zahniser and Doolen, 2001; Torres et al., 2003; Lee et al.
2004; Melikian, 2004; Valjent et al., 2005). Furthermore, psychostimulants can
modulate DAT function by phosphorylation of DAT. For example, amphetamine
activates protein kinase C and mitogen activated protein kinase which enhances
amphetamine stimulated DA release through DAT (Park et al., 2003; Johnson et
al., 2005). DAT can also be modulated by interneuronal signaling such as nitric
oxide (Kiss et al., 2004), which can inhibit DAT function. Nitric oxide is able to
diffuse between different neurons and thus provides a mechanism for other
neurotransmitter systems to modulate DAT.
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V. Nicotine
Nicotine (Figure 2) is the most common drug of abuse and tobacco
dependence the leading preventable cause of death in the USA (Surgeon
General’s Report, 1988; Jaffe, 1990; USDHS, 2001). Despite the deleterious
effects of tobacco, ~23% of the US population continues to use tobacco
(Trosclair et al., 2002). About 70% of smokers want to quit, ~40% make an
attempt to quit, however, only ~5% are successful at cessation for a period of 312 months (Trosclair et al., 2002). Nicotine, the most abundant alkaloid in
tobacco (Bush et al., 1993), has intrinsic rewarding properties, which are
believed to be responsible for tobacco dependence (Koob, 1992; Corrigall et al.,
1992; Stolerman and Jarvis, 1995; Di Chiara, 2000; Balfour, 2002; Mathieu-Kia et
al., 2002; Garrett et al., 2003). Volunteers who habitually smoke and are tobacco
deprived will self-administer nicotine (Henningfield and Goldberg, 1983; Harvey
et al., 2004; Johnson et al., 2004). Indicative of its reinforcing properties, nicotine
is self-administered in animal models using both fixed-ratio schedules (Goldberg
et al., 1981; Henningfield and Goldberg, 1983; Cox et al., 1984; Corrigall and
Coen, 1989; Corrigall et al., 1992, 1994; Sannerud et al., 1994; Donny et al.,
1998, 2003; Rose and Corrigall, 1997; Shoaib et al., 1997; Valentine et al., 1997;
Rasmussen and Swedberg, 1998; Caggiula et al., 2001, 2002; Suto et al., 2001;
LeSage et al., 2002, 2003; Fu et al., 2003; Paterson et al., 2004) and
progressive-ratio schedules (Donny et al., 1999; Bruijnzeel and Markou, 2003).
While the maintenance of smoking is believed to be due to the reinforcing
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properties of nicotine, it is also possible that people continue to smoke to avoid
the withdrawal symptoms instead of for reinforcement.

Some of the rewarding properties of nicotine are considered beneficial
such as mood elevation, arousal and learning and memory enhancement
(Clarke, 1987; Pomerleau and Pomerleau, 1992). The mechanisms underlying
the reinforcing properties of nicotine are not well understood, but are important
for understanding the initiation and maintenance of tobacco smoking behavior.
Although the mechanisms underlying nicotine’s reinforcing properties are not well
understood, the mesocorticolimbic and nigrostriatal DA systems are believed to
be involved. For example, activation of the immediate early gene, c-fos, in the
anterior cingulate cortex, nucleus accumbens and striatum has been
demonstrated in nicotine self-administering rats (Pagliusi et al., 1996; Merlo-Pich
et al., 1997). Additionally, cortical c-fos has been shown to be activated following
exposure to environmental cues associated with repeated nicotine administration
(Schroeder et al., 2001). The latter results from animal studies are consistent
with findings showing that in tobacco smokers, nicotine dose-dependently
increases neuronal activity in the cingulate cortex, frontal lobe and nucleus
accumbens, as determined using functional MRI (Stein et al., 1998).

Elucidating the mechanism of nicotine action and determining the effects
of chronic nicotine administration are of importance in understanding the initiation
and maintenance of tobacco smoking behavior and in overcoming the difficulties
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habitual smokers experience in extinguishing this behavior. As previously
discussed, evidence for the reinforcing properties of nicotine includes studies
reporting nicotine self-administration by many species on various reinforcement
schedules (Goldberg et al., 1981; Henningfield and Goldberg, 1983; Cox et al.,
1984; Corrigall et al., 1992, 1994; Sannerud et al., 1994; Donny et al., 1996) and
nicotine-induced conditioned place preference in rats (Fudala et al., 1985; Shoaib
et al., 1994; Risinger and Oakes, 1995). Studies clearly indicate that under an
FR5 schedule as well as when nicotine is given to an animal contingently,
nicotine is avidly self-administered by rats (Corrigall and Coen, 1989; Corrigall et
al., 1992, 1994; Donny et al., 1996). Also, nicotine self-administration, both
fixed- and progressive-ratio, is decreased in animals and humans by
mecamylamine and other nicotinic receptor antagonists indicating nicotinic
receptor involvement (Meltzer and Rosecrans, 1981; Stolerman et al., 1973,
1984; Corrigall et al., 1994a; Rose et al., 1994; Mansbach et al., 2000; Shoaib et
al., 1997, 2002, 2003; Markou and Paterson, 2001; Glick et al., 2002;
Mansvelder and McGehee, 2002; Bruijnzeel and Markou, 2003; Rauhut et al.,
2002, 2003).

Concomitant with the intrinsic reinforcing effects of nicotine, there is strong
evidence indicating that nicotine stimulates locomotor behavior. In drug-naïve
rats, acute nicotine administration produces an initial depressant effect on activity
followed by hyperactivity lasting 1 hour or longer (Clarke and Kumar, 1983;
Clarke, 1990). With chronic nicotine administration, tolerance develops to the
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transient hypoactive phase (Stolerman et al., 1973, 1974; Collins et al., 1988,
1990; Martin et al., 1990), whereas sensitization develops with respect to the
hyperactive phase (Clarke and Kumar, 1983; Ksir et al., 1985, 1987; Clarke et
al., 1988; Fung and Lau, 1988; Schoaib and Stolerman, 1992; Benwell and
Balfour, 1992; Ksir, 1994; Stolerman et al., 1995). Mecamylamine blocks both
the hypoactive and hyperactive phases following acute nicotine injection and also
blocks the development of behavioral sensitization occurring following chronic
nicotine administration (Clarke and Kumar, 1983). Drugs of abuse, including
nicotine, amphetamine and cocaine, have been suggested to produce their
locomotor stimulant and reinforcing effects by activating the nigrostriatal and
mesolimbic DA systems, respectively (Fibiger and Phillips, 1987; Corrigall et al.,
1992, 1994; Balfour and Benwell, 1993). This pathway regulates cognitive and
emotional behaviors (Simon et al., 1980) and is particularly sensitive to the acute
effects of psychostimulants (Roberts and Koob, 1983; Wise and Bozarth, 1987;
Self and Nestler, 1995). Furthermore, chronic nicotine exposure increases the
maximal binding (Bmax) of nicotinic receptors (Collins et al., 1990; Bhat et al.,
1991, 1994; Marks et al., 1992; Sanderson et al., 1993), demonstrating nicotineinduced upregulation of nicotinic receptors.

VI. Nicotinic Receptors
Extracellular DA concentrations are increased following nicotine
stimulation of nicotinic acetylcholine receptors in the cell body and terminal
regions of the mesocorticolimbic and nigrostriatal systems. Nicotinic receptors
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are a family of ligand-gated transmembrane ion channels that are activated
physiologically by acetylcholine (Figure 2) and pharmacologically by nicotine.
Both acetylcholine and nicotine activate all known nicotinic receptor subtypes,
whereas mecamylamine noncompetitively inhibits all known subtypes (Varanda
et al., 1985; Loiacono et al., 1993; Peng et al., 1994). Mecamylamine (Figure 2)
is a nonselective, noncompetitive nicotinic receptor antagonist that blocks the
opening of nicotinic receptors by binding in the pore of the receptor (Varanda et
al., 1985; Loiacono et al., 1993; Peng et al., 1994). Nonselective antagonists are
not specific for a certain subtype of receptor, in the case of mecamylamine, it
inhibits all nicotinic receptor subtypes. Noncompetitive antagonists are
antagonists that do not compete for the agonist binding site on the receptor, but
act at an allosteric site on the protein removed from the agonist recognition site.
Therefore, noncompetitive inhibition cannot be overcome by increasing the
agonist concentration. While much is known about the function of nicotinic
receptors, the specific subunit composition of native nicotinic receptors in brain
has not been elucidated. Therefore, native nicotinic receptors in brain are only
putatively designated.

Once these receptors are activated, they undergo a transition from the
closed, resting conformation to an open state, conducting cations (Na+, K+, Ca++)
through the channel down their electrochemical gradients, causing rapid
depolarization of the target cell (McGehee and Role, 1995; Role and Berg, 1996;
Alkondon et al., 1997; Dani et al., 2001). Heteropentameric nicotinic receptors
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require two molecules of acetylcholine or nicotine to bind in order for the ion
channel to open, whereas, homopentamers can bind up to five molecules of
acetylcholine or nicotine.

As shown in Figure 5, nicotinic receptors are pentameric structures
composed of nine different alpha (α2 - α10) and three different beta (β2 – β4)
subunits, with a general stoichiometry of 2α and 3β (Luetje et al., 1990; Anand et
al., 1991; Cooper et al., 1991; Deneris et al., 1991; Luetje and Patrick, 1991;
Role, 1992; Sargent, 1993; Elgoyhen et al., 1994; McGehee and Role, 1995;
Elgoyhen et al., 2001). α7 nicotinic receptors are homopentamers thus
containing 5 different α7 subunits. Amino acid sequencing determined that
nicotinic receptor subunits have four membrane spanning regions (M1-M4). The
M2 region from each of the five subunits is believed to form the wall of the pore in
the assembled functional receptor (Galzi and Changeux, 1995). Mutation of the
M2 region has been shown to alter the Ca++ permeability of α7 nicotinic receptors
(Bertrand et al., 1992). The alpha subunits are identified by a pair of adjacent
cysteine residues in the amino terminal domain, and are thought to be the
agonist binding subunits (Jensen et al., 2005). The beta subunit appears to be a
codeterminant of the functional properties of the receptor (Cachelin and Rust,
1995; Jensen et al., 2005). While much is known about the function of nicotinic
receptors, the specific subunit composition of native nicotinic receptors in brain
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has not been elucidated. Therefore, native nicotinic receptors in brain are only
putatively designated (indcated by an asterisk).

Hybridization cloning has revealed a surprising degree of subtype diversity
among neuronal nicotinic receptors (Luetje et al., 1990; Luetje and Patrick, 1991;
Deneris et al., 1991; Role, 1992; Sargent, 1993; Elgoyhen et al., 1994; McGehee
and Role, 1995). The α2, α3 and α4 subunits form functional receptors with
either β2 or β4 when coexpressed in Xenopus oocytes. In contrast, α7, α8 and
α9 form functional homo-oligomers in oocytes (Couturier et al., 1990; Séquéla et
al., 1993; Elgoyhen et al., 1994; Gerzanich et al., 1994; Peng et al., 1994; Briggs
et al., 1995, 1998; Chavez-Noriega et al., 1997; Rothlin et al., 1999). α7 nicotinic
receptors are highly permeable to Ca++ and have fast desensitization kinetics in
the presence of agonist. The α5, α6 and β3 subunits do not form functional
receptors on their own or in combination with another single subunit in oocytes.
However immunoprecipitation studies indicate that in vivo, α5 complexes with α3
and β4, and more recently, that α3 combines with α4β2 and α4β4, suggesting
that more than two different subunits may assemble together forming a receptor,
which greatly increases the potential diversity of native nicotinic receptors
(Conroy et al., 1992; Keyser et al., 1993; Vernallis et al., 1993; Ramirez-Lattore
et al., 1996; Forsayeth et al., 1995; Wang et al., 1996; Campos-Caro et al., 1997;
Forsayeth and Kobrin, 1997). The functional significance of subtype diversity is
still unknown; however, both native and cloned subtypes are pharmacologically

19

distinct in their response to both nicotinic agonists and antagonists (Luetje and
Patrick, 1995; Luetje et al., 1990; Role, 1992; Luetje, 1993; Amar et al., 1993;
Sargent, 1993; Cachelin and Rust, 1995; Decker, 1995).

Heteromeric α4β2* nicotinic receptors are most abundant in brain, and
second most abundant are homomeric α7* nicotinic receptors (Whiting and
Lindstrom, 1986; Wada et al., 1989; Morris et al., 1990; Schoepfer et al., 1990;
Anand et al., 1991; Flores et al., 1992; Lukas et al., 1999). The subunits display
different, but overlapping, patterns of expression in brain (e.g., β2 mRNA
expression is prominent in the cerebellum, which exhibits no α4 hybridization;
Wada et al., 1989). mRNA for nine subunits (α2–α7 and β2–β4) of nicotinic
receptors have been identified in SN and VTA dopaminergic neurons (Klink et al.,
2001, Zoli et al., 2002; Azam et al., 2002; Wooltorton et al., 2003), indicating that
potentially a large number of heteromeric nicotinic receptor subtypes of
pentameric structure may be expressed by these neurons.

Nicotinic receptors are localized on presynaptic terminals and cell bodies
of VTA and SN DA neurons (Schwartz et al., 1984; Clarke and Pert, 1985;
McGehee and Role, 1995; Wonnacott, 1997; Quik et al., 2005); and evidence
indicates that nicotinic receptor subtypes at cell body and terminal locations differ
pharmacologically (Reuben et al., 2000; Champtiaux et al., 2003). In striatal
synaptosomes, nicotine has a lower affinity for nicotinic receptors than
acetylcholine, and acetylcholine has equal affinity to epibatidine (a nicotinic
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receptor agonist; Reuben et al., 2000). However, in a dendrosomal preparation,
nicotine has equal affinity to epibatidine (Reuben et al., 2000), suggesting that
the nicotinic receptors in the terminal regions differ from those in the cell body
regions. Furthermore, α6β2* receptors have been shown to be located on DA
terminals, whereas nonα6(α4β2)* receptors represent the majority of functional
receptors on DA cell bodies (Champtiaux et al., 2003). The selective α6 nicotinic
receptor antagonist, α-conotoxin MII, has been shown to decrease nicotineevoked DA release, suggesting the involvement of the α6 subunit in nicotineevoked DA release (Salminen et al., 2004). Both the α-conotoxin MII sensitive
and resistant nicotinic receptor subtypes required the β2 subunit, however only
the α-conotoxin MII sensitive subtype required the β3 subunit; whereas the αconotoxin MII resistant subtypes required α4. These data suggest that the
primary subtypes involved in DA release are the α6β3β2* and α4β2* subtypes
(Salminen et al., 2004). Importantly, α-conotoxin MII inhibits nicotine-evoked
[3H]DA overflow by only 50%, implicating involvement of at least two different
nicotinic receptor subtypes in this response (Zoli et al., 2002; Salminen et al.,
2004; Azam and McIntosh 2005). It is likely that the difference in pharmacology
between the nicotinic receptors in the cell body regions and the nerve terminal
regions indicates that these receptors play different physiological roles.

VII. Nicotine Modulation of DA System Function
The pharmacological effects of nicotine are complex. Nicotine can
stimulate release of many different hormones including prolactin, vasopressin
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and adrenocorticotropin (Cam et al., 1979; Conte-Devolx et al., 1981; Andersson
et al., 1983; Mendelson et al., 2003; Sun et al., 2005). Furthermore, nicotine
increases blood pressure and heart rate (Benowitz et al., 1982; Benowitz et al.,
1988; Kadoya et al., 1994; Fattinger et al., 1997), and increases cerebral blood
flow (Kodaira et al., 1992; Stein et al., 1998; Ernst et al., 2001; Rose et al., 2003;
Domino et al., 2004). To add to the complexity of nicotine dependence, genetics
as well as socioeconomic status play important rolls in the development of
dependence to cigarette smoking (Boomsma et al., 1994; Breslau et al., 2001;
Berrettini and Lerman, 2005). Nicotine not only releases DA as described
above, but also releases other neurotransmitters such as norepinephrine and
serotonin (Yoshida et al., 1980; Toth et al., 1992; Sharp and Matta, 1993; Yu and
Wecker, 1994; Rao et al., 2003; Shearman et al., 2005). While nicotine has
many different effects, the current project will focus on the effects of nicotine on
the DA system.

Nicotine-evoked DA release is observed at nicotine concentrations (0.10.8 μM) within the range found in smokers’ blood (Russell et al., 1980; Kogan et
al., 1981). Nicotine increases DA release in striatum, nucleus accumbens and
MPFC in vitro (Giorguieff-Chesselet et al., 1979; Arqueros et al., 1978; Westfall,
1974; Westfall et al., 1983; Chesselet, 1984; Rowell et al., 1987; Rapier et al.,
1988, 1990; Fung, 1989; Westfall et al., 1989; Izenwasser et al., 1991; Grady et
al., 1992, 1994; Harsing et al., 1992; Rowell and Hillebrand, 1994; Schulz et al.,
1993; El-Bizri and Clarke, 1994; Rowell, 1995; Sacaan et al., 1995; Teng et al.,
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1997; Puttfarcken et al., 2000; Wonnacott et al., 2000; Zhou et al., 2001; Grady
et al., 2002; Mogg et al., 2002; Wilkins et al., 2002; Grinevich et al., 2003; Crooks
et al., 2004; Dwoskin et al., 2004; Rice and Cragg, 2004; Zhang and Sulser,
2004). Nicotine also increases DA release in striatum, accumbens and MPFC in
vivo (Imperato et al., 1986; Damsma et al., 1989; Brazell et al., 1990; Toth et al.,
1992; Benwell et al., 1993, 1995; Bassareo et al., 1996; Marshall et al., 1997;
Maisonneuve and Glick, 1999; Di Chiara, 2000; Fu et al., 2000; Sziraki et al.,
2002; Tizabi et al., 2002; Bednar et al., 2004; Brody et al., 2004b; Rahman et al.,
2004). Systemic nicotine administration also markedly increases the firing rate of
mesolimbic DA neurons recorded extracellularly (Grenhoff et al., 1986).

Importantly, nicotinic receptors localized to cell bodies mediate nicotineinduced DA release locally (somatodendritic), as well as at terminals (Clarke et
al., 1988; Corrigall et al., 1994; Nisell et al., 1994a,b 1995; Fu et al., 2000; Sziraki
et al., 2002; Tizabi et al., 2002; Champtiaux et al., 2003; Rahman et al., 2003;
Laviolette and van der Kooy, 2003). Nicotine-evoked DA release is inhibited by
mecamylamine and/or di-hydro beta-erythroidine (a competitive nicotinic receptor
antagonist; DHβE), and is Ca++ dependent (Westfall et al., 1987; Rapier et al.,
1990; Grady et al., 1992; El-Bizri and Clarke, 1994; Nisell et al., 1994; Crooks et
al., 1995; Sacaan et al., 1995; Rowell, 1995; Teng et al., 1997). Pre-exposure of
striatal slices or synaptosomes from mice or rats with nicotine results in
functional desensitization, such that subsequent nicotine exposure produces a

23

diminished [3H]DA release (Rapier et al., 1988; Grady et al., 1994; Rowell and
Hillebrand, 1994; Rowell, 1995). The desensitization induced by nicotine is
reversible, and is observed even with pre-exposure concentrations which
produce no detectable stimulation of [3H]DA release.

Controversy exists regarding the exact subunit composition of nicotinic
receptor subtypes mediating nicotine evoked DA release, and great effort is
focused on elucidating specific nicotinic receptor subtypes involved. Using
electrophysiology, a hypertonic sucrose solution allows for measurement of the
size of the readily releasable pool of vesicles from synaptosomes (Turner, 2004).
Repeated application of nicotine to the synaptosomes increased DA release by
increasing the size of the readily releasable pool of vesicles. This effect is
inhibited by α-bungarotoxin, suggesting a role for the α7* nicotinic receptor
subtype in nicotine-evoked DA release (Turner, 2004). Subtype assignment of
native nicotinic receptors mediating nicotine evoked DA release has been based
largely on inhibition of agonist-induced response by subtype selective
antagonists defined by inhibitory activity in cell systems expressing nicotinic
receptor subtypes of known composition (Grady et al., 2002; Zoli et al., 2002;
Everhart et al., 2004; Azam and McIntosh, 2005), by results from studies using
nicotinic receptor subunit knockout mice (Picciotto et al., 1998; Champtiaux et al.,
2002, 2003; Whiteaker et al., 2002; Marubio et al., 2003), and by in situ
hybridization and single cell polymerase chain reaction of mRNA in DA cell
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bodies (Deneris et al., 1989; Wada et al., 1989; Le Novere et al., 1996;
Charpantier et al., 1998; Klink et al., 2001; Azam et al., 2002).

Initially, specific subunit combinations of nicotinic receptors mediating
nicotine-evoked DA release (Imperato et al., 1986; Vezina et al., 1992; Nisell et
al., 1996, 1997; Teng et al., 1997; Zhou et al., 2001) were thought to be the
α3β2* (Schulz and Zigmond, 1989; Luetje and Patrick, 1991; Grady et al., 1992;
Cartier et al., 1996; Kaiser and Wonnacott, 2000) and α4β2* (Grady et al., 1992;
Rapier et al., 1990; Kulak et al., 1997; Kaiser and Wonnacott, 2000; Sharples et
al., 2000) nicotinic receptor subtypes. More recently, the selective α6 nicotinic
receptor antagonist, α-conotoxin MII, has been shown to decrease DA release,
suggesting the involvement of the α6 subunit in nicotine-evoked DA release
(Salminen et al., 2004). As previously discussed, DA neurons express α3 - α7
and β2 - β4 mRNAs (Deneris et al., 1989; Wada et al., 1989; Le Novere et al.,
1996; Charpantier et al., 1998; Klink et al., 2001; Azam et al., 2002) resulting in a
number of nicotinic receptor subtypes and subunit combinations that may be
involved in nicotine-evoked DA release. For example, α -conotoxin MII is a
nicotinic receptor antagonist, which inhibits electrophysiological responses in
Xenopus oocytes expressing α3/α6 and α6/α4 nicotinic receptors containing
either β2 or β4 subunits (Luetje et al., 1990; Cartier et al., 1996; Kuryatov et al.,
2000; Luetje, 2004). Importantly, α-conotoxin MII inhibits nicotine-evoked [3H]DA
overflow by only 50%, implicating involvement of at least two different nicotinic
receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh
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2005). Immunoprecipitation of nicotinic receptors from DA terminals as well as
electrophysiological studies in DA neurons from various nicotinic receptor
knockout mice suggest the involvement of α4β2*, α6β2*, α6α4β2* nicotinic
receptors in DA release (Champtiaux et al., 2003). Furthermore, striatal lesion
with 6-OHDA determined that possibly α3-, α4- or α5-containing nicotinic
receptors were present on DA terminals and could be involved in nicotinic
receptor modulation of DA release (Zoli et al., 2002). α-Conotoxin MII binds with
high affinity to immunopurified α6β2 nicotinic receptors (Zoli et al., 2002;
McIntosh et al., 2004), which is eliminated in α6-knockout mice, but not in α3- or
α4-knockout mice (Champtiaux et al., 2002; Whiteaker et al., 2002; Marubio et
al., 2003); suggesting that α-conotoxin MII is a selective antagonist for α6
containing receptors. Nicotine does not evoke DA release in microdialysis
experiments using α4-knockout mice (Marubio et al., 2003), indicating that α4
nicotinic receptors are critical for DA release, at least in ventral striatum.
However, the latter study also reported that basal DA release in α4-knockout
mice was significantly greater than in the wild-type, suggesting that α4-knockout
resulted in a compensatory response (altered tonic activity). Evidence is also
emerging suggesting that different DA neurons can be categorized based upon
the expression of particular nicotinic receptor subtypes with varying compositions
of nicotinic receptor subunits (Azam et al., 2002). Chronic nicotine administration
to β2 nicotinic receptor knockout mice did not increase locomotor activity, which
is suggested to be a DA dependent behavior. Thus the β2 subunit plays an
important role in DA-dependent behavior (King et al., 2004). Thus, we are only
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beginning to obtain a comprehensive understanding of the heterogeneous
population of nicotinic receptors that mediate nicotine-evoked DA release and
DA-dependent behaviors.

VIII. Nicotine Modulation of DAT
Extracellular DA concentrations are the net result of exocytotic DA release
from presynaptic terminals and reuptake of DA into presynaptic terminals
(clearance) via DAT. Nicotine-induced stimulation of nicotinic receptors results in
depolarization of the plasma membrane (Calabresi et al., 1989), which would be
expected to decrease DAT function and decrease DA clearance, thereby
increasing extracellular DA concentrations. Many psychostimulants act at DAT
as part of their mechanism of action. Thus, studies determining the effect of
nicotine on DAT function are important to pursue.

Recently, α4 nicotinic receptor subunit knockout mice have been shown to
have a decreased DAT function compared to wild type mice (Parish et al., 2005).
These data suggest that nicotinic receptors may be involved in modulating basal
DAT function. Furthermore, nicotine (0.4 mg/kg) has been reported to increase
DA clearance (enhance DAT function) in the nucleus accumbens in anesthetized
rats (Hart and Ksir, 1996). The latter results also contrast findings in vitro in
which nicotine and another nicotinic agonist, 1,1-dimethyl-4-phenyl-piperazinium,
have been reported to decrease [3H]DA uptake into chopped striatum and PC12
cells, respectively (Izenwasser et al., 1991; Huang et al., 1999). However, these
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in vitro findings have not been replicated (Kramer et al., 1989; Carr et al., 1989;
Rowell and Hill 1993; Zhu et al., 2003).

The observation that nicotine enhances DAT function in nucleus
accumbens in vivo (Hart and Ksir, 1996) is unexpected considering the
electrogenic nature of the transporter. As described previously, translocation of
DA by DAT across the membrane is coupled to the cotransport of two Na+ ions
and one Cl- ion down their electrochemical gradients, generating a small inward
current (Kanner and Schuldiner, 1987; Rudnick and Clark, 1993; Hitri et al.,
1994). Moreover, the DA neuron membrane potential influences DAT function,
such that hyperpolarization increases the velocity of DA transport by DAT and
depolarization decreases DA transport velocity (Sonders et al., 1997). As such,
nicotine-induced stimulation of nicotinic receptors, which results in depolarization
of the plasma membrane (Calabresi et al., 1989), would be expected to decrease
DAT function and decrease DA clearance, thereby increasing extracellular DA
concentrations. Recently DAT has been shown to act as a channel, not just as a
transporter (Carvelli et al., 2004). This would suggest that DAT has another role
and can itself modulate membrane potential.

With respect to nicotinic receptor modulation of DAT function, nicotine has
also been reported to enhance amphetamine-evoked [3H]DA release from MPFC
slices incubated in assay buffer in the absence of calcium (Drew et al., 2000).
These assay conditions precluded nicotine-evoked exocytotic DA release,
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suggesting the involvement of DAT in the nicotine-induced augmentation of the
response to amphetamine. Surprisingly, nicotine did not enhance amphetamineevoked [3H]DA release in striatum or nucleus accumbens (Drew et al., 2000),
indicating that this effect was specific to MPFC. The observed nicotine
enhancement of the effect of amphetamine in MPFC was inhibited by nicotinic
receptor antagonists, mecamylamine and DHβE, but not by α-bungarotoxin,
indicating that specific, non α7 containing, nicotinic receptor subtypes are
involved (Drew et al., 2000). The latter findings suggest that nicotinic receptors
may modulate DAT function under physiological conditions, i.e., in the presence
of extracellular calcium, at least in MPFC. Thus, determining the ability of
nicotine to modulate DAT function in striatum and MPFC, areas involved in
reward, is important for understanding the rewarding properties associated with
tobacco smoking and nicotine self-administration.

IX. Specific Aims and Hypotheses:
The work presented in this dissertation was based on the formation of four
specific aims: 1) Determine the dose-response relationship for systemic nicotine
to modulate DAT function in striatum and MPFC via a nicotinic receptor-mediated
mechanism; 2) Determine the effect of repeated peripheral nicotine
administration on DAT function in striatum and MPFC to assess differential brainregion specific nicotine-induced regulation of DAT using in vivo voltammetry; 3)
Determine if an increase in DAT efficiency is responsible for the nicotine-induced
increase in DAT function; and 4) Determine if increased trafficking of DAT from
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internal sites to the presynaptic terminal membrane accounts for the increase in
DA clearance in response to nicotine administration.

Specific Aim 1
Hypothesis #1
Nicotine will increase DA clearance in the striatum and MPFC in a dosedependent manner, and this increase in clearance will be mediated by nicotinic
receptors.

Hypothesis #2
Nornicotine, similar to nicotine, will increase DA clearance in the striatum via a
nicotinic receptor-mediated mechanism.

Specific Aim 2
Hypothesis #3
Repeated nicotine administration will further enhance the nicotine-induced
increase in DA clearance in striatum and MPFC.

Specific Aim 3
Hypothesis #4
Systemic pretreatment with nicotine will increase DAT function in striatal
synaptosomes in vitro, similar to the increase in DA clearance observed in
striatum in vivo.
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Hypothesis #5
The effect of nicotine to increase the Vmax of [3H]DA uptake in striatum is
mediated by nicotinic receptors located on DA nerve terminals in striatum.

Hypothesis #6
Systemic administration of nicotine will increase the number of DAT sites in
striatum as measured by radioligand binding.

Specific Aim 4
Hypothesis #7
Systemic administration of nicotine will increase the trafficking of DAT to the
neuronal cell surface in striatum.
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Figure 1. Sagittal slice through a rat brain. Straight lines represent
dopaminergic pathways and dotted lines indicate cholinergic projections.
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Figure 3. Cartoon representation of a DA nerve terminal. Adapted from
Cooper, Bloom and Roth; The Biochemical Basis of Neuropharmacology.
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Figure 4. Diagram of a dopamine transporter. DAT has 12
transmembrane domains with intracellular amino and carboxy termini.
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Figure 5. Representation of a neuronal nicotinic acetylcholine receptor.
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Chapter Two
Nicotine Increases Dopamine Transporter Function In Vivo in Striatum and
Medial Prefrontal Cortex via a Nicotinic Receptor-Mediated Mechanism
I. Introduction
Previous research on the neurobiology of reward and drug addiction has
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the
role of the nucleus accumbens, MPFC and striatum. The accumbens shell,
which is innervated by dopaminergic projections from the ventral tegmental area,
and its associated neurocircuitry are believed to encode primary appetitive stimuli
associated with unconditioned drug reward (Wise and Bozarth, 1987; Robbins
and Everitt, 1996; Bardo, 1998; Koob, 1999; DiChiara, 2000; Kelley and
Berridge, 2002). The MPFC, which includes the anterior cingulate cortex and is
innervated by dopaminergic projections from the ventral tegmental area, is
believed to encode secondary conditioned stimuli associated with environmental
cues paired with drug, leading to reward expectancy, which is recognized as
important to the process of addiction and relapse to drug use (Berridge and
Robinson, 1998; Shima and Tanji, 1998; Kelley, 1999; DiChiara, 2000; Kelley
and Berridge, 2002; Peoples, 2002). Integration of the motivational information
from the MPFC occurs at least in part in striatal neurons, which are innervated by
dopaminergic projections from the nigra, leading to the initiation and execution of
movement in reward expectancy and detection of reward (Martin-Soelch et al.,
2001).
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Nicotine is the most common drug of abuse and tobacco dependence the
leading preventable cause of death in the USA (Surgeon General’s Report, 1988;
Jaffe, 1990). Nicotine, the most abundant alkaloid in tobacco, has intrinsic
rewarding properties, which are believed to be responsible for tobacco
dependence (Koob,1992; Corrigall et al., 1992; Stolerman and Jarvis, 1995;
Garrett et al., 2003). The mechanisms underlying the reinforcing properties of
nicotine are not well understood, although the mesocorticolimbic and nigrostriatal
DA systems are believed to be involved. For example, c-fos activation of the
anterior cingulate cortex, nucleus accumbens and striatum has been
demonstrated in nicotine self-administering rats (Pagliusi et al., 1996; Merlo-Pich
et al., 1997), and cortical c-fos has been shown to be activated following
exposure to environmental cues associated with repeated nicotine administration
(Schroeder et al., 2001).

The latter results from animal studies are consistent

with findings showing that in tobacco smokers, nicotine dose-dependently
increased neuronal activity in the cingulate cortex, frontal lobe and nucleus
accumbens, as determined using functional MRI (Stein et al., 1998).

Extracellular DA concentrations are increased following nicotine
stimulation of nicotinic acetylcholine receptors in terminal regions of the
mesocorticolimbic and nigrostriatal systems. mRNA for nine subunits (α2–α7
and β2–β4) of nicotinic receptors have been identified in substantia nigra and
ventral tegmental dopaminergic neurons (Klink et al., 2001, Zoli et al., 2002;
Azam et al., 2002; Wooltorton et al., 2003), indicating that potentially a large
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number of heteromeric nicotinic receptor subtypes of pentameric structure may
be expressed by these neurons. Specific subunit combinations of nicotinic
receptors mediating nicotine-evoked DA release (Imperato et al., 1986; Vezina et
al., 1992; Nisell et al., 1996, 1997; Teng et al., 1997; Zhou et al., 2001) have not
been elucidated conclusively.

Extracellular DA concentrations are the net result of exocytotic DA release
from presynaptic terminals and reuptake of DA into presynaptic terminals
(clearance) via the DAT. DA is also removed from the extracellular space by
metabolism and diffusion, the latter factor playing a larger role in brain regions
with sparse dopaminergic innervation and lower DAT density, such as the MPFC.
DAT is the major presynaptic terminal protein regulating extracellular DA
concentrations and is a presynaptic target for psychostimulant drugs of abuse, as
well as for several antidepressant agents. Psychostimulants, such as
amphetamine, increase extracellular DA concentrations by reverse transport of
DAT (Liang and Rutledge, 1992; Sulzer et al., 1995). Cocaine inhibits DAT
function, which results in increased extracellular DA concentrations (Kuhar et al.,
1991). The antidepressant and tobacco use cessation agent, bupropion, inhibits
DAT function, but also is a nicotinic receptor antagonist (Hurt et al., 1997;
Slemmer et al., 2000; Miller et al., 2002). Surprisingly, nicotine (0.4 mg/kg) has
been reported to increase DA clearance (enhance DAT function) in the nucleus
accumbens in anesthetized rats (Hart and Ksir, 1996). The latter results also
contrast findings in vitro in which nicotine and another nicotinic agonist, 1,1-
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dimethyl-4-phenyl-piperazinium, have been reported to decrease [3H]DA uptake
into chopped striatum and PC12 cells, respectively (Izenwasser et al., 1991;
Huang et al., 1999). However, these in vitro findings have not been replicated
(Kramer et al., 1989; Carr et al., 1989; Rowell and Hill 1993; Zhu et al., 2003).

The observation that nicotine enhances DAT function in nucleus
accumbens in vivo (Hart and Ksir, 1996) is not expected considering the
electrogenic nature of the transporter. Translocation of DA by DAT across the
membrane is coupled to the cotransport of two Na+ ions and one Cl- ion down
their electrochemical gradients, generating a small inward current (Kanner and
Schuldiner, 1987; Rudnick and Clark, 1993). Moreover, the DA neuron
membrane potential influences DAT function, such that hyperpolarization
increases the velocity of DA transport by DAT and depolarization decreases DA
transport velocity (Sonders et al., 1997). As such, nicotine-induced stimulation of
nicotinic receptors, which results in depolarization of the plasma membrane
(Calabresi et al., 1989), would be expected to decrease DAT function and
decrease DA clearance, thereby increasing extracellular DA concentrations.

With respect to nicotinic receptor modulation of DAT function, nicotine has
also been reported to enhance amphetamine-evoked [3H]DA release from MPFC
slices incubated in assay buffer in the absence of calcium (Drew et al., 2000).
These assay conditions precluded nicotine-evoked exocytotic DA release,
suggesting the involvement of DAT in the nicotine-induced augmentation of the
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response to amphetamine. Surprisingly, nicotine did not enhance amphetamineevoked [3H]DA release in striatum or nucleus accumbens (Drew et al., 2000),
indicating that this effect was specific to MPFC. The observed nicotine
enhancement of the effect of amphetamine in MPFC was inhibited by nicotinic
receptor antagonists, mecamylamine and dihydro-β-erythroidine, but not αbungarotoxin, indicating that specific nicotinic receptor subtypes are involved.
The latter findings suggest that nicotinic receptors may modulate DAT function
under physiological conditions, i.e., in the presence of extracellular calcium, at
least in MPFC.

The goal of the present study was to test the first hypothesis that nicotine
will increase DA clearance in the striatum and MPFC in a dose-dependent
manner, and this increase in clearance will be mediated by nicotinic receptors.
The dose-response relationships for nicotine enhancement of DAT function were
characterized in striatum and MPFC. Furthermore, nicotinic receptor mediation
was determined by assessing mecamylamine inhibition of the nicotine effect on
DAT function in both striatum and MPFC. Under physiological conditions,
clearance of exogenously applied DA was assessed with msec resolution using
in vivo voltammetry, a technique which has been previously shown to reliably
evaluate DAT function (Cass et al., 1992).

II. Methods
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IIa. Materials. S(-)-Nicotine ditartrate (nicotine), 3-hydroxytyramine
hydrochloride (dopamine, DA), mecamylamine HCl (mecamylamine) and sodium
phosphate dibasic were purchased from Sigma/RBI (Natick, MA). Sodium
phosphate monobasic, sodium chloride, ascorbic acid and urethane were
purchased from Fisher Scientific (Pittsburgh, PA). Nafion perfluorinated ionexchange resin was purchased from Aldrich Chemical Co. (Milwaukee, WI).
Dental wax was purchased from Patterson Dental Supply, Inc. (Louisville, KY).
Dental acrylic was purchased from CMA Microdialysis (Acton, MA). Epoxylite
and PX grade Graphpoxy were purchased from Epoxylite Corp. (Irvine, CA) and
Dylon Industries, Inc. (Cleveland, OH), respectively. Carbon fibers of 30 μm
diameter were purchased from Textron, Inc. (Lowell, MA), and 28 gauge lacquercoated copper wire was purchased from Radio Shack (Lexington, KY).

IIb. Animals. Male Sprague Dawley rats (200 – 250 g) were obtained
from Harlan Laboratories (Indianapolis, IN) and were housed two per cage with
free access to food and water in the Division of Lab Animal Resources at the
College of Pharmacy, University of Kentucky. Experimental protocols involving
the animals were in strict concordance with the NIH Guide for the Care and Use
of Laboratory Animals and were approved by the Institutional Animal Care and
Use Committee at the University of Kentucky.

IIc. In vivo Electrochemical Measurements. Rats were anesthetized
with urethane (1.25 - 1.5 g/kg, i.p.) and placed into a Kopf stereotaxic frame
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(David Kopf Instruments, Tujunga, CA). Body temperature was maintained at 37
°C with a heating pad coupled to a rectal thermometer (Harvard Apparatus,
Holliston, MA). The scalp was reflected, and a section of the skull and dura
overlying the frontal cortex were removed. At a location remote from the
recording site, a small hole was drilled in the skull above the posterior cortex for
placement of two Ag/AgCl reference electrodes, which were cemented into place
with dental acrylic.

Electrochemical electrodes were prepared and electrochemical
experiments conducted using previously described methods (Cass et al., 1992;
Gratton et al., 1989). Electrochemical recording electrodes contained a single
carbon fiber (33 μm diameter) in a pulled glass capillary (4 mm outer diameter,
0.80 mm wall diameter) sealed with Epoxylite. Graphite epoxy resin and a 28
gauge lacquer-coated copper wire were inserted into the glass capillary to
establish electrical contact with the carbon fiber. The exposed carbon fiber
extended 50-150 μm beyond the tip of the glass capillary. Electrodes for some
experiments were purchased from Quanteon (Lexington, KY). To enhance
selectivity for DA, the carbon fiber electrode was coated with Nafion polymer (5%
solution, 6 - 8 coats) and cured by heating at 250 °C for 5 min. Electrodes were
calibrated in vitro to determine the sensitivity and selectivity for DA. Calibration
curves were generated using a range of DA concentrations (1.0 – 10 μM, at 22
°C in 0.1 M PBS solution, pH 4.0). Electrodes showed good sensitivity to DA and
were relatively insensitive to ascorbic acid, such that the mean selectivity ratio of
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DA/ascorbic acid was 594 ± 57 to 1 (n = 108). Subsequently, each carbon fiber
electrode was attached to a single barrel micropipette (tip diameter of 10-15 μm)
with dental wax. The tips of the electrode and micropipette were positioned 250 300 μm apart. The electrode micropipette assembly is shown in Figure 6.
Micropipettes were prepared from monofilament glass (1.0 mm O.D., 0.58 mm
I.D.) using a vertical pipette puller (Model 720, David Kopf Instruments, Tujunga,
CA). Single barreled micropipettes were filled with DA (200 μM, in 154 mM NaCl
and 100 μM ascorbic acid, pH 7.4) immediately prior to conducting the
experiment. The concentration of DA for ejection was chosen based on the
linear kinetics of DA uptake at this concentration, i.e., DA concentrations that do
not saturate DAT in striatum (Zahniser et al., 1999).

The electrode/micropipette assembly was lowered into the dorsal striatum
(1.5 mm anterior to bregma, 2.3 mm lateral from midline, and 4.0 - 5.5 mm below
the surface of the cortex) or MPFC (cingulate cortex; 2.9 mm anterior to bregma,
1.0 mm lateral from midline, and 2.5 – 5.0 mm below the surface of the cortex),
according to the rat brain atlas of Paxinos and Watson (1986). Exogenous DA
was pressure ejected (30 - 50 psi, 0.05 ms – 2.5 s) at 5-min intervals using a
Picosprizter II (General Valve Corporation, Fairfield, NJ), until reproducible
baseline signals (variation in signal amplitude < ± 10%) were obtained. Using a
stereomicroscope fitted with a reticule in one eyepiece, ejection volume (250
nl/mm) was monitored by measurement of the fluid displaced from the
micropipette.
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In the first series of experiments, dose-response curves for nicotine
modulation of DAT function in striatum and MPFC were generated, with nicotine
dose and brain region as between-groups factors. Rats were randomly assigned
to 5 treatment groups to assess the effect of nicotine (0.1 - 0.8 mg/kg, s.c.) or
vehicle (saline) on DAT function in striatum. Rats were assigned to 6 treatment
groups to assess the effect of nicotine (0.1 - 0.8 mg/kg, s.c.) or vehicle (saline)
on DAT function in MPFC. In an attempt to generate the full dose-response
relationship in MPFC, the effect of an additional nicotine dose (0.3 mg/kg) was
determined based on the dose-response curve obtained.

For each experiment, nicotine was administered once reproducible baseline
signals were obtained. Pressure ejection of DA continued at 5-min intervals for
60 min following nicotine or vehicle injection. In the majority of MPFC
experiments, rats were pretreated with desipramine (25 mg/kg, s.c.) to assure
that DAT function was measured and that the norepinephrine transporter (NET)
did not play a prominent role. Previous in vivo voltammetry studies have shown
that the MPFC is heterogeneous with respect to transporter regulation of
extracellular DA concentrations (Cass and Gerhardt, 1995). Results from the
latter study reveal that at deep recording depths (2.5 – 5.0 mm below the cortical
surface), DAT primarily clears DA from the extracellular compartment. At more
superficial recording depths (0.5 - 2.25 mm the cortical surface), NET plays a
greater role. As such, local application of desipramine into MPFC at superficial
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depths resulted in inhibition of DA clearance. At deep recording depths,
desipramine had no effect on DA clearance. In contrast, local application of GBR
12909, a selective DAT inhibitor, produced the reverse effect, i.e., inhibited DA
clearance at deep recording depths and had no effect at superficial depths in
MPFC. In the current study, recording was deeper in the MPFC (2.5 – 5.0 mm
below the cortical surface), in an attempt to also ensure that the effect of nicotine
on DAT function was evaluated. Comparisons of results in the absence and
presence of desipramine revealed no significant differences in the effect of
nicotine on DA clearance.

To determine if nicotinic receptors mediated the response to nicotine on DA
clearance in striatum and MPFC, the effect of mecamylamine, a noncompetitive
nicotinic receptor antagonist (Varanda et al., 1985; Loiacono et al., 1993; Peng et
al., 1994), was determined. Rats were randomly assigned to 8 treatment groups
(4 treatment groups/brain region). Each group was injected s.c. with either
mecamylamine or saline, followed 40 min later by a second injection s.c. of
nicotine or saline; such that herein, treatment groups are designated as
first/second injection (i.e., mecamylamine/saline, mecamylamine/nicotine,
saline/nicotine and saline/saline groups). Once reproducible baseline signals
were obtained, mecamylamine (1.5 mg/kg) or vehicle (saline) was injected. The
dose of mecamylamine was chosen primarily based on previous behavioral
studies from our laboratory and others in which a similar dose of mecamylamine
(1.2 mg/kg) inhibited both the acute effects of nicotine on locomotor activity and
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the sensitization induced by repeated administration of nicotine (Miller et al.,
2001). A lower dose of mecamylamine (1.0 mg/kg) was previously shown to
inhibit nicotine-induced locomotor stimulation (Clarke and Kumar, 1983). The
dose of mecamylamine chosen was also within the range of that inhibiting
nicotine self-administration in rats (Rauhut et al., 2002; Rezvani et al., 2002).
Mecamylamine (1.0 mg/kg) also was shown to inhibit the effect of nicotine (0.4
mg/kg) to enhance DA clearance in nucleus accumbens using in vivo
voltammetry (Hart and Ksir, 1996). Previous studies have shown that injection of
mecamylamine 20 min prior to nicotine injection completely inhibited the nicotineinduced increase in locomotor activity for one hour following nicotine injection
(Miller et al., 2001). In the current studies, mecamylamine was injected 40 min
prior to nicotine to ensure that mecamylamine had sufficient time to get to the
brain and to its site of action. Based on results of the current nicotine doseresponse curves in the first series of experiments, nicotine doses (0.8 and 0.4
mg/kg) that produced a maximal effect in striatum and MPFC, respectively, were
chosen. DA was pressure ejected every 5 min during the 40 min period following
the first s.c. injection and for 60 min following the second s.c. injection. For all
experiments, drug dose represents the salt weight, and the injection volume was
1 ml/kg body weight.

High-speed chronoamperometric electrochemical measurements were made
continuously (5 times/s, 5 Hz and averaged to 1 Hz), using an electrochemical
recording system (IVEC 10; Medical Systems Corporation, Greenvale, NY). The
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oxidation potential was a square wave of +0.55 volts applied for 100 ms (versus
the Ag/AgCl reference electrode), and the resting potential was 0.0 volts for 100
ms. When the voltage was applied, DA was oxidized to para-ortho-quinone DA
resulting in the release of 2 electrons (Figure 6). The electrons coming from the
oxidized DA were measured by the electrode and converted to a concentration
measure using the IVEC 10. Oxidation currents were digitally integrated during
the last 80 ms of each 100-ms pulse.

IId. Data and Statistical Analysis. Data are represented as mean
values + S.E.M., and n represents the number of animals in a treatment group.
Three parameters were determined from the DA oxidation currents; maximal
signal amplitude, which is defined by the maximal change in extracellular DA
concentration; T80, the time for the signal to decay by 80% minus the rise time of
the signal; and DA clearance rate, the slope of the initial pseudolinear portion of
the decaying signal (between the T20 and T60 time points; Figure 7), integrating
signal amplitude and time course of decay. During the conduct of this
dissertation project, attention was brought to the measure of the clearance rate
parameter in that the presentation of the data was backwards from the result of
the experiments. Therefore, to alleviate confusion the classical pharmacokinetic
measure was utilized (discussed in Chapter Three).

For the first series of experiments generating nicotine dose-response
curves in striatum and MPFC, time courses for the nicotine dose effect were
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analyzed by two-way mixed-factor ANOVA, with dose as a between-groups
factor and time as within-subjects factor. A separate ANOVA was performed to
analyze the time course for each of the three parameters assessed, maximal
signal amplitude, T80 and clearance rate for each brain region. To determine the
dose-related effect of nicotine, one-way ANOVAs were conducted on the signal
amplitude data from striatum at each 5-min time point during the 30-60 min
period following nicotine injection. One-way ANOVAs were also conducted on
the dose response for signal amplitude and clearance rate data from MPFC at
each time point during the 30-60 min period following nicotine injection. The
time period chosen for the latter analyses was based on previous results in rat
nucleus accumbens following a single dose (0.4 mg/kg, s.c.) of nicotine (Hart and
Ksir, 1996). Dunnett’s post hoc analysis was performed to determine differences
from saline control. Additionally, specific within-subject contrasts determined the
time point at which nicotine significantly decreased signal amplitude compared to
baseline (prior to drug injection). Furthermore, for both striatum and MPFC,
signal amplitude data were summed across the 60-min recording period to
assess nicotine dose-response relationships, and these data were analyzed by
one-way ANOVA and Tukey test to determine the nicotine dose that significantly
decreased signal amplitude.

Analysis of mecamylamine-induced inhibition of the effect of nicotine on
each of the three parameters (maximal signal amplitude, T80 and clearance rate)
for each brain region was accomplished using separate three-way mixed-factor
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ANOVAs, with mecamylamine and nicotine as between-group factors and time
as a within-subjects factor. Significant interactions were found for the data
expressed as signal amplitude and clearance rate, such that one-way ANOVAs
were utilized to assess the effect of nicotine and mecamylamine at individual time
points. Additionally, specific within-subjects contrasts were performed for the
group administered saline followed by nicotine to determine the time point at
which nicotine significantly decreased signal amplitude compared to baseline.

ANOVA, specific contrasts and post hoc analyses were performed using
SPSS (standard version 11.0, Chicago, IL). p < 0.05 was considered significant.
Based on the apriori directional hypothesis being tested, one-tailed tests were
considered statistically significant; however, two-tailed tests were reported herein
unless otherwise indicated. Nonlinear curve fitting of the cumulative nicotine
dose-response data was performed by Prism through a nonweighted iterative
process (Prism v3.0, GraphPad software, Inc., San Diego, CA).

III. Results
IIIa. Effect of Nicotine on Exogenous DA Clearance in Striatum. The
effect of systemic administration of nicotine (0.1 – 0.8 mg/kg) on exogenous DA
clearance in the medial dorsal striatum of urethane-anesthetized rats was
determined. Pressure ejection of 200 μM DA every 5 min resulted in stable
baseline signals, with a maximal signal amplitude of 4.21 μM (± 0.22 μM; mean ±
S.E.M.; range, 1.51 – 9.90 μM), T80 value of 32.6 s (± 3.1 s) and clearance rate of
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0.307 μM/s (± 0.056 μM/s; n = 32 independent experiments). Maximal signal
amplitude during measurement of basal DA clearance varied with the placement
of the electrode/micropipette assembly in the striatum. While there was some
between group variability in maximal signal amplitude, the within animal baseline
signals were stable. Figure 7 illustrates the reproducible pattern of a series of
baseline signals for a representative rat obtained prior to systemic injection of
nicotine (0.8 mg/kg) or saline (Figure 7, top panel). Maximal signal amplitude
under basal conditions for the represented rat was 3.64 μM, which was near the
median response and within one SD of the mean response of the group. Once
baseline signals had stabilized, rats were injected with either nicotine or saline
(control), and pressure ejection of DA continued every 5 min for 60 min. The
effect of nicotine on maximal signal amplitude, T80 and clearance rate was
determined at 5 min intervals and compared to that after saline injection. An
overlay of representative signals, obtained in striatum at the 45-min time point
after injection when the maximal effect of nicotine (0.8 mg/kg) was observed,
reveals a large decrease (45%) in maximal signal amplitude (Figure 7, bottom
panel). Rise time, duration and decay of the DA signal were not different
between nicotine- and saline-treated rats.

Analysis of the data from the control group (saline injected) reveals that
DA signal amplitude gradually decreased by ~15% of baseline during the 55-min
period after saline injection; however, a decrease (~23%) in signal amplitude was
significant only at the 60-min time point (Figure 8, top panel). Following repeated
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DA pressure ejection in the saline control rats, DA signal amplitude decreases
and DA clearance increases slightly across the 60-min recording session. It is
possible that the decrease in signal amplitude is due to changes in the properties
of the recording electrode. During the experiment the electrodes become less
sensitive to DA (30% decrease in sensitivity). Therefore, the decrease in signal
amplitude may be due to at least in part a decrease in sensitivity of the electrode.
While the electrodes are less sensitive, the electrodes retain selectivity for DA. It
is also possible that following repeated DA pressure ejection the extracellular
space around the ejection site is altered. Thus, changes in extracellular space
could modulate DA clearance and play a role in the slight decrease decrease in
signal amplitude observed in the saline control group.

T80 did not change

across the time course of the experiment in the saline-injected group (Figure 8,
middle panel). Similar to signal amplitude, DA clearance rate also gradually
decreased by ~15% of baseline across the time course of the session (Figure 8,
bottom panel). The bottom panel illustrates that at the 60-min time point, DA
clearance rate decreased by 40%; however, there were no significant main
effects or interactions, such that posthoc analyses were not performed. Thus,
repeated DA application at 5-min intervals following saline injection resulted in a
small increase in DAT function across the 60-min session.

The dose response for nicotine-induced modulation of DAT function in
striatum was determined and the results are shown in Figure 8. The parameters
of DAT function (maximal signal amplitude, T80 and clearance rate) were
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analyzed using separate two-way ANOVAs. With respect to signal amplitude, a
significant interaction of dose and time was found (F52,351 = 1.58, p < 0.05). To
further analyze the interaction, separate one-way ANOVAs of signal amplitude
were conducted on the data from each 5-min time point during the 30-60 min
after injection (Figure 8, top panel). Dose-related decreases in signal amplitude
were observed at various time points. Significant main effects of nicotine dose
were found at 40-45 min (p < 0.05), and at the 35 min and 50-55 min time points
(p < 0.05, one-tailed) after injection. Dunnett’s post hoc analysis revealed that
DA signal amplitude was decreased 35-55 min in the 0.8 mg/kg group compared
to the control group. Signal amplitude decreased by a maximum of 48% of
control at 45 min after the 0.8 mg/kg dose of nicotine (between-groups
comparison); however, when signal amplitude at this time point was compared to
the baseline response (within-subject comparison), a 60% decrease in signal
amplitude was found. To determine the onset of the effect of nicotine, specific
within-subjects contrasts were performed comparing DA signal amplitude at each
time point following nicotine injection compared to signal amplitude at baseline.
A significant decrease in signal amplitude occurred 15 min following nicotine
injection (0.8 mg/kg, p < 0.01). In contrast to the effect of nicotine on signal
amplitude, no significant main effects or interactions were found for T80 or
clearance rate, when the data were analyzed by two-way ANOVA (Fig 8, middle
and bottom panels, respectively). With respect to clearance rate, the highest
dose (0.8 mg/kg) of nicotine tended to increase clearance rate, but did not reach
significance. Thus, compared to T80 and clearance rate, DA signal amplitude is
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the more sensitive parameter for detection of the effect of nicotine on DAT
function.

To further evaluate the nicotine dose-response relationship, DA signal
amplitude data for each dose were cumulated across the 60-min sampling period
to generate a dose-response curve (Figure 9). The nicotine dose-response
curve was monophasic, and nonlinear regression revealed a significant fit to the
data (r2 = 0.99). Thus, as the nicotine dose increased, DA signal amplitude
decreased, indicating that in a dose-related fashion nicotine enhances DAT
function in striatum.

IIIb. Effect of Nicotine on Exogenous DA Clearance in MPFC. To
assess the effect of nicotine on DAT function in the mesocorticolimbic system, a
range of nicotine doses (0.1 – 0.8 mg/kg) was administered s.c. to separate
groups of rats, and exogenous DA clearance in MPFC was determined.
Pressure ejection of DA (200 μM) resulted in stable baseline signals with a
maximal signal amplitude of 4.54 μM (± 0.18 μM; mean ± S.E.M), T80 value of
76.8 s (± 4.62 s), and clearance rate of 0.085 μM/s (± 0.011 μM/s; n = 33
independent experiments). Once baseline signals had stabilized, groups of rats
were injected with either a dose of nicotine (0.1 – 0.8 mg/kg, s.c.) or saline and
DA pressure ejection continued at 5-min intervals for 60 min. The effect of
nicotine on maximal signal amplitude, T80 and clearance rate was determined at
5-min intervals and compared to the saline-injected control group (Figure 10).
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Analysis of the data from the saline-injected control group revealed that
DA signal amplitude gradually decreased by ~13% during the first 55 min of the
session (Figure 10, top panel). At 60 min after the injection of saline, signal
amplitude was significantly decreased by 15% (p < 0.001). T80 was not different
from baseline across the duration of the session (Figure 10, middle panel). DA
clearance rate tended to decrease (~15% of baseline) across the session time
course, but did not reach significance (Figure 10, bottom panel). Thus, under
control conditions, repeated DA application at 5-min intervals resulted in a small
increase in DAT function across the 60-min session, similar to that observed in
striatum.

When the effect of nicotine on both signal amplitude and clearance rate
were analyzed by two-way ANOVA, significant interactions of dose and time
were found (F65,351 = 1.95, p < 0.001 and F65,351 = 1.74, p < 0.01, respectively).
No significant main effects or interactions were observed for T80. Signal
amplitude data were analyzed further by one-way ANOVAs at individual 5-min
time points, revealing dose-related decreases in signal amplitude at 15-30 min
and 50-60 min (p < 0.05; at 35 min, p < 0.05, one-tailed, Figure 10, top panel).
Dunnett’s post hoc analysis revealed that compared to the control group, DA
signal amplitude was decreased in the 0.4 mg/kg group at 15-30 min (p < 0.05),
and at the 35 min and 50-55 min time points (p < 0.05, one-tailed). Compared
with the control group, a maximal decrease of 46% in signal amplitude was
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observed 30 min after injection of nicotine (0.4 mg/kg); and when the data at this
time point were compared to the within-subject baseline, a 53% decrease in
signal amplitude was observed. To assess the onset of nicotine effect, specific
within-subjects contrasts were performed comparing signal amplitude at each
time point after injection to that at baseline. A significant (p < 0.001) decrease in
signal amplitude was observed 10 min following nicotine (0.4 mg/kg) injection.

With respect to clearance rate, one-way ANOVAs were conducted to
assess the nicotine dose-response at each 5-min time point after injection
(Figure 10, bottom panel). Dose-related decreases in clearance rate were
observed at 15-25 min and 60 min (p < 0.05), and at the 30 min and 50-55 min
time points (p < 0.05, one-tailed) post injection. Dunnett’s post hoc analysis
revealed that DA clearance rate was decreased in the 0.4 mg/kg group
compared to the control group at 15-25 min (p < 0.05) and at 30 min (p < 0.05,
one-tailed) after injection. Compared to the control, clearance rate after 0.4
mg/kg decreased by a maximum of 33% at the 45-min time point; whereas a
maximum decrease of 44% was observed when compared to the within-subject
baseline response. The onset of the nicotine effect on clearance rate occurred at
10 min following nicotine injection (0.4 mg/kg, p < 0.01).

DA signal amplitude was also expressed as a cumulative change across
the 60-min sampling period to evaluate the nicotine dose-response relationship
(Figure 11). Surprisingly, a U-shaped dose-response relationship was apparent.
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Only the 0.4 mg/kg dose of nicotine decreased DA signal amplitude in MPFC.
Similarly, a U-shaped dose-response relationship was observed for clearance
rate (data not shown). Thus, nicotine also modulates DAT function in MPFC;
however, the dose-response pattern was different from that observed in striatum,
and the time of onset and of maximal response occurred more rapidly after
systemic nicotine injection in MPFC than in striatum.

IIIc. Effect of Mecamylamine on Nicotine-induced Modulation of DAT
Function in Striatum. To ascertain if the effect of nicotine on DAT function is
mediated by nicotinic receptors, the ability of mecamylamine to inhibit the
nicotine-induced increase in DA signal amplitude was determined. Pressure
ejection of DA (200 μM) resulted in a maximal signal amplitude of 6.75 μM (±
0.43 μM; mean ± S.E.M.), T80 value of 23.8 s (± 4.60 s), and clearance rate of
0.902 μM/s (± 0.119 μM/s; n = 26 independent experiments). Once baseline
signals stabilized, groups of rats were injected with mecamylamine (1.5 mg/kg,
s.c.) or saline, and 40 min later with nicotine (0.8 mg/kg, s.c.) or saline. The dose
of nicotine was chosen based on the above dose-response analysis. DA
pressure ejection continued every 5 min after mecamylamine or saline and every
5 min for 60 min after nicotine or saline. Data for the three parameters of DA
clearance are illustrated in Figure 12.

Since signal amplitude was the only parameter which detected the dose
relationship for nicotine to enhance DAT function in striatum, a three-way
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ANOVA on signal amplitude data was performed to determine if mecamylamine
inhibited the effect of nicotine. A significant three-way interaction of
mecamylamine x nicotine x time was found (F13,286 = 1.82, p < 0.05). As
previously observed, DA signal amplitude tended to gradually decrease across
the 60-min session when compared to baseline in the Saline-Saline control
group; however, only at the 60-min time point did the decrease (25%) in signal
amplitude reach significance. In the Saline-Nicotine group, the onset of the effect
of nicotine to decrease signal amplitude (30%) occurred at 25 min after nicotine
injection (within-subject comparisons, p < 0.01). At the 55-min time point,
nicotine maximally decreased signal amplitude by 56% compared to baseline. At
the latter time point, comparison of the Saline-Nicotine and Saline-Saline groups
revealed that nicotine decreased signal amplitude by a maximum of 36%. With
respect to the Mecamylamine-Saline group, no within-subject differences were
observed across the time course of the session compared to baseline, indicating
that mecamylamine alone had no effect on DAT function. To determine if
mecamylamine inhibited the effect of nicotine, one-way ANOVAs compared the
treatment groups at each time point beginning at the onset of nicotine’s effect
(i.e., 25-60 min). At the 40, 45, 55 and 60 min time points, signal amplitude in
the Mecamylamine-Nicotine group was significantly greater than that in the
Saline-Nicotine group (p < 0.05, one-tailed) and not different from that in the
Saline-Saline group, indicating that mecamylamine completely inhibited the effect
of nicotine on DAT function in striatum.
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IIId. Effect of Mecamylamine on Nicotine-induced Modulation of DAT
Function in MPFC. To ascertain if nicotinic receptors also mediate nicotineinduced modulation of DAT function in MPFC, the ability of mecamylamine to
inhibit the nicotine-induced decrease in signal amplitude in urethaneanesthetized rats was determined. Stable baseline signals, obtained in response
to pressure ejection of 200 μM DA, exhibited a maximal signal amplitude of 4.14
μM (± 0.27 μM; mean ± S.E.M.), T80 value of 80.5 s (± 6.02 s), and clearance rate
of 0.066 μM/s (± 0.008 μM/s; n = 24 independent experiments). Once baseline
signals stabilized, experiments were performed as described above, except that
electrochemical measurements were made in MPFC (Figure 13). A three-way
ANOVA was performed to determine if mecamylamine inhibited the nicotineinduced decrease in DA signal amplitude in MPFC. A significant interaction of
mecamylamine x nicotine x time (F13,260 = 2.08; p < 0.02) was found. DA signal
amplitude decreased to a maximum of 20% compared to baseline at 60 min
following the second saline injection in the Saline-Saline group. Within-subjects
comparison in the Saline-Nicotine group revealed that the onset of the nicotine
effect occurred 15 min after nicotine injection, at which time a significant (p <
0.001) decrease in signal amplitude was observed compared to baseline
response. At the 35 min time point, nicotine produced a maximal decrease in
signal amplitude (45%) compared to baseline; between-groups comparison of the
response in the Saline-Nicotine and Saline-Saline groups revealed a maximum
decrease of 25% at this time point. Within-subjects comparisons in the
Mecamylamine-Saline group revealed no differences across the session
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compared to baseline, indicating that mecamylamine alone had no effect on DAT
function in MPFC. One-way ANOVA followed by Dunnett’s test compared data
from the Mecamylamine-Nicotine and Saline-Nicotine groups at each time point
from 15-60 min, when nicotine decreased signal amplitude compared to baseline.
Signal amplitude was greater in the Mecamylamine-Nicotine group than that in
the Saline-Nicotine group at 20-30, 40 and 50 min (p < 0.05) and 35, 45 and 60
min (p < 0.05, one-tailed) of the session. Importantly, the response in the
Mecamylamine-Nicotine group was not different from that in the Saline-Saline
group at these time points, indicating that mecamylamine completely inhibited the
effect of nicotine on DAT function in MPFC. Thus, these results suggest that
nicotine modulates DAT function via a nicotinic receptor-mediated mechanism in
MPFC.

IV. Discussion
The results from the current in vivo voltammetry study demonstrate that
nicotine in a dose-related manner decreases DA signal amplitude in both
striatum and MPFC, indicating that nicotine enhances DA clearance in both brain
regions. However, across the same nicotine dose range, differential patterns in
the nicotine dose-response curve were observed in striatum and MPFC. That is,
a monophasic dose-response curve was observed in striatum, whereas a Ushaped curve was found in MPFC, both curves having a maximal 50% effect.
Maximal effect occurred at a lower dose in MPFC than in striatum (0.4 and 0.8
mg/kg, respectively). In both brain regions, the onset of a significant effect on DA

60

clearance occurred 10-15 min after nicotine injection; however, DA clearance
tended to increase by 5 min after nicotine injection. Additionally, the time to
maximal response was more rapid in MPFC compared to striatum (30 and 45
min, respectively). The time course of the response to nicotine in both brain
regions is in good agreement with pharmacokinetic data showing a maximal
nicotine concentration in rat brain at 5 min after peripheral nicotine injection and
a brain t1/2 of 52 min (Ghosheh et al., 2001). Of note, the nicotine-induced
increase in DA clearance in striatum lasted for at least 2 hours following nicotine
injection. Thus, the effect of nicotine on DAT function is long-lasting.
Nevertheless, the pattern of the nicotine dose-response curve in the present
study was different between MPFC and striatum, with MPFC showing greater
sensitivity to nicotine.

The current results support and extend previous findings, showing that
systemically administered nicotine increases DA clearance in several
dopaminergic terminal regions, including MPFC and striatum (current study), and
nucleus accumbens (Hart and Ksir, 1996). The latter results are surprising since
stimulation of nicotinic receptors results in depolarization of the plasma
membrane (Calabresi et al., 1989) and since depolarization of the membrane
generally decreases DA transport velocity (Sonders et al., 1997). However, this
was not the case with nicotine. The current results demonstrate a dose-related
nicotine-induced enhancement of DAT function in striatum and MPFC, and
extend the findings of Hart and Ksir (1996) in nucleus accumbens.
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Interestingly, following nicotine injection, nicotine-induced increases in DA
release are not observed using this procedure. It is possible that the electrodes
used in the current study are not sensitive enough to be able to detect the
released DA. However, a more likely explanation is that the amount of DA
released by nicotine at the recording site was not large enough to be detected.
Thus, while nicotine has been shown in several studies to release DA, this
mechanism does not appear to have an effect on the nicotine-induced increase
in DA clearance.

The present study also demonstrates that the nicotine-induced
enhancement of DA clearance in both MPFC and striatum was inhibited by
pretreatment of the rats with mecamylamine, a nonselective nicotinic receptor
antagonist (Varanda et al., 1985). These results suggest that nicotine stimulates
nicotinic receptors to increase DAT function in these brain regions. In the current
study, mecamylamine had no effect on its own, but inhibited the effect of nicotine
on DA clearance in both striatum and MPFC. The current results are in
agreement with the work of Hart and Ksir (1996), who also reported no effect of
mecamylamine alone on DAT function in nucleus accumbens. The observation
that mecamylamine had no effect alone, suggests that nicotinic receptors, which
modulate DAT function in these brain regions, are not tonically activated.

The involvement of distinct nicotinic receptor subtypes in striatum and
MPFC provides a likely explanation for the differential nicotine dose-response
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pattern observed in the current study. Recent studies have demonstrated the
presence of multiple mRNAs for nicotinic receptor subunits (α2-α7 and β2-β4)
and their respective proteins in DA cell bodies in both substantia nigra and
ventral tegmental area; however, differences in the relative abundance of these
subunits in substantia nigra and ventral tegmental area have also been reported
(Klink et al., 2001; Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003).
The nicotinic receptors expressed in the nigrostriatal and mesocorticolimbic DA
systems depend on the specific combinations of subunits forming functional
nicotinic receptors. Pairwise expression of nicotinic receptor subunits in
Xenopus oocytes initially revealed characteristic pharmacological profiles, i.e.,
relative sensitivity and responsiveness to a range of nicotinic ligands (Luetje and
Patrick, 1991). Inclusion of a third type of subunit (e.g., α5 with α3 and β2
subunits) in similar expression systems further altered the physiological
response, calcium permeability and desensitization characteristics of the
expressed nicotinic receptor subtypes (Gerzanich et al., 1998). Characterization
of the physiological response of individual neurons in midbrain slices revealed
four different patterns of nicotinic receptor-mediated currents, revealing the
complexity of native nicotinic receptors which purportedly contained as many as
four different subunits (Klink et al, 2001).

Although the specific subunit composition of nicotinic receptor modulating
DAT function in either striatum or MPFC is not known, the nicotinic receptor
subtype modulating DAT function in MPFC may be more sensitive to nicotine
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than the specific nicotinic receptor subtype modulating DAT function in striatum,
since the nicotine dose producing an enhancement of DA clearance is lower in
MPFC than in striatum. The current results show that in both striatum and
MPFC, 0.1 and 0.3 mg/kg produce no effect on DAT function; however, 0.4
mg/kg enhances DAT function in MPFC, whereas 0.8 mg/kg enhances DAT
function in striatum. Thus, the descending portion of the dose-response in MPFC
resembles the dose-response in striatum, but the curve from MPFC is shifted to
the left of that from striatum. Doses of nicotine above 0.8 mg/kg were not
examined in the current study, since such doses elicit seizures that may have
confounded the results. Thus, the differential pattern of response observed in
the present study in MPFC and striatum with respect to nicotinic receptormediated modulation of DAT function is likely the result of stimulation of distinct
nicotinic receptor subtypes.

An alternative explanation for the differential nicotine dose-response
relationships in striatum and MPFC is the lower dopaminergic terminal density in
MPFC compared to striatum, and the decreased number of DAT per terminal in
MPFC compared to striatum (Sesack et al., 1998). It may be that a higher dose
of nicotine is required to observe the modulation of DAT function in striatum
simply due to the greater number of DAT protein in striatum compared to MPFC.

Another potential explanation for the difference in regional dose-response
is that the local neuronal circuitry is different between these two brain regions,
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i.e., different afferents impinge on the dopaminergic terminals in striatum and
MPFC potentially providing differential regulation of DAT function. In this regard,
the U-shaped function in MPFC may be the result of nicotine-induced stimulation
of an additional neurotransmitter system in the MPFC. The result of activation of
the additional neurotransmitter may have opposed the nicotinic receptormediated enhancement of DAT function. For example, high concentrations of
nicotine have been shown to activate alpha7 nicotinic receptors, resulting in
glutamate release in frontal cortex (Kaiser and Wonnacott, 2000; Schilstrom et
al., 2000; Marchi et al., 2002). For example, stimulation of metabotropic
glutamate receptors have been reported to decrease DAT function (Page et al.,
2001). Thus, activation of alpha7 receptors indirectly through glutamate
neurotransmission could result in inhibition of DAT function, counteracting
activation of the high affinity heteromeric nicotinic receptors, which enhance DAT
function.

Alternatively, nicotinic receptors may indirectly modulate DAT function
through activation of neural circuitry at the cell body level. Local administration of
nicotine into the substantia nigra and ventral tegmental area has been shown to
evoke DA release in striatum and nucleus accumbens, respectively, via
stimulation of nicotinic receptors in the cell body region (Blaha and Winn, 1993;
Sziraki et al., 2002). Additionally, the effect of peripheral administration of
nicotine to increase DA release in the nucleus accumbens determined using
microdialysis was inhibited by local administration of mecamylamine into the
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ventral tegmental area (Sziraki et al., 2002). Thus, it seems plausible that in the
current study, peripherally administered nicotine may be acting at nicotinic
receptors at the level of the cell body to modulate DAT function at the terminal.
Furthermore, different nicotinic receptor subtypes expressed at the cell body may
be responsible for the different dose-response patterns observed in MPFC and
striatum with respect to DA clearance.

In both striatum and MPFC, the mechanism by which nicotine modulates
DAT function may be via nicotinic receptor-induced augmentation of DAT
trafficking to the presynaptic terminal membrane consistent with an increase in
DA clearance. The relatively rapid nicotine-induced increase in DA clearance
suggests that new synthesis of DAT protein is not responsible. Rather, the time
course of response is consistent with trafficking of intracellular stores of DAT
protein to the terminal membrane. Cocaine, another drug of abuse, has been
shown to dynamically regulate DAT function by increasing DAT trafficking to the
plasma membrane in cells expressing hDAT (Little et al., 2002). In contrast,
amphetamine diminished DAT localization at the plasma membrane in hDAT
expressing cells (Saunders et al., 2000) and in rat striatal dopaminergic terminals
(Fleckenstein et al., 1997). Investigation of the effect of nicotine on DAT
trafficking is warranted based on the enhanced DA clearance using in vivo
voltammetry in the current study.
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Due to the lower DAT density and decreased number of DAT per terminal
in MPFC compared to striatum, metabolism and diffusion likely play a larger role
in clearing DA from the extracellular space in MPFC under physiological
conditions. However, following pharmacological treatment with nicotine,
enhanced DAT function in MPFC would be predicted to have a large impact on
dopaminergic transmission. Nicotine enhancement of DAT function would result
in more efficient DA clearance from the extracellular space, and cortical function
would be disinhibited. Thus, the ability of nicotinic receptors to modulate DAT
function, and thereby extracellular DA concentration, may have physiological
importance with respect to nicotine enhancement of cognitive processes such as
attention, learning and memory, as well as important clinical relevance with
respect to schizophrenia and drug abuse.
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Figure 6. Schematic representation of the electrode micropipette
assembly. A micropipette filled with DA is attached to a nafion-coated electrode.
Following DA pressure ejection, DA is oxidized to para-ortho-quinone DA
releasing 2 electrons. The electrons are measured by the electrode and the
electrochemical signal is converted to a concentration measurement using the
IVEC-10 system allowing for determination of the DA concentration at the
electrode site.
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DA

Figure 7. Representative DA signals in striatum of urethane-anesthetized
rats prior to (top panel) and 45 min following nicotine or saline injection
(bottom panel). Reproducible electrochemical signals were obtained following
pressure ejection of DA (200 μM) and represent the baseline response (top
panel). Representative DA signals 45 min following injection of nicotine (NIC; 0.8
mg/kg, s.c.) or saline are represented by dashed and solid lines, respectively
(bottom panel). Data are expressed as μM DA as a function of time (sec) after
DA pressure ejection. DA concentrations were calculated based on calibration
curves generated in vitro.
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Figure 8. Dose-response for systemically administered nicotine to alter DA
signal amplitude (top panel), T80 (middle panel), and clearance rate (bottom
panel) in striatum of urethane-anesthetized rats. Nicotine in a dose-related
manner decreased signal amplitude, but did not significantly alter T80 or
clearance rate across 60-min recording sessions. After stable baseline signals
were obtained in response to pressure ejection of DA (200 μM) at 5-min intervals,
either a dose of nicotine (NIC; 0.1 – 0.8 mg/kg) or saline was injected s.c.
(indicated by the arrow), and pressure ejection of DA at 5-min intervals continued
for 60 min. Data are expressed as mean, S.E.M. as a percentage of the
respective baseline values as a function of time (min). Mean baseline values for
each parameter are provided in the Results section. (n = 5 - 8 rats/group)
* difference from saline control at the corresponding time point (p < 0.05); + first
time point at which nicotine decreased signal amplitude compared to the
corresponding basal.
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Figure 9. In a dose-related manner, nicotine decreased signal amplitude
cumulated across the 60-min sampling period. For each experiment, the
change in signal amplitude was cumulated across the 60-min period of
electrochemical recording in striatum. Data are expressed as mean + S.E.M. as
a percent of baseline. (n = 5 – 8 rats/group)
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Figure 10. Dose-response for systemically administered nicotine to alter
DA signal amplitude (top panel), T80 (middle panel) and clearance rate
(bottom panel) in MPFC of urethane-anesthetized rats. Nicotine in a doserelated manner decreased signal amplitude (top panel) and DA clearance rate
(bottom panel), but did not alter the T80 (middle panel) across the 60-min
recording session. After stable baseline signals were obtained in response to
pressure ejection of DA (200 μM) at 5-min intervals, either a dose of nicotine
(NIC; 0.1 – 0.8 mg/kg) or saline was injected s.c. (indicated by the arrow), and
DA pressure ejection continued at 5-min intervals for 60 min. Data are
expressed as mean, S.E.M. as a percentage of within-subject baseline values as
a function of time (min). Baseline values for each parameter are provided in the
Results section. (n = 5 - 7 rats/group) * difference from saline control at the
corresponding time point (p < 0.05); # difference from saline control at the
corresponding time point (p < 0.05; one-tailed);
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Figure 11. In a dose-related manner, nicotine decreased signal amplitude
cumulated across the 60-min sampling period. For each experiment, the
change in signal amplitude was cumulated across the 60 min period of
electrochemical recording in MPFC. Data are expressed as mean + S.E.M. as a
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Figure 12. Effect of mecamylamine to inhibit the nicotine-induced decrease
in signal amplitude in striatum. Signal amplitude is shown in the top panel; T80
and clearance rate are shown in middle and bottom panels, respectively, for
comparison. No significant differences in were observed in T80 or clearance rate.
After stable baseline signals were obtained in response to pressure ejection of
DA (200 μM) at 5-min intervals, either mecamylamine (MEC; 1.5 mg/kg) or saline
was injected s.c. and 40 min later nicotine (NIC; 0.8 mg/kg) or saline was injected
s.c.(second injection indicated by the arrow). DA continued to be pressure
ejected at 5-min intervals for 60 min following the second injection. Data are
expressed as mean, S.E.M. as a percentage of the respective baseline values as
a function of time (min). Baseline values for each parameter are indicated in the
Results section. Legend indicates treatment group designating first and second
injections. (n = 6 - 7 rats/group)
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Figure 13. Effect of mecamylamine to inhibit the nicotine-induced decrease
in signal amplitude in MPFC. Signal amplitude is shown in the top panel; T80
and clearance rate are shown in middle and bottom panels, respectively, for
comparison. No significant differences in were observed in T80 or clearance rate.
After stable baseline signals were obtained in response to pressure ejection of
DA (200 μM) at 5-min intervals, either mecamylamine (MEC; 1.5 mg/kg) or saline
was injected s.c. and 40 min later injected s.c. with nicotine (NIC; 0.4 mg/kg) or
saline (second injection indicated by the arrow). DA was pressure ejected at 5min intervals for 60 min following the second injection. Data are expressed as
mean, S.E.M. as a percentage of the respective baseline values as a function of
time (min). Baseline values for each parameter are indicated in the Results
section. Legend indicates treatment group designating first and second
injections. (n = 5 - 7 rats/group) * difference between Mecamylamine/Nicotine
group and Saline/Nicotine group at the corresponding time point (p < 0.05); #
difference between Mecamylamine/Nicotine group and Saline/Nicotine group at
the corresponding time point (p < 0.05; one-tailed); + first time point at which
nicotine decreased signal amplitude compared to the corresponding basal.
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Chapter Three
Nornicotine Decreases Dopamine Transporter Function In Vivo in Striatum
via a Nicotinic Recpetor-Mediated Mechanism
I. Introduction
Tobacco use is the number one preventable cause of death in the US
(USDHS, 1998), which has prompted the development of cessation
pharmacotherapies. Nicotine is believed to be the alkaloid in tobacco that is
primarily responsible for chronic tobacco use and dependence (Clarke, 1987;
Pomerleau and Pomerleau, 1992). Activation of nicotinic receptors by nicotine
results in an increase in the extracellular DA concentrations in brain, which is
generally accepted as mediating at least in part, reward produced by nicotine,
which subsequently leads to tobacco dependence (Koob, 1992; Corrigall et al.,
1992; Stolerman and Jarvis, 1995). The mesocorticolimbic and nigrostriatal DA
systems, including the nucleus accumbens, medial prefrontal cortex and striatum
and the associated circuitry, have been implicated in drug-induced reward. The
nucleus accumbens shell is believed to encode primary appetitive stimuli
associated with unconditioned drug reward (Wise and Bozarth, 1987; Bardo,
1998; Koob, 1999; Kelley and Berridge, 2002), including reward produced by
nicotine (Fibiger and Phillips, 1987; Corrigall et al., 1992; Mansvelder and
McGehee, 2002; Mathieu-Kia et al., 2002). The medial prefrontal cortex encodes
secondary conditioned stimuli associated with environmental cues paired with
drug, integrating sensory information and leading to reward expectancy,
recognized as important to the addiction process and to relapse to drug use
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(Berridge and Robinson, 1998; Shima and Tanji, 1998; Kelley and Berridge,
2002; DiChiara et al., 2004; Rose and Behm, 2004; Brody et al., 2004).
Integration of the motivational information from medial prefrontal cortex occurs at
least in part in striatum leading to the initiation and execution of movement in
reward expectancy and detection of reward (Martin-Soelch et al., 2001). In
smokers, nicotine dose-dependently increases neuronal activity in these brain
regions assessed using fMRI and PET (Stein et al., 1998; Barrett et al., 2004).

Current tobacco use cessation pharmacotherapies (i.e., bupropion and
nicotine) have demonstrated only limited efficacy, since relapse rates are
reported to be high (Hurt et al., 2003; George and O’Malley, 2004; Wileyto et al.,
2004), indicating a need for the development of alternative, more efficacious
smoking cessation therapies. Bupropion acts as an inhibitor of neurotransmitter
transporters resulting in increased extracellular DA concentrations (Richelson
and Pfenning; 1984; Nomikos et al., 1989; Ascher et al., 1995; Li et al., 2002;
Damaj et al., 2004). Recently, bupropion has been reported to also act as a
nicotinic receptor antagonist within the same concentration range that it inhibits
neurotransmitter transporter function (Fryer and Lukas, 1999; Slemmer et al.,
2000; Miller et al., 2002; Gumilar et al., 2003; Damaj et al., 2004). The use of
nicotine replacement as a cessation therapy is based on activation of nicotinic
receptors resulting in DA release. Nicotine-induced DA release is concentrationdependent and observed in presynaptic terminal regions in both the mesolimbic
(Imperato et al., 1986; Rowell et al., 1987; Clarke et al., 1988; Vezina et al., 1992;
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Wonnacott, 1997) and nigrostriatal (Westfall et al., 1983; Teng et al., 1997;
Wonnacott, 1997; Kaiser et al., 1998; Dwoskin et al., 1999; Vezina et al., 1992)
DA systems in both in vivo and in vitro studies. This effect of nicotine is inhibited
by mecamylamine, a nonselective and noncompetitive nicotinic receptor
antagonist (Mifsud et al., 1989; Nisell et al., 1994a; Sacaan et al., 1995; Teng et
al., 1997).

Extracellular DA concentrations are the net result of DA release from the
presynaptic terminal and DA uptake back into the terminal by the DA transporter
(DAT). Systemic administration of nicotine has been shown to modulate DAT
function in vivo in striatum, nucleus accumbens and medial prefrontal cortex,
resulting in an increase in DA clearance (Ksir et al., 1995; Hart and Ksir, 1996;
Middleton et al., 2004). Nicotine enhancement of DAT function is mediated by
nicotinic receptors, as indicated by mecamylamine inhibition of this effect
(Middleton, et al., 2004). Considering that DAT function is inhibited by membrane
depolarization (Sonders et al., 1997; Huang et al., 1999), it is surprising that
nicotine, which depolarizes neurons, enhances DAT function. The nicotineinduced increase in DA release and the concurrent enhancement of DAT function
appear to produce a sharpened DA signal. In contrast, when synaptosomes from
drug-naïve rats are exposed to nicotine, DAT function is not altered (Zhu et al.,
2003), suggesting that nicotine acts at nicotinic receptors located at sites other
than on DA terminals to modulate DAT function.
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Attention has focused on the N-demethylated nicotine metabolite and
minor tobacco alkaloid, nornicotine, as contributing to the neuropharmacological
effects of nicotine exposure and tobacco use (Crooks and Dwoskin, 1997).
Nornicotine inhibits [3H]nicotine binding to rat brain membranes with a 50-fold
lower affinity (Ki = 47 nM) compared with nicotine (Ki = 1.0 nM) (Reavill et al.,
1988; Copeland et al., 1991; Zhang and Nordberg, 1993; Xu et al., 2001). In
contrast, nicotine and nornicotine exhibit similar affinities for the
[3H]methyllycaconitine binding site (Ki = 770 nM and 1340 nM, respectively) in
brain (Xu et al., 2001). These results indicate interaction of these alkaloids with
both α4β2* and α7* nicotinic receptors. Similar to nicotine, nornicotine evokes a
concentration-dependent, Ca2+-dependent and mecamylamine-sensitive increase
in DA release from rat striatal and nucleus accumbens slices (Dwoskin et al.,
1993; Teng et al., 1997; Green et al., 2001), indicating that nornicotine acts as an
agonist at nicotinic receptor subtypes modulating DA release. In the latter
studies, whereas nicotine and nornicotine were equipotent in releasing DA from
striatal slices, nicotine was 43-fold more potent than nornicotine (EC50 = 70 nM
and 3.0 μM, respectively) in releasing DA from nucleus accumbens slices. It is
interesting to note that nornicotine has a longer half-life than nicotine in plasma
and brain (Kyerematen et al., 1990; Crooks et al., 1995, 1997; Ghosheh et al.,
2001); and following chronic treatment with nicotine, nornicotine accumulates in
brain reaching pharmacologically relevant concentrations (Ghosheh et al., 2001).
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In order to more fully elucidate the pharmacological actions of nornicotine,
the ability of nornicotine to modulate striatal DAT function was assessed using in
vivo voltammetry and in vitro synaptosomal [3H]DA uptake. The hypothesis is
that nornicotine, similar to nicotine, will increase DA clearance in the striatum via
a nicotinic receptor-mediated mechanism. Thus, the current study provides
preclinical data on the pharmacology of nornicotine and provides additional
information to assess its potential utility as a new tobacco use cessation agent.

II. Methods
IIa. Chemicals.
[3H]DA (3,4-ethyl-2-[N-3H]-dihydroxyphenylethylamine; specific
activity, 27.1 Ci/mmol) was purchased from PerkinElmer Life Science (Boston,
MA). S(-)-Nornicotine was prepared as previously described (Swango et al.,
1999), and was utilized as the perchlorate salt. S(-)-Nicotine di–d-tartrate,
mecamylamine hydrochloride, nomifensine maleate, catechol, pargyline HCl, Dglucose, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) and
bovine serum albumin (BSA) were purchased from Sigma/RBI (Natick, MA).
Sodium chloride, potassium phosphate, potassium chloride, magnesium sulfate,
calcium chloride, and disodium ethylenediamine tetraacetate used in the
preparation of the uptake assay buffer were purchased from Fisher Scientific
International Inc. (Pittsburgh, PA).

IIb. Subjects
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Male Sprague Dawley rats (200–250 g) were obtained from Harlan
Laboratories (Indianapolis, IN) and were housed two per cage with free access to
food and water in the Division of Lab Animal Resources at the College of
Pharmacy, University of Kentucky. Experimental protocols involving the animals
were in strict accord with the NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Committee
at the University of Kentucky.

IIc. DAT Function In Vivo.
Electrochemical electrodes were prepared and experiments conducted
using previously described methods (Middleton et al., 2004). Electrodes
contained a single carbon fiber (33 μm diameter) in a pulled glass capillary (4
mm outer diameter, 0.80 mm wall diameter). The exposed carbon fiber extended
50-150 μm beyond the tip of the glass capillary. Electrodes for some
experiments were purchased from Quanteon (Lexington, KY). To enhance
selectivity for DA, the carbon fiber electrode was coated with Nafion polymer (5%
solution, 6-8 coats). Electrodes were calibrated in vitro to determine the
sensitivity and selectivity for DA. Calibration curves were generated using a
range of DA concentrations (1.0 – 10 μM, at 22 °C in 0.1 M phosphate buffered
saline solution, pH 4.0). Electrodes were sensitive to DA and the mean
selectivity ratio of DA/ascorbic acid was 606 ± 71 to 1 (n = 57). Subsequently,
each carbon fiber electrode was attached to a single barrel micropipette (tip
diameter of 10-15 μm) with dental wax. The tips of the electrode and
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micropipette were positioned 250 - 300 μm apart. Micropipettes were prepared
from monofilament glass (1.0 mm O.D., 0.58 mm I.D.) using a vertical pipette
puller (Model 720, David Kopf Instruments, Tujunga, CA). Single barreled
micropipettes were filled with DA (200 μM, in 154 mM NaCl and 100 μM ascorbic
acid, pH 7.4) immediately before conducting the experiment. The concentration
of DA for ejection was chosen based on the linear kinetics of DA uptake at this
concentration, i.e., DA concentrations that do not saturate DAT in striatum
(Zahniser et al., 1999).

Rats were anesthetized with urethane (1.25 - 1.5 g/kg, i.p.) and placed
into a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA). Body
temperature was maintained at 37 °C with a heating pad coupled to a rectal
thermometer (Harvard Apparatus, Holliston, MA). The scalp was reflected, and a
section of the skull and dura overlying the frontal cortex was removed. A small
hole was drilled in the skull above the posterior cortex for placement of two
Ag/AgCl reference electrodes, which were cemented into place with dental
acrylic. The electrode/micropipette assembly was lowered into the dorsal striatum
(1.5 mm anterior to bregma, 2.3 mm lateral from midline, and 4.0 - 5.5 mm below
the surface of the cortex) according to the rat brain atlas of Paxinos and Watson
(1986). Exogenous DA was pressure ejected (30 - 50 psi, 0.05 ms – 2.5 s) at 5min intervals using a Picosprizter II (General Valve Corporation, Fairfield, NJ),
until reproducible baseline signals (variation in signal amplitude < ± 10%) were
obtained. Using a stereomicroscope fitted with a reticule in one eyepiece,
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ejection volume (250 nl/mm) was monitored by measurement of the fluid
displaced from the micropipette. High-speed chronoamperometric
electrochemical measurements were made continuously (5 times/s, 5 Hz and
averaged to 1 Hz), using an electrochemical recording system (IVEC 10; Medical
Systems Corporation, Greenvale, NY). The oxidation potential was a square
wave of +0.55 volts applied for 100 ms (versus the Ag/AgCl reference electrode),
and the resting potential was 0.0 volts for 100 ms. Oxidation currents were
digitally integrated during the last 80 ms of each 100-ms pulse.

Dose-response curves for nornicotine modulation of DAT function in
striatum were generated, and each animal received only one dose of nornicotine
(0, 0.35 – 12.0 mg/kg, s.c.). Data for the nornicotine dose-response were
collected as part of a larger study in which the dose-response for nicotine was
also determined (Middleton et al., 2004). As such, the saline condition was used
as the control for both nicotine and nornicotine dose-response analyses.
Nornicotine or vehicle (0.9% saline) was administered once reproducible
baseline signals were obtained. Pressure ejection of DA continued at 5-min
intervals for 60 min following nornicotine or saline injection.

To determine if nicotinic receptors mediate the response to nornicotine on
DA clearance in striatum, the effect of mecamylamine was determined in
separate experiments. Once reproducible baseline signals were obtained, rats
were injected s.c. with either mecamylamine (1.5 mg/kg) or saline, followed 40
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min later by a second s.c. injection of nornicotine (8.0 mg/kg) or saline.
Nornicotine dose was chosen based on the dose-response curves generated in
the above experiments, i.e., maximal inhibition of DAT function was observed at
8.0 mg/kg. The mecamylamine dose was chosen based on its ability to inhibit
the acute locomotor stimulant effects of nicotine (Miller et al., 2001). DA was
pressure ejected every 5 min during the 40 min period following the first s.c.
injection and for 60 min following the second s.c. injection. Doses of nornicotine
represent the perchlorate salt weight, and the injection volume was 1 ml/kg body
weight.

IId. [3H]DA Uptake Assay.
[3H]DA uptake assays were performed using rat striatal synaptosomes as
previously described (Teng et al., 1997). Striata from individual rats were
homogenized in 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM
NaHCO3, pH 7.4) with 14 passes of a Teflon pestle homogenizer (clearance
0.003 inches). Homogenates were centrifuged (2000g, 10 min, 4°C), and
resulting supernatants were centrifuged (20,000g, 15 min, 4°C). Pellets were
resuspended in 2.4 ml of ice-cold assay buffer (125 mM NaCl, 5 mM KCl, 1.5 mM
MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM -D-glucose, 25 mM HEPES,
0.1 mM EDTA, 0.1 mM pargyline, and 0.1 mM ascorbic acid, saturated with 95%
O2/5% CO2, pH 7.4). Final protein concentration was 20 µg/ml. Assays were
performed in duplicate in a total volume of 500 µl. Aliquot parts of synaptosomal
suspension (50 µl) were added to tubes containing 350 µl of buffer and 50 µl of
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one of nine concentrations of nornicotine or nicotine followed by 50 µl of [3H]DA
(final concentration, 0.1 µM). Accumulation proceeded for 10 min at 34°C, and
was terminated by addition of 3 ml of ice-cold buffer containing catechol (1 mM),
followed by rapid filtration through Whatman GF/B glass fiber filters presoaked
with catechol (1 mM). Filters were washed three times with ice-cold buffer,
transferred to scintillation vials and radioactivity determined.

IIc. Data Analysis
In vivo voltammetry data are represented as mean values + SEM, and n
represents the number of animals in a treatment group. Three parameters were
determined from the DA oxidation currents; Amax, which is defined by the maximal
change in extracellular DA concentration; T80, the time for the signal to decay by
80% minus the rise time of the signal; and DA clearance rate (CLDA), which
provides a measure of the efficiency of DAT to remove DA from the extracellular
space and is defined as the amount of DA pressure ejected, divided by the area
under the curve for the DA signal (AUCDA). AUC DA was determined by fitting the
decay segment of each DA signal trace following the maximal DA signal
amplitude to the following equation: AUCDA = Σ (yi + yi+1 / 2)*(ti+1- ti); where y is
the amplitude of the DA signal (micromolar concentration) at any time (t,
seconds) following DA ejection, and i is initial amplitude of the DA signal trace at
time zero. AUCDA of the decay segments of DA signals in striatum were
determined for the duration of the signal. Thus, CLDA (L/sec) for each DA signal
was derived from the amount of ejected DA (moles) divided by the AUCDA
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(moles/L/sec) for each DA signal. Figure 14 shows a representative baseline
signal from striatum and illustrates the parameters utilized to assess DA
clearance. Amax is influenced by the clearance at the point in time at peak DA
concentration. CLDA is a time-averaged estimate over the entire interval of the DA
signal. Thus, the observed changes in Amax and CLDA following nornicotine
injection may not be equivalent.

Nornicotine dose-response curve and time course were analyzed by twoway mixed-factor ANOVA, with dose as a between-groups factor and time as
within-subjects factor. A separate ANOVA was performed to analyze the time
course for each of the three parameters, Amax, T80 and CLDA. To determine the
dose-related effect of nornicotine, one-way ANOVAs were conducted on the Amax
and CLDA data at each 5-min time point during the 10-60 min period following
nornicotine injection. Dunnett’s post hoc analysis was performed to determine
differences between treatment means and control mean. Additionally, apriori
specific within-subject contrasts determined the time point at which nornicotine
increased Amax and decreased CLDA compared to baseline (i.e., prior to drug
injection).

Analysis of mecamylamine-induced inhibition of the effect of nornicotine
on Amax, T80 and CLDA was accomplished using separate three-way mixed-factor
ANOVAs, with mecamylamine and nornicotine as between-group factors and
time as a within-subjects factor. One-way ANOVAs were utilized to assess the
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effect of nornicotine and mecamylamine at individual time points. Additionally,
apriori specific within-subjects contrasts were performed for each group to
determine the time point at which Amax and CLDA increased compared to
baseline. ANOVA, specific contrasts and post hoc analyses were performed
using SPSS (standard version 11.0, Chicago, IL); p < 0.05 two-tailed was
considered significant, unless otherwise indicated.

For [3H]DA uptake assays, to generate IC50 values for each concentrationresponse curve nonlinear regression with sigmoidal curve fit were used
(GraphPad Prism, version 3.0; GraphPad Software, San Diego, CA).

III. Results
IIIa. Effect of nornicotine on DAT function.
In the previous chapter data were calculated according to methods
reported in the literature (Chapter One: Figure 8). To compare the effect of
nornicotine on CLDA to the effect of nicotine on CLDA, data from Figure 8 (bottom
panel) were re-analyzed using the classical pharmacokinetic measure of DA
clearance described in the Methods section. Following systemic administration,
nicotine increases CLDA in striatum (Figure 15). Nicotine in a dose-related
manner increased CLDA across 55-min recording sessions. Two way repeated
measures ANOVA revealed a significant dose x time interaction (F24,156 = 4.87, p
< 0.001). Dunnett’s post hoc analysis determined that the nicotine (0.8 mg/kg)
group was significantly (p < 0.02) different from the saline control group. After
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stable baseline signals were obtained in response to pressure ejection of DA
(200 μM) at 5-min intervals, either a dose of nicotine (0.6 or 0.8 mg/kg) or saline
was injected s.c., and pressure ejection of DA at 5-min intervals continued for 60
min. Compared to the previous method of calculating DA clearance in Figure 8
(Chapter One), the graphical presentation shows the curve projected upward
reflecting an increase in DA clearance (increased CLDA).

The effect of systemic administration of nornicotine (0.35 – 12.0 mg/kg) on
exogenous DA clearance was determined in the medial dorsal striatum of
urethane-anesthetized rats using in vivo voltammetry. Pressure ejection of 200
μM DA into the striatum at 5-min intervals resulted in stable baseline signals, with
an Amax of 3.90 μM (± 0.24 μM; mean ± SEM), T80 value of 29.9 s (± 4.09 s) and
CLDA of 3.54 x 10-8 L/sec (± 0.61 x 10-8 L/sec; n = 32 independent experiments).
Once the baseline signal stabilized, rats were injected with either a dose of
nornicotine or saline (control); pressure ejection of DA was continued at 5-min
intervals for 60 min. The effect of nornicotine on Amax, T80 and CLDA was
determined and compared to that obtained after saline injection. Rise time,
duration and decay of the baseline DA signal were not different between
nornicotine- and saline-treated rats.

The dose response for nornicotine-induced modulation of DAT function in
striatum was determined and the results are shown in Figure 16. Amax, T80 and
CLDA were analyzed using separate two-way ANOVAs. With respect to Amax and
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CLDA, significant interactions of dose and time were found (F52,351 = 3.58, p <
0.001 and F52,364 = 1.41, p< 0.05; respectively). No significant main effects or
interactions were observed for T80. To further analyze the interaction for Amax,
separate one-way ANOVAs were conducted on the data at each 5-min time point
beginning 10 min after injection of nornicotine or saline (Figure 16, top panel). A
nornicotine dose-related increase in Amax was observed; such that significant
effects of the 8 mg/kg dose of nornicotine were found at 15-40 min and of the 12
mg/kg dose at 10-60 min (ps < 0.05). Within subject comparisons revealed that
the Amax for the saline control group gradually decreased by ~15% of baseline
during the 55-min period after injection; however, at the 60-min time point, the
decrease (~23%) in Amax reached significance. To determine the onset of the
effect of nornicotine, specific within-subjects contrasts were performed
comparing Amax at each time point following nornicotine injection to Amax at
baseline. A significant increase in Amax was observed 20 min following both the
8.0 and 12.0 mg/kg doses of nornicotine (p < 0.05). Amax was increased by a
maximum of 43% of baseline after the highest dose of nornicotine at the 60 min
time point.

One-way ANOVAs were conducted also on the CLDA data to assess the
dose-response at each 5-min time point after nornicotine or saline injection
(Figure 16, bottom panel). For the group administered saline, CLDA gradually
increased by ~25% of baseline across the time course of the session,
demonstrating that DA application at 5-min intervals across the 60-min session
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resulted in a small increase in DAT function in the control condition. Nornicotine
dose-related decreases in CLDA were observed at 15, 25-45 and 55-60 min (ps <
0.05). Dunnett’s post hoc analysis revealed that CLDA was decreased from 25-45
min in the 8 mg/kg group and at 15, 25-45 and 55-60 min in the 12 mg/kg group
compared to the control group. Onset of the effect of nornicotine after the 8.0
and 12.0 mg/kg doses on CLDA occurred at 20 and 25 min respectively, following
administration. A maximum decrease of 30% was observed after 12 mg/kg,
when compared to the within-subject baseline response. Comparing the
nornicotine dose-response curves for Amax and CLDA reveals that the percent
increase in Amax was similar to the percent decrease in CLDA, suggesting similar
kinetics over the time course of ~ 60 sec (Figure 16).

To ascertain if the effect of nornicotine on DAT function was mediated by
nicotinic receptors, the ability of mecamylamine to inhibit nornicotine-induced
modulation of Amax, T80 and CLDA was determined. Pressure ejection of DA (200
μM) resulted in an Amax of 5.78 μM (± 0.58 μM; mean ± SEM), T80 value of 17.4 s
(± 3.49s), and CLDA value of 4.82 x 10-8 L/sec (± 0.80 x 10-8 L/sec; n = 25
independent experiments). Once the baseline signals stabilized, groups of rats
were injected with mecamylamine (1.5 mg/kg, s.c.) or saline, and 40 min later
with nornicotine (8 mg/kg, s.c.) or saline. DA pressure ejection continued at 5min intervals for 40 min after the first injection and at 5-min intervals for 60 min
after the second injection. Data for the three parameters of DA clearance for
these experiments are illustrated in Figure 17.
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Three-way ANOVAs on Amax, T80 and CLDA data were performed to
determine if mecamylamine inhibited the effect of nornicotine on DAT function. A
significant three-way interaction of mecamylamine x nornicotine x time was found
(F13,325 = 4.04, p < 0.001 and F13,325 = 2.47, p < 0.01) for Amax and CLDA,
respectively. No significant interactions or main effects were observed for T80. In
the control group injected only with saline, Amax tended to decrease across the
60-min session when compared to its baseline; and significance was reached at
45 min following the second saline injection. For the group administered
mecamylamine and saline, no differences were observed across the time course
of the session when compared to within-subject baseline response, indicating
that mecamylamine alone had no effect on Amax. For the group administered
saline and nornicotine, the onset of the nornicotine-induced increase in Amax
occurred 25 min after the nornicotine injection (within-subject comparison, p <
0.05). At the 60-min time point, nornicotine maximally increased Amax by 32%
compared to baseline. To determine if mecamylamine inhibited the effect of
nornicotine, one-way ANOVAs were performed to compare the treatment groups
at each time point, beginning at the onset of the nornicotine effect (i.e., from 2560 min). From 45-60 min, Amax for the group administered mecamylamine and
nornicotine was significantly less than that for the group administered saline and
nornicotine (p < 0.05), and not different from the group administered only saline,
indicating that mecamylamine completely inhibited the effect of nornicotine.
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Similar results were obtained when the CLDA parameter was analyzed
(Figure 17, bottom panel). As in the previous experiments described above, oneway ANOVA comparing the groups at each time point revealed that CLDA for the
group administered saline and nornicotine was lower at 15-25, 35, 45, and 55
min than that for the control group administered only saline (p < 0.05, one tailed).
Moreover, CLDA for the group administered saline and nornicotine was lower than
the group administered mecamylamine and nornicotine across the same time
period. Importantly, the group administered mecamylamine and nornicotine was
not different from the control group only administered saline, indicating that
mecamylamine completely inhibited the effect of nornicotine.

Comparing the percent change in Amax and CLDA for the group
administered mecamylamine and saline and for the group administered saline
and nornicotine revealed similar percentage changes. However, comparison of
the percentage change in Amax and CLDA for the saline control group and for the
group administered mecamylamine and nornicotine revealed a decrease in Amax
of 20% for each group, whereas CLDA increased 50% and 60%, respectively.
These results appear to be due to greater variability in the CLDA estimates
relative to the estimate for Amax.

To determine if nicotine and nornicotine were acting at nicotinic receptors
located on DA nerve terminals to inhibit DAT function, the [3H]DA uptake assay
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was performed using striatal synaptosomes from drug-naïve rats. [3H]DA uptake
was not inhibited by either nicotine or nornicotine (IC50 > 100 μM; Table 1).

IV. DISCUSSION

Results from the current in vivo voltammetry study show that systemic
administration of nornicotine decreased DA clearance in striatum in a doserelated manner, demonstrating that nornicotine inhibits striatal DAT function. The
nornicotine-induced decrease in DA clearance was inhibited completely by
mecamylamine, a noncompetitive and nonselective nicotinic receptor antagonist,
indicating that this effect of nornicotine on DAT function is mediated by nicotinic
receptors. In contrast, nornicotine did not inhibit [3H]DA uptake into striatal
synaptosomes obtained from drug-naïve rats. Taken together, these results
suggest that nornicotine activates nicotinic receptors which are located at sites
other than on DA nerve terminals in striatum to inhibit DAT function in vivo.
In the current studies mecamylamine was chosen as the nicotinic receptor
antagonist to show nicotinic receptor mediation of the effect of nornicotine. The
hallmark of an action at nicotinic receptors is blockade by mecamylamine. This
is the first approach that the majority of studies use to show nicotinic receptor
involvement (Meyer et al., 1997; Papke et al., 2001; Middleton et al., 2004;
Damaj et al., 2005; Levin et al., 2005; Sacco et al., 2005). It will be interesting in
future studies to examine the effects of subtype selective antagonists on the
nornicotine-induced decrease in DA clearance.
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Previous studies have shown that nicotine and nornicotine evoke DA
release from rat striatal slices (Dwoskin et al., 1993; Teng et al., 1997;
Puttfarcken et al., 2000; Wonnacott et al., 2000; Green et al., 2001).
Furthermore, in a dose-related manner, nicotine enhances DAT function in
striatum, as demonstrated by increased DA clearance using in vivo voltammetry
(Middleton et al., 2004). In contrast to nicotine, the current study shows that
nornicotine decreases DA clearance in vivo using the same methodological
preparation. The observation that nornicotine exhibits antipodal effects
compared to nicotine with respect to DAT function in vivo was unexpected and
does not support the hypothesis. Potential mechanisms underlying the diametric
effects of nicotine and nornicotine on DAT function may be due to the
involvement of different nicotinic receptor subtypes modulating DAT function
and/or may be associated with differential neural circuitry (see Chapter Six for
further discussion).
The current study also shows that both nornicotine and nicotine have no
effect on [3H]DA uptake into striatal synaptosomes, which is consistent with
previous reports determining the effect of nicotine in vitro (Carr et al., 1989; Zhu
et al., 2003). Taken together with the results from the in vivo voltammetry
studies, these findings suggest that the nicotinic receptors mediating DAT
function in vivo are located on dopaminergic cell bodies in the substantia nigra or
in brain regions other than striatum. However, procedural differences between
the in vivo and in vitro preparations, such as the use of the urethane anesthetic in
vivo, may also contribute to the differential results obtained. Evidence supporting
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a critical role for nicotinic receptors at the level of the dopaminergic cell body is
provided from studies in which local administration of nicotine into the substantia
nigra or ventral tegmental area evokes DA release in striatum and nucleus
accumbens, respectively (Blaha and Winn, 1993; Nisell et al., 1994b; Panagis et
al., 1996; Sziraki et al., 2002). Additionally, local administration of
mecamylamine into the ventral tegmental area was shown to inhibit DA release
in the nucleus accumbens following peripheral administration of nicotine (Sziraki
et al., 2002). Thus, as has been suggested for nicotine, nicotinic receptors at the
level of the substantia nigra may be involved in modulating DAT function in
striatum following peripheral nornicotine administration.

DA cell bodies in substantia nigra have mRNAs that express multiple
nicotinic receptor subunits (α2- α7 and β2- β4; Klink et al., 2001; Azam et al.,
2002; Zoli et al., 2002; Wooltorton et al., 2003). The specific nicotinic receptor
subtypes expressed by nigrostriatal neurons are defined by specific combinations
of subunits expressed. Pair-wise expression of nicotinic receptor subunits in
Xenopus oocytes initially revealed characteristic pharmacological profiles, i.e.,
relative sensitivity and responsiveness to a range of nicotinic agonists and
antagonists (Luetje and Patrick, 1991). Furthermore, inclusion of a third type of
subunit (e.g., α5 with α3 and β2) in cell expression systems resulted in an altered
responsiveness (i.e., calcium permeability and desensitization characteristics)
when compared with pair-wise subunit expression (Gerzanich et al., 1998).
Moreover, patch-clamp results from neurons in midbrain slices revealed four
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different patterns of nicotinic receptor-mediated currents, suggesting stimulation
of structurally complex native nicotinic receptors potentially containing
combinations of as many as four different subunits (Klink et al, 2001).
Furthermore, nicotinic receptor subtypes expressed at the level of the substantia
nigra may be different from those at the terminals in striatum (Klink et al., 2001;
Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003), which also could
explain the lack of nornicotine inhibition of DA uptake using striatal
synaptosomes. More than one nicotinic receptor subtype has been suggested to
mediate nicotine-evoked DA release in striatum (Kulak et al., 1997; Kaiser et al.,
1998; Dwoskin et al., 2004). The current evidence provides the first report that
more than one nicotinic receptor subtype may mediate DAT function, since
nicotine and nornicotine both mediate DAT function but in a qualitatively different
manner.

Nicotine is an effective pharmacotherapy for the cessation of tobacco
smoking when used alone or in combination with other drugs or clinical programs
(Po, 1993; Rose et al., 1994; Balfour and Fagerstrom, 1996; Glover and Glover,
2001; Karnath, 2002). However, despite efficacy with nicotine replacement, the
majority of smokers continue to relapse, suggesting that more efficacious
therapeutic agents are needed. Nornicotine may offer a beneficial alternative to
nicotine as a tobacco use cessation agent. The pharmacokinetic profile of
nornicotine, with its longer half-life and slower clearance compared to nicotine
(Kyerematen et al., 1990; Crooks and Dwoskin, 1997; Ghosheh et al., 1999), may
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afford additional advantages over nicotine. Furthermore, since nornicotine is
significantly less potent than nicotine in increasing blood pressure and heart rate
(Mattila, 1963; Risner et al., 1988; Stairs et al., submitted 2005), the safety index
for nornicotine may be greater than that for nicotine, especially among smokers
with advanced cardiovascular disease. Moreover, the ability of nornicotine to
decrease DAT function in vivo, as shown in the present study, may afford another
advantage over nicotine as a tobacco use cessation agent. In this respect, the
antidepressant agent, bupropion, which inhibits both DAT and norepinephrine
transporter function (Ascher et al., 1995), has been shown to be efficacious as a
tobacco smoking cessation agent (Hurt et al., 1997; Jorenby et al., 1999;
Shiffman et al., 2000). Thus, nornicotine incorporates both inhibition of DAT
function and promotion of DA release properties into one molecule, and these
pharmacological effects have been associated with the clinical efficacy of the
currently available tobacco cessation products, nicotine and bupropion.

Behavioral studies using animal models also provide support for the use of
nornicotine as a tobacco use cessation agent. Nornicotine produces nicotine-like
discriminative stimulus effects (Rosecrans and Meltzer, 1981; Goldberg, et al.,
1989; Bardo et al., 1997; Desai et al., 1999), as well as nicotine-like effects on
schedule-controlled operant responding (Risner et al., 1985; 1988). Recent
results indicate that nornicotine functions as a positive reinforcer (Bardo et al.,
1999); however, under similar experimental conditions, nornicotine is associated
with a lower rate of responding in comparison with nicotine (Corrigall and Coen,
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1989; Donny et al., 1995; Bardo et al., 1999), suggesting that nornicotine has a
lower reinforcing efficacy. Moreover, nornicotine has been shown to decrease
self-administration of nicotine in rats (Green et al., 2000). Furthermore, across
repeated nornicotine pretreatments, tolerance did not develop to nornicotineinduced decrease in nicotine self-administration. Thus, a simple structural
change, i.e., removal of the N-methyl group from the pyrrolidine ring nitrogen of
nicotine which affords nornicotine, causes a profound change in its effect on DAT
function, which may be beneficial with respect to its pharmacological profile. In
summary, the current preclinical results suggest that nornicotine could be a
promising candidate for development as a smoking cessation agent.
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Figure 14. Representative baseline DA signal in striatum of urethaneanesthetized rats prior to nicotine or saline challenge. Electrochemical
signals were obtained following pressure ejection of DA (200 μM) and represent
the baseline response. Three parameters are obtained from each DA signal;
Amax, T80 and CLDA. Data are expressed as μM DA as a function of time (sec)
after DA pressure ejection. DA concentrations were calculated based on
calibration curves generated in vitro.
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Figure 15. Following systemic administration, nicotine increases CLDA in
striatum. Nicotine in a dose-related manner increased CLDA across 55-min
recording sessions. After stable baseline signals were obtained in response to
pressure ejection of DA (200 μM) at 5-min intervals, either a dose of nicotine (0.6
or 0.8 mg/kg) or saline was injected s.c. (indicated by the arrow), and pressure
ejection of DA at 5-min intervals continued for 60 min. Data are expressed as
mean, S.E.M. as a percentage of the respective baseline values as a function of
time (min). (n = 4 - 7 rats/group) *indicates significant difference from control.
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Figure 16. Dose-response for systemically administered nornicotine to
alter DA signal amplitude (top panel), T80 (middle panel), and CLDA (bottom
panel) in striatum of urethane-anesthetized rats. Nornicotine in a doserelated manner increased signal amplitude and decreased CLDA, but did not
significantly alter T80 across 60-min recording sessions. After stable baseline
signals were obtained in response to pressure ejection of DA (200 μM) at 5-min
intervals, either a dose of nornicotine (0.35 – 12.0 mg/kg) or saline was injected
s.c. (indicated by the arrow), and pressure ejection of DA at 5-min intervals
continued for 60 min. Data are expressed as mean + SEM as a percentage of
the respective baseline values as a function of time (min). Mean baseline values
for each parameter are provided in the Results section. *indicates significant
difference between the norNIC (8.0 mg/kg) group and saline; # indicates
significant difference between the norNIC (12.0 mg/kg) group and saline; norNIC,
nornicotine; n = 6 - 7 rats/group.
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Figure 17. Effect of mecamylamine to inhibit the nornicotine-induced
increase in signal amplitude in striatum. Signal amplitude is shown in the top
panel; T80 and CLDA are shown in middle and bottom panels, respectively, for
comparison. After stable baseline signals were obtained in response to pressure
ejection of DA (200 μM) at 5-min intervals, either mecamylamine (1.5 mg/kg) or
saline was injected s.c., and 40 min later nornicotine (8.0 mg/kg) or saline was
injected s.c.(second injection indicated by the arrow). DA continued to be
pressure ejected at 5-min intervals for 60 min following the second injection.
Data are expressed as mean + SEM as a percentage of the respective baseline
values as a function of time (min). Baseline values for each parameter are
indicated in the Results section. Legend indicates treatment group designated
as first/second injection: saline/saline, saline/nornicotine, mecamylamine/saline
and mecamylamine/nornicotine groups. norNIC, nornicotine; MEC,
mecamylamine; *indicates significant difference between the saline,norNIC group
and mec-norNIC group; n = 7 - 9 rats/group.
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Table 1. Nicotine and nornicotine do not inhibit [3H]DA uptake into striatal
synaptosomes.

[3H]DA Uptake (pmol/min/mg)
mean ± S.E.M.
Drug

Control

1 nM

10 nM

100 nM

1 µM

10 µM

100 µM

Nicotine

18.6±1.9

16.6±1.6

17.4±2.6

18.2±2.4

18.0±1.8

17.6±1.8

15.2±1.3

Nornicotine

10.9±1.6

10.2±1.7

10.9±1.8

10.6±1.4

10.8±1.4

10.4±1.0

10.7±1.1
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Chapter Four
Tolerance Develops to the Nicotine-Induced Increase
in Dopamine Transporter Function
I. Introduction
Nicotine is generally accepted to be the active alkaloid in tobacco
responsible for the reinforcing effects of tobacco (Clarke, 1987; Pomerleau and
Pomerleau, 1992). The mesocorticolimbic DA system has been implicated in the
rewarding properties of drugs of abuse leading to addiction (Tzschentke, 2001).
Dependence liability for nicotine stems from its intrinsic reinforcing properties and
the result of activation of DA pathways in brain (Fibiger and Phillips, 1987;
Corrigall et al., 1992, 1994; Balfour and Benwell, 1993). The mesocorticolimbic
and nigrostriatal DA systems, including the nucleus accumbens, MPFC and
striatum and the associated circuitry, have been implicated in drug-induced
reward. The nucleus accumbens shell encodes primary appetitive stimuli
associated with unconditioned drug reward (Kelley and Berridge, 2002), including
that produced by nicotine (Corrigall et al., 1992; Mathieu-Kia et al., 2002). The
MPFC encodes secondary conditioned stimuli associated with environmental
cues which have been paired with drug, and integration of the motivational
information from MPFC occurs at least in part in striatum leading to the initiation
and execution of movement in expectancy and detection of reward (Kelley and
Berridge, 2002; Martin-Soelch et al., 2001).
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Nicotine releases DA from its presynaptic terminals in a concentrationdependent manner in both the mesolimbic (Clarke et al., 1988; Vezina et al.,
1992; Marshall et al., 1997; Puttfarcken et al., 2000; Grady et al., 2002; Bednar
et al., 2004) and nigrostriatal (Giorguieff-Chesselet et al., 1979; Grady et al.,
1992, 1994; Harsing et al., 1992; Vezina et al., 1992; El-Bizri & Clarke, 1994;
Marshall et al., 1997; Teng et al., 1997; Kaiser et al., 1998; Puttfarcken et al.,
2000; Wonnacott et al., 2000; Zhou et al., 2001; Grady et al., 2002; Mogg et al.,
2002; Rice and Cragg, 2004) DA systems. Nicotine-evoked DA release is
inhibited by mecamylamine, a nicotinic receptor antagonist (Teng et al., 1997).
Nicotinic receptors are located on cell bodies and nerve terminals of
dopaminergic pathways (Clarke and Pert, 1985; Varanda et al., 1985; Banerjee
et al., 1990; Wonnacott, 1997).

Although there are some studies (Grilli et al., 2005) that found that 10
days of nicotine treatment did not change the releasing effect of nicotine in
striatal or accumbal synaptosomes, i.e. nicotine released the same amount of
dopamine after chronic treatment compared to acute nicotine, the majority of
studies show an enhanced DA release following chronic nicotine. In a number of
studies, the effect of nicotine to release DA has been shown to be enhanced
following repeated nicotine administration compared with its acute administration.
Following 10 days of nicotine pretreatment, nicotine-evoked DA release from
superfused striatal slices was greater than nicotine-evoked DA release from a
control group of rats injected with saline for ten days (Yu and Wecker, 1994). In
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in vivo microdialysis studies, nicotine-evoked DA release in the prefrontal cortex
and striatum was enhanced in rats pretreated with nicotine for 7 or 12 days,
compared nicotine-evoked DA release from rats receiving acute nicotine (Nisell
et al., 1996; Marshall et al., 1997). Also in nucleus accumbens, extracellular DA
levels in rats pretreated once daily for 5 days with nicotine were increased
following nicotine challenge compared to the DA levels in rats acutely
administered nicotine (Benwell et al., 1995). A study examining the chronic use
of tobacco in humans determined that DA levels were elevated in the striatum of
smokers compared to nonsmokers (Court et al., 1998). Although the effects of
chronic nicotine on DA release have been studied, the effect of repeated nicotine
on DA transporter (DAT) function and the role that DAT plays in enhancing
extracellular DA concentrations in response to repeated nicotine have not been
examined.

Nicotine-induced alterations in DAT function may contribute to the
observed nicotine-induced increase in extracellular DA concentrations described
above. DAT functions to regulate extracellular DA concentrations, and DAT is a
target for psychostimulant drugs of abuse. For example, amphetamine increases
extracellular DA concentrations directly through an interaction with DAT,
promoting reverse transport of DA (Liang and Rutledge, 1992; Sulzer et al.,
1995). Cocaine inhibits DAT function, also resulting in increased extracellular DA
concentrations (Kuhar et al., 1991). Additionally, drugs indirectly alter DAT
function through activation of specific receptors, e.g., raclopride inhibits DA D2
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receptors which indirectly inhibit DAT function (Cass and Gerhardt, 1994) and
NMDA stimulates ionotropic glutamate receptors to increase DAT function
(Welch and Justice, 1996). Acutely, nicotine also indirectly augments DAT
function through activation of nicotinic receptors (Middleton et al., 2004). In
studies using high speed chronoamperometic recordings to assess DA clearance
in vivo, acute systemic administration of nicotine dose-dependently increased DA
clearance in nucleus accumbens, striatum and MPFC of anesthetized rats (Hart
and Ksir, 1996; Middleton et al., 2004), and the effect of nicotine in MPFC and
striatum was inhibited by mecamylamine, a noncompetitive, nonselective
nicotinic receptor antagonist (Middleton et al., 2004).

The goal of the current study was to test the hypothesis that repeated
nicotine administration will further enhance the nicotine-induced increase in DA
clearance in striatum and MPFC. The results of these studies thereby begin to
delineate the role that DAT plays in enhancing extracellular DA concentrations in
response to repeated nicotine administration.

II. Methods
IIa. Materials. S(-)-Nicotine ditartrate (nicotine), 3-hydroxytyramine
hydrochloride (dopamine, DA), mecamylamine HCl (mecamylamine),
desipramine hydrochloride and sodium phosphate dibasic were purchased from
Sigma-Aldrich (Natick, MA). Sodium phosphate monobasic, sodium chloride,
ascorbic acid and urethane were purchased from Fisher Scientific (Pittsburgh,
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PA). Nafion perfluorinated ion-exchange resin was purchased from Aldrich
Chemical Co. (Milwaukee, WI). Dental wax was purchased from Patterson
Dental Supply, Inc. (Louisville, KY). Dental acrylic was purchased from CMA
Microdialysis (Acton, MA). Epoxylite and PX grade Graphpoxy were purchased
from Epoxylite Corp. (Irvine, CA) and Dylon Industries, Inc. (Cleveland, OH),
respectively. Carbon fibers of 30 μm diameter were purchased from Textron, Inc.
(Lowell, MA), and 28 gauge lacquer-coated copper wire was purchased from
Radio Shack (Lexington, KY).

IIb. Animals. Male Sprague Dawley rats (200 – 250 g) were obtained
from Harlan Laboratories (Indianapolis, IN) and were housed two per cage with
free access to food and water in the Division of Lab Animal Resources at the
College of Pharmacy, University of Kentucky. Experimental protocols involving
the animals were in strict concordance with the NIH Guide for the Care and Use
of Laboratory Animals and were approved by the Institutional Animal Care and
Use Committee at the University of Kentucky.

IIc. Treatment Protocol. Groups of rats were pretreated (s.c.) with
nicotine (0.4 or 0.8 mg/kg, 1 ml/kg, for MPFC and striatal experiments,
respectively) or saline once daily for 5 days. Twenty-four hours after the last
nicotine or saline injection, in vivo voltammetry was performed. During the
voltammetry experiment, rats were injected with a challenge dose of either
nicotine or saline. For MPFC experiments, rats received a challenge injection of
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either nicotine (0.4 mg/kg, salt weight) or saline. For striatal experiments, rats
received a challenge injection of either nicotine (0.8 mg/kg, salt weight) or saline.
Thus, for each brain region, 4 groups of rats were used and are designated by
pretreatment/challenge injections, i.e., saline/saline, saline/nicotine,
nicotine/saline, nicotine/nicotine.

IId. In Vivo Electrochemical Measurements. Clearance of exogenously
applied DA using in vivo voltammetric measurements has been previously shown
to reliably evaluate DAT function (Wightman et al., 1988; Cass et al., 1992).
Rats were anesthetized with urethane (1.25 - 1.5 g/kg, i.p.) and placed into a
Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA). Previous studies
from our laboratory have shown that a systemic injection of nicotine (0.4 and 0.8
mg/kg salt weight for MPFC and striatum, respectively) increased DA clearance
by ~50% (Middleton et al., 2004). Thus, these doses of nicotine were chosen for
the current study to examine the effect of repeated nicotine administration on DA
clearance. Body temperature was maintained at 37 °C with a heating pad
coupled to a rectal thermometer (Harvard Apparatus, Holliston, MA). The scalp
was reflected, and a section of the skull and dura overlying the frontal cortex was
removed. A small hole was drilled in the skull above the posterior cortex for
placement of two Ag/AgCl reference electrodes, which were cemented into place
with dental acrylic.
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Electrochemical electrodes were prepared and electrochemical
experiments were conducted using previously described methods (Middleton, et
al., 2004). Electrochemical recording electrodes contained a single carbon fiber
(33 μm diameter) in a pulled glass capillary (4 mm outer diameter, 0.80 mm wall
diameter) sealed with Epoxylite. Graphite epoxy resin and a 28 gauge lacquercoated copper wire were inserted into the glass capillary to establish electrical
contact with the carbon fiber. The exposed carbon fiber extended 50-150 μm
beyond the tip of the glass capillary. Electrodes for some experiments were
purchased from Quanteon (Lexington, KY). To enhance selectivity for DA, the
carbon fiber electrode was coated with Nafion polymer (5% solution, 6 - 8 coats)
and cured by heating at 250 °C for 5 min. Electrodes were calibrated in vitro and
calibration curves were generated using a range of DA concentrations (1.0 – 10
μM, at 22 °C in 0.1 M PBS solution, pH 4.0) to determine the sensitivity and
selectivity for DA. Electrodes were sensitive to DA and the mean selectivity ratio
of DA/ascorbic acid was 3806 ± 549 to 1 (n = 69). Each carbon fiber electrode
was attached to a single barrel micropipette (tip diameter of 10-15 μm) with
dental wax. The electrode and micropipette were positioned 250 - 300 μm apart.
Micropipettes were prepared from monofilament glass (1.0 mm O.D., 0.58 mm
I.D.) using a vertical pipette puller (Model 720, David Kopf Instruments, Tujunga,
CA). Single barreled micropipettes were filled with DA (200 μM, in 154 mM NaCl
and 100 μM ascorbic acid, pH 7.4) immediately prior to conducting the
experiments. The concentration of DA for ejection was chosen based on the
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linear kinetics of DA uptake at this concentration, i.e., DA concentrations that do
not saturate DAT in striatum (Zahniser et al., 1999).

The electrode/micropipette assembly was lowered into the MPFC (2.9 mm
anterior to bregma, 1.0 mm lateral from midline, and 2.5 – 5.0 mm below the
surface of the cortex) or dorsal striatum (1.5 mm anterior to bregma, 2.3 mm
lateral from midline, and 4.0 - 5.5 mm below the surface of the cortex) according
to the rat brain atlas of Paxinos and Watson (1986). Exogenous DA was
pressure ejected at 5-min intervals using a Picosprizter II (General Valve
Corporation, Fairfield, NJ). Using a stereomicroscope fitted with a reticule in one
eyepiece, ejection volume (250 nl/mm) was monitored by measurement of the
fluid displaced from the micropipette. The volume and amount of DA pressure
ejected was constant within each experiment, but varied between experiments
(12.5 – 200 nl, 2.5 – 40 pmol, 30 - 50 psi, 0.05 ms - 2.5 s). Ejection volume for
each experiment was chosen to provide reproducible baseline signals with a
maximum peak height of ~4 μM (variation in signal amplitude < ± 10%). Highspeed chronoamperometric electrochemical measurements were made
continuously (5 times/s, 5 Hz and averaged to 1 Hz), using an electrochemical
recording system (IVEC 10; Medical Systems Corporation, Greenvale, NY). The
oxidation potential was a square wave of +0.55 volts applied for 100 ms (versus
the Ag/AgCl reference electrode), and the resting potential was 0.0 volts for 100
ms. Oxidation currents were digitally integrated during the last 80 ms of each
100-ms pulse. Electrodes were stable throughout the time course of the
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experiment, maintaining sensitivity and selectivity for DA. In some cases,
electrodes were used for multiple experiments.
For each experiment, nicotine or saline challenge injection (s.c.) was
administered once reproducible baseline signals were obtained. Pressure
ejection of DA continued at 5-min intervals for 60 min following nicotine or saline
injection. In experiments performed in MPFC, rats were pretreated with
desipramine (25 mg/kg, s.c.) to block DA uptake via the norepinephrine
transporter (Carboni et al., 1990).
IIe. Data and Statistical Analysis. In vivo voltammetry data are
represented as mean values + SEM, and n represents the number of animals in
a treatment group. Figure 18 shows a representative baseline signal obtained
from MPFC and illustrates the parameters utilized to assess DA clearance. Three
parameters were determined from the DA oxidation currents; Amax, which is
defined by the maximal change in extracellular DA concentration; T80, the time for
the signal to decay by 80% minus the rise time of the signal; and DA clearance
rate (CLDA), which provides a measure of the efficiency of DAT to remove DA
from the extracellular space and is defined as the amount of DA pressure
ejected, divided by the area under the curve for the DA signal (AUCDA). AUC DA
was determined by fitting each DA signal trace following DA application to the
following equation: AUCDA = ∑(yi + yi+1 / 2)*(ti+1- ti); where y is the amplitude of
the DA signal (micromolar concentration) at any time (t, seconds) following DA
ejection, and where i is an integral number from 1 to n that starts at the initial
time point where the amplitude of the DA signal trace moves above the baseline
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level. AUCDA of the DA signals were determined for the duration of each DA
signal trace. Thus, CLDA (L/s) for each DA signal was derived from the amount of
ejected DA (pmoles) divided by the AUCDA (s * pmoles/L) for each DA signal and
is based on classical pharmacokinetic analysis (Ito et al., 1998; Shargel et al.,
2005). The half-life or its reciprocal (i.e., the rate constant KT) which has been
used to describe DA elimination is dependent upon both the volume into which
the DA distributes as well as the clearance of DA. The current study focused on
CLDA, which is a physiological measurement of DA elimination independent of the
amount or volume of DA that was pressure ejected and independent of the
volume into which the DA distributes under linear conditions. Thus, CLDA is a
direct determination of the physiological process(es) responsible for the removal
of DA from the pressure ejection site.
Amax, expressed as amount (μM) at a point in time, is a single
measurement that defines when the rate of DA dispersal from the ejection site to
the detector electrode becomes exactly balanced by all rate processes (uptake
and/or diffusion) that act to lower DA concentrations at a single instant in time.
As such, Amax represents an instantaneous composite of DA dispersion, diffusion
and uptake processes. CLDA is a time-averaged estimate over the entire interval
of the DA signal that more effectively defines the average efficiency of DA uptake
into neurons. Thus, drug-induced changes in Amax and CLDA, which measure
different components of DA disposition, need not be equivalent.
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Analysis of the effect of repeated nicotine administration on each of the
three parameters (Amax, T80 and CLDA) for both brain regions was accomplished
using separate three-way mixed-factor ANOVAs, with pretreatment and
challenge as between-group factors and time as a within-subjects factor. In both
MPFC and striatum, significant interactions were found for the data expressed as
Amax and CLDA such that one-way ANOVAs were utilized subsequently to assess
the effect of repeated nicotine at individual time points. Additionally, specific
within-subjects contrasts were performed to determine the time point at which
nicotine significantly altered Amax and CLDA compared to baseline. ANOVA,
specific contrasts and post hoc analyses were performed using SPSS (standard
version 11.0, Chicago, IL). p < 0.05 was considered significant, two-tailed.
Graphs were generated using GraphPad Prism software (Prism v3.0, GraphPad
software, Inc., San Diego, CA).

III. Results
IIIa. Effect of Repeated Nicotine Administration on Clearance of
Exogenous DA in MPFC. The effect of repeated nicotine (0.4 mg/kg) or saline
administration (s.c.) on clearance of exogenous DA was determined in the MPFC
using in vivo voltammetry. Pressure ejection of 200 μM DA into the MPFC at 5
min intervals resulted in stable baseline signals, with an Amax value of 4.44 μM (±
0.20 μM; mean ± S.E.M), T80 value of 64.6 s (± 5.61 s), and CLDA of 4.40 x 10-8
L/s (± 0.67 x 10-8 L/s; n = 33 independent experiments). Once baseline signals
stabilized, rats were injected with either a challenge dose of nicotine (0.4 mg/kg)
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or saline; DA pressure ejection continued at 5-min intervals for 60 min. The
effect of the challenge dose of nicotine on Amax, T80 and CLDA was determined
and compared to that obtained after saline injection (Figure 19). Rise time,
duration and decay of the baseline DA signal were not different between the rats
repeatedly treated with nicotine compared to the saline control rats repeatedly
injected with saline.

The ability of a challenge dose of nicotine to alter DA clearance in MPFC
in rats either repeatedly injected with nicotine or saline was determined and the
data for each parameter (Amax, T80 and CLDA) analyzed using separate three-way
ANOVAs. No significant main effects or interactions were observed for T80. With
respect to Amax, the 3-way pretreatment x challenge x time interaction was not
significant; however, the pretreatment x time interaction (F13, 377 = 5.35, p <
0.001) and the challenge x time interaction (F13, 377 = 2.41, p < 0.01) were
significant. Analysis of the data from the group of rats receiving saline once daily
for 5 days and then a saline challenge on the experiment day (saline control
group) revealed that compared to baseline, Amax gradually decreased by ~18%
during the 60-min period, reaching significance at 25 min and at 35-60 min
following the saline challenge injection (Figure 19, top panel). Thus, in the saline
control group, DA application at 5-min intervals for 60 min resulted in a small, but
significant, decrease in Amax.
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Interestingly, this effect only occurred in the saline control group (rats
injected with saline for 5 days and challenged with saline on the experiment day).
In the groups repeatedly injected with nicotine (both when challenged with saline
or nicotine on the experiment day) no significant decreases were observed in
Amax. It appears that repeated nicotine treatment produces tolerance to the
increase in DAT function that was observed following saline injection.

Between groups comparisons also revealed that Amax for the group of rats
injected with saline for 5 days and challenged with nicotine on the experiment
day (the nicotine control group) was significantly different (p < 0.01) from all of
the other treatment groups (Figure 19, top panel). Subsequent one-way
ANOVAs conducted at each 5-min time point from 10-60 min following challenge
injection revealed that Amax values for the nicotine control group were different (p
< 0.05) from all other treatment groups during the period from 45-60 min.
Compared to the baseline response (within-subject comparisons), the onset of
the nicotine-induced decrease in Amax for the nicotine control group was 20 min
following nicotine challenge, and a 41% decrease in Amax was observed at the 60
min time point in this group. In contrast, within-subject comparisons also
revealed that Amax values did not differ from baseline across the 60 min session
for the group injected with nicotine for 5 days followed by the nicotine challenge.
Moreover, from 45-60 min, Amax was decreased in the nicotine control group
compared to the group repeatedly injected with nicotine and then challenged with
nicotine on the experimental day. Furthermore, no differences were observed in
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Amax values between the group repeatedly injected with nicotine and challenged
with nicotine and the saline control group. Taken together, these results indicate
that repeated treatment with nicotine resulted in tolerance to the effect of nicotine
to decrease Amax.

Analysis of the effect of the nicotine challenge on CLDA revealed a
significant pretreatment x time interaction (F13,377, p < 0.01) and challenge x time
interaction (F13,377, p < 0.05). With respect to the saline control group, there were
no significant changes in CLDA during the 60 min recording period following
saline injection compared to baseline, although there was a trend for CLDA to
increase (Figure 19, bottom panel). With respect to the nicotine control group,
compared to baseline, the onset of the nicotine-induced increase in CLDA
occurred at 25 min after nicotine challenge (p < 0.05); and nicotine increased
CLDA by 59% compared to the saline control group at the 55-min time point. In
contrast, within-subject comparisons revealed that CLDA did not differ from
baseline across the 60 min session in the group repeatedly treated with nicotine
and then challenged with nicotine on the experimental day. Between groups
comparisons also revealed that the nicotine control group was significantly
different from the group repeatedly injected with nicotine and then challenged
with nicotine (p < 0.01). Separate one-way ANOVAs conducted at each time
point from 10-60 min revealed that at 50 and 55 min, CLDA in the nicotine control
group was significantly greater (81%) than that in the group repeatedly injected
with nicotine followed by nicotine challenge. Furthermore, no significant
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differences were observed in CLDA values between the nicotine challenge group
which was repeatedly injected with nicotine and the saline control group. These
results indicate that repeated treatment with nicotine resulted in tolerance to the
effect of nicotine to increase CLDA in MPFC.

IIIb. Effect of Repeated Nicotine Administration on Clearance of
Exogenous DA in Striatum. The effect of repeated nicotine (0.8 mg/kg) or
saline administration (s.c.) on clearance of exogenous DA was determined in the
striatum. Pressure ejection of 200 μM DA into striatum at 5 min intervals resulted
in stable baseline signals, with an Amax value of 4.28 μM (± 0.14 μM; mean ±
S.E.M.), T80 value of 18.8 s (± 2.51 s) and CLDA of 0.218 L/s (± 0.028 L/s; n = 33
independent experiments). Once baseline signals stabilized, rats were injected
with either a challenge dose of nicotine (0.8 mg/kg) or saline; DA pressure
ejection continued at 5-min intervals for 60 min. The effect of the challenge dose
of nicotine on Amax, T80 and CLDA was determined and compared to that obtained
after saline injection (Figure 20). Rise time, duration and decay of the baseline
DA signal were not different between the rats repeatedly treated with nicotine
and the saline control rats.

The ability of a challenge dose of nicotine to alter DA clearance in striatum
in rats either repeatedly injected with nicotine or saline was determined and the
data for each parameter (Amax, T80 and CLDA) analyzed using separate three-way
ANOVAs. With respect to Amax, a significant interaction of pretreatment x
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challenge x time was found (F13,403 = 2.22, p < 0.01). Analysis of the data from
the saline control group revealed that compared to baseline, Amax gradually
decreased by ~10% during the 60-min period, however no significant effect was
observed (Figure 20, top panel). Thus, in the saline control group, DA
application into striatum at 5-min intervals for 60 min did not alter Amax.

To further analyze the interaction, subsequent between-groups one-way
ANOVAs were conducted on the data from each 5-min time point from 10-60 min
after injection (Figure 20, top panel). These analyses revealed that the nicotine
control group (rats repeatedly injected with saline and challenged with nicotine on
the experiment day) was significantly different (p < 0.05) from all of the other
treatment groups from 10-35 min. Compared to the baseline response (withinsubject comparisons), the onset of the nicotine-induced decrease in Amax for the
nicotine control group was 10 min after the nicotine challenge (p < 0.05), the
duration of the decrease was from 10-35 min, and a maximal 36% decrease in
Amax was observed at the 30 min point. In contrast, within-subject comparisons
also revealed that Amax values did not differ from baseline across the 60 min
session for the group injected with nicotine for 5 days followed by the nicotine
challenge. Furthermore, no differences were observed in Amax values between
the group repeatedly injected with nicotine then challenged with nicotine and the
saline control group. Taken together, these results indicate that repeated
treatment with nicotine resulted in tolerance to the effect of nicotine to decrease
Amax.
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In contrast to the effect of nicotine on Amax, no significant main effects or
interactions were observed for T80 and CLDA, when the data were analyzed by
three-way ANOVA (Fig 20, middle and bottom panels, respectively). CLDA in the
nicotine control group tended to increase, but this effect did not reach
significance. Thus, compared to T80 and CLDA, Amax appears to be the more
sensitive parameter for detection of the effect of repeated nicotine on clearance
of exogenous DA in striatum.

IV. Discussion
The results from the current in vivo voltammetry study demonstrate that
tolerance develops to the nicotine-induced increase in clearance of exogenous
DA in MPFC and striatum. Following repeated injection with saline, challenge
with nicotine resulted in an increase in DA clearance in MPFC and striatum
consistent with previous findings (Middleton et al., 2004). The current study
shows that in both MPFC and striatum, DA clearance was decreased in the
group repeatedly administered nicotine and then challenged with nicotine on the
experimental day compared to the nicotine control group, which was repeatedly
administered saline and challenged with nicotine. Furthermore, DA clearance in
the group repeatedly administered nicotine and then challenged with nicotine
was not different from the saline control group, which was repeatedly
administered saline and then challenged with saline. The data obtained from the
CLDA parameter is more variable than the Amax parameter. This is likely due to
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the fact that CLDA takes into account multiple measurements over time, whereas,
Amax only measure a single point. Thus, tolerance develops to the nicotineinduced increase in exogenous DA clearance in both MPFC and striatum. The
current results extend previous findings showing that nicotine acutely increases
DA clearance in the MPFC, striatum, and nucleus accumbens and that this effect
is mediated by nicotinic receptors (Hart and Ksir, 1996; Middleton et al., 2004).

Previously, exogenous DA clearance has been defined as Amax/T80 with
units of concentration/time (Zahniser et al., 1999). In more recent assessments
of DAT function by this group (Sabeti et al., 2002), another parameter has been
elaborated called DA clearance efficiency. DA clearance efficiency has been
defined as a rate constant k, with units of s−1 and is determined by fitting the DA
signal to a first-order exponential decay function, i.e., A(t)=Amax*e-k(t-t0) (where A
is the signal amplitude (µM) at any time t (s) following peak signal amplitude
(Amax), and k is the first-order rate constant of decay of the DA signal). However,
the classical physiological measure of clearance is not represented by either
Amax/T80 (DA clearance) or k (DA clearance efficiency). In the current study, the
classical pharmacokinetic approach has been utilized to assess exogenous DA
clearance (Ito et al., 1998; Shargel et al., 2005). The parameter determined in
the current study, CLDA, was calculated as the amount of DA pressure ejected
divided by the AUC for each DA signal, with units of volume/time. CLDA can be
directly equated to the physiological process of DA elimination from the ejection
site and provides a direct measure of DA transport via DAT. Importantly, CLDA is

128

independent of dose or volume of DA pressure ejected and is independent of the
volume into which DA distributes under linear conditions. Thus, this analysis
directly measures the efficiency of DA removal after its exogenous application,
i.e., the transport process via DAT.

Nicotinic receptor activation acutely results in exocytotic DA release and
an increase in the clearance of DA from the extracellular space. The increase in
DA clearance may result in a sharpening of the DA signal. In both in vitro
superfusion assays and in vivo microdialysis studies, nicotine-evoked DA release
striatum and prefrontal cortex was reported to be greater following repeated
systemic administration of nicotine than that in rats repeatedly injected with
saline (Yu and Wecker, 1994; Nisell et al., 1996; Marshall et al., 1997).
However, the role that DAT may play in the increase in extracellular DA levels
following repeated nicotine was not considered in the previous studies. Previous
research shows that nicotine acutely increases DA clearance, in MPFC, striatum,
and nucleus accumbens (Hart and Ksir, 1996; Middleton et al., 2004), which
would result in decreased extracellular DA concentrations. The current study
shows that tolerance develops to the increase in DAT function (DA clearance) in
MPFC and striatum following repeated nicotine administration. Thus, diminished
DAT function as a result of repeated nicotine administration would be expected to
result in greater extracellular DA concentrations consistent with the results of
previous in vitro superfusion and in vivo microdialysis studies (Yu and Wecker,
1994; Marshall et al., 1997). The greater concentrations of DA in the
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extracellular space may contribute to the salience of the environmental cues
associated with chronic tobacco use, resulting in an enhancement of conditioned
reward, making smoking cessation difficult.

Nicotinic receptor activation may modulate DAT function by alterations in
DA reuptake into the presynaptic terminal and/or by altering DA efflux through
the transporter under certain conditions. Nicotine has been reported to enhance
amphetamine-evoked [3H]DA release from MPFC slices incubated in assay
buffer in the absence of calcium (Drew et al., 2000). The absence of calcium in
the assay buffer in the latter study precludes nicotine-evoked exocytotic DA
release and suggest that nicotine-induced augmentation of the response to
amphetamine involves DAT. The observed nicotine enhancement of the effect of
amphetamine was inhibited by nicotinic receptor antagonists, mecamylamine and
dihydro-β-erythroidine, but not by α-bungarotoxin, indicating the involvement of
heteromeric nicotinic receptors. Interestingly, nicotine did not enhance
amphetamine-evoked [3H]DA release in striatum or nucleus accumbens (Drew et
al., 2000). Furthermore, the nicotine-induced enhancement of amphetamineevoked [3H]DA release from MPFC was maintained after 10 days of nicotine
administration (Drew and Werling, 2003). Thus, these findings suggest that
nicotinic receptors also modulate DAT function to enhance amphetaminestimulated reverse transport of DA by DAT, although in contrast to the current
study, tolerance did not develop to the nicotinic receptor enhancement of reverse
transport of DA by DAT.
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One mechanism by which nicotine may modulate DAT function is via
nicotinic receptor-induced augmentation of DAT trafficking to the presynaptic
terminal membrane. The relatively rapid nicotine-induced increase in DA
clearance suggests that new synthesis of DAT protein is not responsible.
Rather, the time course of response is consistent with trafficking of intracellular
stores of DAT protein to the terminal membrane. One potential explanation could
involve the activation of second messenger signaling cascades. A study in
hippocampal neurons revealed that nicotinic receptor activation resulted in an
increase in intracellular calcium, activating mitogen-activated protein (MAP)
kinase and calcium/calmodulin-dependent protein kinase pathways to activate
the cyclic AMP response element binding protein producing transcriptional
effects (Hu et al., 2002). Inhibition of the MAP kinase pathway results in
trafficking of DAT from the plasma membrane to intracellular pools measured by
biotinylation assays conducted in human embryonic kidney 293 cells (Morón et
al., 2003). Taken together, these data suggest a potential role of the MAP kinase
pathway to increase DAT localization on the plasma membrane, which could
increase DA clearance following acute administration of nicotine. Repeated
nicotine may result in an inhibition of the MAP kinase pathway resulting in
trafficking of DAT from the plasma membrane, resulting in tolerance to the
nicotine-induced increase in DA clearance.
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Tolerance to chronic nicotine administration has been shown in various
animal models, i.e., locomotor activity, striatal dopamine metabolism and of
nicotine-induced antinociception (Stolerman et al., 1973; Marks et al., 1983;
Marks et al., 1991; McCallum et al., 2000; Pietila and Ahtee, 2000). Another
potential explanation for the observed tolerance to the nicotine-induced
enhancement of DA clearance is nicotinic receptor desensitization. Chronic
nicotine application resulted in an upregulation of α4β2 receptors in Xenopus
oocytes (Fenster et al., 1999). Furthermore, the EC50 for nicotine to produce
desensitization was the same as that required for upregulation, suggesting that
upregulation occurs as a result of desensitization. Using various doses of
nicotine and different dosing regimens, Rowell and Li (1997) showed that
nicotinic receptor desensitization was dependent on dose and regimen of
administration. Concentrations of nicotine that are achieved by smokers
desensitize nicotinic receptors located on the mesolimbic DA neurons
(Pidoplichko et al., 1997). Tolerance following chronic nicotine has been shown
in the absence of upregulation of nicotinic receptors (Pauly et al., 1992;
McCallum et al., 2000). However, it is also possible that the observed tolerance
is due to nicotinic receptor upregulation. Mice chronically treated with nicotine
have shown and increase in nicotine binding sites in brain (Marks et al., 1983;
Schwartz and Kellar 1983; Collins et al., 1988; Kassiou et al., 2001; Nuutinen et
al., 2005). Recently, in β2 knockout mice, following chronic nicotine treatment,
upregulation of nicotine binding sites is no longer observed (McCallum et al.,
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2005). Therefore, nicotine may have differential effects on DAT function
following repeated administration compared to acute nicotine administration.

More than one nicotinic receptor subtype is thought to be located on DA
neurons. Neurotoxins (α-Conotoxin MII) as well as small molecules have been
shown to inhibit only 50% of nicotine evoked [3H]DA release, suggesting the
involvement of more than one nicotinic receptor subtype in the DA releasing
properties of nicotine (Kulak et al., 1997; Kaiser et al., 1998; Wilkins et al., 2002;
Grinevich et al., 2003; Wei et al., 2005). Furthermore, nicotinic receptor subtpes
also desensensitize at different rates, i.e., α7 desensitizes more rapidly than
α4β2 (Fenster et al., 1997). It is possible that the subtypes mediating DA release
and those modulating DAT function desensitize differently. Therefore, following
repeated nicotine treatment the nicotinic receptors modulating exocytotic DA
release may not desensitize leading to an increase in DA release, while the
nicotinic receptors modulating DAT may desensitize resulting in tolerance to the
nicotine-induced increase in DA clearance. Together these mechanisms would
result in an increase in the extracellular DA concentration. Thus, chronic nicotine
is enhancing DA release and concomitantly decreasing DA clearance (current
study), which may be an important mechanism involved the maintenance of
smoking behavior.
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Finally, tolerance to the nicotine-induced increase in DA clearance may be
due to an increase in nornicotine production. Nornicotine decreases DAT
function (Chapter Three). Following systemic nicotine injection, nicotine reaches
maximal brain concentration within 5 min and has a brain t1/2 of 52 min.
However, nicotine metabolism results in production of nornicotine (Ghosheh et
al., 1999). Following nicotine injection nornicotine reaches maximal brain
concentrations 60 min following nicotine injection and has a brain t1/2 of 166 min
(Ghosheh et al., 1999). Furthermore, following repeated nicotine treatment,
nornicotine accumulates in brain (Ghosheh et al., 2001). Therefore, it is possible
the nicotine is no longer able to increase DAT function following repeated
nicotine treatment because nornicotine is inhibiting DAT function.

In summary, the current study shows that tolerance develops to nicotineinduced enhancement of DAT function following repeated nicotine administration.
Tolerance to the nicotine-induced increase in DA clearance may be important to
our understanding of the rewarding properties of tobacco use. Further studies
are warranted to examine the pathways involved in the modulation of DAT
function following both acute and repeated nicotine administration.
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Figure 18. Representative baseline DA signal in MPFC of urethaneanesthetized rats prior to nicotine or saline challenge. Electrochemical
signals were obtained following pressure ejection of DA (200 μM) and represent
the baseline response. Three parameters are obtained from each DA signal;
Amax, T80 and CLDA. Data are expressed as μM DA as a function of time (s) after
DA pressure ejection. DA concentrations were calculated based on calibration
curves generated in vitro.
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Figure 19. Tolerance develops to the nicotine-induced decrease in Amax and
increase in CLDA in MPFC. Amax, T80 and CLDA are illustrated in the top, middle
and bottom panels, respectively. Rats were injected (s.c.) with nicotine (0.4
mg/kg) or saline once daily for 5 days; 24 hr after the last injection, rats were
anesthetized and exogenous DA clearance determined using in vivo
voltammetry. After stable baseline signals were obtained in response to
pressure ejection of 200 μM DA at 5-min intervals, rats were challenged with
nicotine (0.4 mg/kg) or saline and exogenous DA applied at 5-min intervals for 60
min. Arrow indicates the time point that rats received the challenge injection.
Data are expressed as mean and S.E.M. as a percentage of the respective
baseline values as a function of time (min). Baseline values for each parameter
are provided in the Results section. Legend indicates treatment groups, i.e.,
repeated injection - challenge injection. SAL-SAL indicates the saline control
group; SAL-NIC indicates the nicotine control group; NIC-SAL indicates the
group repeatedly administered nicotine followed by saline challenge; NIC-NIC
indicates the group repeatedly administered nicotine followed by nicotine
challenge (n = 8 – 10 rats/group). # difference compared to baseline for the SALSAL group; * difference between SAL-NIC group and all other groups.
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Figure 20. Tolerance develops to the nicotine-induced decrease in Amax
and increase in CLDA in striatum. Amax, T80 and CLDA are illustrated in the top,
middle and bottom panels, respectively. Experiments were conducted as
described in Figure 19, except that the nicotine dose was 0.8 mg/kg and
exogenous DA clearance was determined in striatum. Baseline values for each
parameter are indicated in the Results section. Legend is as described in Figure
19. (n = 8 – 10 rats/group). Arrow indicates the time point that rats received the
challenge injection. * difference between SAL-NIC group and all other groups.
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Chapter Five
Nicotine Increases Dopamine Transporter Function
via a Trafficking-Independent Mechanism
I. Introduction
Nicotine is generally accepted to be the alkaloid in tobacco primarily
responsible for nicotine dependence (Clarke, 1987; Pomerleau and Pomerleau,
1992). Activation of nicotinic receptors by nicotine results in an increase in the
extracellular concentration of DA, which is thought to mediate the rewarding
effects of nicotine and maintain tobacco use in dependent individuals (Corrigall et
al., 1992; Koob,1992; Stolerman and Jarvis, 1995). Acute nicotine increases DA
release from its presynaptic terminals in the striatum in a concentrationdependent manner (Andersson et al., 1981; Dwoskin et al., 1999; Kaiser et al.,
1998; Ksir et al., 1995; Pontieri et al., 1996; Rowell et al., 1987; Vezina et al.,
1992; Westfall et al., 1983). Synaptic DA concentrations are regulated by the
DAT, which transports extracellular DA into the presynaptic terminal. DAT is a
major target for psychostimulants, e.g., cocaine and amphetamine (Horn, 1990).
DAT has been shown to be regulated by constitutive internalization and recycling
(i.e., trafficking), involving transporter phosphorylation and protein-protein
interactions (Kahlig and Galli, 2003; Loder and Melikian, 2003; Melikian, 2004;
Torres et al., 2003; Zahniser and Doolen, 2001).

Psychostimulants and second messengers alter DAT function and
trafficking (Garcia et al., 2005; Gnegy et al., 2004; Kahlig et al., 2004; Holton et
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al., 2005; Sorkina et al., 2005). For example, cocaine and amphetamine act at
DAT to decrease DA clearance in in vivo voltammetry studies (Cass et al., 1993;
Zahniser et al., 1999). In contrast, nicotine has been shown to increase the
clearance of exogenously applied DA in rat striatum, nucleus accumbens and
medial prefrontal cortex in in vivo voltammetry studies (Hart and Ksir, 1996;
Middleton et al., 2004). DAT surface expression in cell expression systems is
also acutely sensitive to amphetamine and cocaine, which decreases and
increases DAT surface levels, respectively (Daws et al., 2002; Little et al., 2002;
Saunders et al., 2000; Zahniser and Sorkin, 2004). Although through different
mechanisms, nicotine and amphetamine both evoke [3H]DA release from
superfused rat striatal slices (Corrigall et al., 1992; Koob, 1992; Stolerman and
Jarvis, 1995). Previous results shows that nicotine does not alter [3H]DA uptake
into striatal synaptosomes upon in vitro exposure to nicotine (Carr et al., 1989;
Zhu et al., 2003). However, the effect of nicotine on [3H]DA uptake into striatal
synaptosomes and on DAT trafficking has not been determined following
systemic nicotine administration.

Thus, the present study determined if nicotine administration altered
[3H]DA uptake into rat striatal synaptosomes and the cellular localization of DAT
in striatum using cell surface biotinylation and subfractionation approaches. The
ability of nicotine to modulate DAT function, and thereby extracellular DA
concentration, may have physiological importance with regards to nicotine
enhancement of cognitive processes such as attention, learning and memory, as
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well as important clinical relevance with respect to schizophrenia and drug
abuse. Therefore, understanding nicotine-induced regulation of DAT function
may provide further insights into the mechanisms of nicotine action.

The current series of experiments will test the hypotheses that 1) systemic
pretreatment with nicotine will increase DAT function in striatal synaptosomes in
vitro, similar to the increase in DA clearance observed in striatum in vivo, 2) the
effect of nicotine to increase the Vmax of [3H]DA uptake in striatum is mediated
by nicotinic receptors located on DA nerve terminals in striatum, 3) systemic
administration of nicotine will increase the number of DAT sites in striatum as
measured by radioligand binding, and 4) systemic administration of nicotine will
increase the trafficking of DAT to the neuronal cell surface in striatum.

II. Methods
IIa. Materials. Antibodies recognizing rat DAT (sc-1433; goat polyclonal
antibody), calnexin (sc-11397; rabbit polyclonal antibody); β-actin (sc-7210;
rabbit polyclonal antibody) and protein phosphatase 2A (PP2A; sc-6110; goat
polyclonal antibody) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Rabbit anti-goat antibody was purchased from Dako Cytomation (#Z
0454; Carpinteria, CA). Horseradish peroxidase (HRP) conjugated goat antirabbit antibody was purchased from Bio-Rad (Hercules, CA). GBR 12909,
nicotine ditartrate and nomifensine maleate were purchased from Sigma
Chemical Co. (St. Louis, MO). Sulfosuccinimidobiotin (sulfo-NHS-biotin) and
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immunoPure immobilized monomeric avidin gel were purchased from Pierce
Biotechnology, Inc. (Rockford, IL). [3H]Dopamine (3,4-ethyl-2 [N-3H]
dihydroxyphenylethylamine; specific activity 31 Ci/mmol) and [3H]GBR 12935
([Propylene-2,3-3H] (1-[2-diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine);
specific activity 43.5 Ci/mmol) were purchased from New England Nuclear
(Boston, MA). D-Glucose was purchased from Aldrich Chemical Co, Inc.
(Milwaukee, WI). All other chemicals were purchased from Fisher Scientific
(Pittsburgh, PA).

IIb. Animals. Male Sprague-Dawley rats were obtained from Harlan
Laboratories (Indianapolis, IN) and were housed with free access to food and
water in a colony room in the Division of Laboratory Animal Resources in the
College of Pharmacy at the University of Kentucky. Animal handling procedures
were approved by the Institutional Animal Care and Use Committee (IACUC) at
the University of Kentucky and were performed in accordance with the 1996
version of the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.

IIc. Synaptosomal [3H]DA uptake. [3H]DA uptake assays were
conducted using a previously published method (Zhu et al. 2003). Separate
groups of rats were injected with nicotine (0.8 mg/kg, s.c.) or saline. Nicotine
dose was chosen based on previous studies from our laboratory showing that
nicotine (0.32 mg/kg, s.c.) increased DA clearance (~60%) in striatum in vivo
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(Middleton et al., 2004). In the current study, rats were killed 5, 10, 40 or 60 min
post-injection. Striata were homogenized in 20 ml of ice-cold 0.32 M sucrose
solution containing 5 mM sodium bicarbonate (pH 7.4) with 16 passes of a Teflon
pestle homogenizer (clearance, 0.015 in). Homogenates were centrifuged (2,000
g, 4 °C, 10 min), and resulting supernatants were centrifuged (20,000 g, 4 °C, 15
min). Resulting pellets were resuspended in 2.4 ml of ice-cold assay buffer (125
mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO4, 10 mM
glucose, 25 mM N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]
(HEPES), 0.1 mM EDTA, 0.1 mM pargyline and 0.1 mM L-ascorbic acid,
saturated with 95% O2/5% CO2, pH 7.4). Striatal synaptosomes (20 µg protein in
50 µl) were incubated in an oxygenated environment for 5 min at 34 °C.
Subsequently, one of ten [3H]DA concentrations (1 nM - 5 µM) were added to
each tube. Total assay volume was 500 µl. Nonspecific [3H]DA uptake was
determined in the presence of 10 µM nomifensine. Incubation continued for 10
min at 34 °C and was terminated by the addition of 3 ml of ice-cold assay buffer
containing pyrocatechol (1 mM), followed by immediate filtration through
Whatman GF/B glass fiber filters (presoaked with 1 mM pyrocatechol for 3 h).
Filters were washed 3 times with 3 ml ice-cold buffer containing 1 mM
pyrocatechol using a Brandel cell harvester (Model MP-43RS; Biochemical
Research and Development Laboratories Inc., Gaithersburg, MD). Radioactivity
was determined by liquid scintillation spectrometry (Model B1600TR, PerkinElmer Life Sciences, Downers Grove, IL). Protein concentrations were
determined with bovine serum albumin as the standard (Bradford, 1976). Vmax
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and Kt were determined using GraphPad Prism software (GraphPad Prism,
version 3.0; GraphPad Software, San Diego, CA).

IId. [3H]GBR 12935 Binding. To determine if nicotine pretreatment
alters the total number of DAT sites, [3H]GBR 12935 binding assays were
performed using striata obtained from groups of rats injected with nicotine (0.8
mg/kg, s.c.) or saline and killed 5, 10 or 40 min post-injection. Striata was
obtained and stored at -70 °C until assay. Striata were homogenized with a
polytron homogenizer (setting 40; Tekmar, Cincinnati, OH), in 10 volumes of icecold assay buffer (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, and 1.2 mM
MgSO4, pH 7.5). Homogenates were incubated at 37 °C for 5 min, placed on ice,
and centrifuged (25,000 g, 20 min, 4 °C). Pellets were resuspended in 10
volumes of ice-cold Milli-Q water, incubated at 37 °C for 5 min, and centrifuged
(25,000 g, 20 min, 4 °C). Pellets were resuspended in 10 volumes of ice-cold
10% assay buffer and incubation and centrifugation steps repeated twice. Final
pellets were stored in 10% assay buffer at -70 °C until assay, where upon pellets
were resuspended in 20 ml assay buffer. Samples (250 μl), consisting of 100 –
140 μg of membrane protein and a range of [3H]GBR 12935 concentrations (0.1–
35 nM) in assay buffer containing 50 mM Tris, were incubated for 90 min at 4 °C.
Nonspecific binding was determined in the presence of 10 μM GBR 12909.
Reactions were terminated by dilution of the samples with 3 ml of ice-cold 20 mM
Krebs-HEPES buffer followed by immediate filtration through Whatman GF/B
glass fiber filters presoaked for 2 hrs in 0.5% polyethylenimine using the Brandel
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harvester. Filters were rinsed 3 times with 3 ml of ice-cold 20 mM buffer,
transferred to vials, and scintillation cocktail (4 ml) added. Radioactivity was
determined using a Tri-Carb 2100 TR liquid scintillation analyzer (PerkinElmer
Life Sciences). Protein concentrations were determined as previously described.
Kinetic parameters (Bmax and Kd) of [3H]GBR 12935 binding were determined
using GraphPad Prism software, version 3.0.

IIe. Biotinylation and Immunoblotting Assay. For the determination of
total, surface and intracellular levels of DAT protein in striatal synaptosomes,
surface biotinylation and immunoblot analysis were performed as described
previously (Apparsundaram et al., 1998; Melikian et al., 1996; Ramamoorthy et
al., 1998; Zhu et al., 2005). Striatal synaptosomes were obtained as described
above for [3H]DA uptake assays. Impermeant biotinylation reagent sulfo-NHSbiotin was used for the isolation of plasma membrane proteins. DAT protein was
identified using polyclonal DAT antibody (Taubenblatt et al., 1999; Salvatore et
al., 2003; Vaughan et al., 1997).

Specifically, samples of striatal synaptosomes (500 µg total protein) were
incubated for 1 h at 4 °C with continual shaking in 500 µl of 1.5 mg/ml sulfo-NHSbiotin in phosphate buffered saline/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5
mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.3). After
incubation, samples were centrifuged (8,000 g, 4 °C, 4 min). To remove the free
biotinylation reagent, the resulting pellet was resuspended in 1 ml of ice-cold 100
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mM glycine in PBS/Ca/Mg buffer and centrifuged (8,000 g, 4 °C, 4 min). The
resuspension and centrifugation steps were repeated. Final pellets were
resuspended in 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg buffer and
incubated with continual shaking for 30 min at 4 °C. Samples were centrifuged
(8,000 g, 4 °C, 4 min) and the resulting pellets were resuspended in 1 ml ice-cold
PBS/Ca/Mg buffer and centrifuged again. Resuspension and centrifugation
steps were repeated twice to remove excess glycine. Final pellets were lysed by
sonication for 2-4 s in 300 µl Triton X-100 buffer (10 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1.0% Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM
pepstatin, 250 µM phenylmethysulfonyl fluoride) followed by incubation and
continual shaking for 20 min at 4 °C. Lysates (300 µl) were centrifuged (21,000
g, 4 °C, 20 min). Pellets were discarded and 100 µl of each supernatant was
stored at -20 °C for determination of total immunoreactive DAT. Remaining
supernatant was incubated with continuous shaking in the presence of
monomeric avidin beads in Triton-X100 buffer (100 µl/tube) for 1 h at 22-24 °C.
Samples were centrifuged (17,000 g, 4 min, 4 °C), and supernatants containing
non-biotinylated proteins (intracellular) were stored at -20 °C. Resulting pellets
containing biotinylated proteins (cell-surface) were resuspended in 1 ml of 1.0%
Triton X-100 buffer and centrifuged (17,000 g, 4 min, 4 °C), and the pellets were
resuspended and centrifuged two times. Final pellets consisted of biotinylated
proteins adsorbed to monomeric avidin beads. Biotinylated proteins were eluted
by incubating with 50 µl Laemmli buffer (62.5 mM Tris-HCl, 20% glycerol, 2%
sodium dodecyl sulfate (SDS), 0.05% β-mercaptoethanol and 0.05%
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bromophenol blue, pH 6.8) for 20 min at 22-24 °C. Total, intracellular and cell
surface fractions were stored at -20 °C.

Samples (total, intracellular and cell surface fractions) were thawed and
subjected to gel electrophoresis and Western blotting as previously described
(Melikian et al. 1994; Salvatore et al. 2003; Zhu et al., 2005). Briefly, proteins
were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
for 90 min at 150 V and transferred to Immobilon-P transfer membranes (Cat #
IPVH00010, 0.45 µm pore size; MILLIPORE Co., Bedford, MA) in transfer buffer
(50 mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd., Hercules, CA) for 110
min at 72 V. Transfer membranes were incubated with blocking buffer (5% milk
powder in PBS containing 0.5% Tween 20) for 1 h at 22-24 °C, followed by
incubation with goat polyclonal DAT antibody (1 µg/ml in blocking buffer)
overnight at 4 ºC. Transfer membranes were washed 5 times with wash buffer
(PBS containing 0.5% Tween 20) at 22-24 °C, and then incubated with rabbit
anti-goat antibody (1:2500 dilution in blocking buffer) for 1 h at 22-24 °C.
Transfer membranes were then washed and incubated with peroxidaseconjugated goat anti-rabbit antibody (diluted 1:5000) for 1 h at 22-24 °C. Protein
bands were detected using enhanced chemiluminescence and developed on
Hyperfilm (ECL-plus; Amersham Biosciences UK Ltd., Little Chalfont
Buckinghamshire, UK). After detection and quantification of DAT protein, each
blot was stripped using Tris buffer (62.5 mM Tris-HCl with 2% SDS and 100 mM
β-mercaptoethanol, pH 6.8) and reprobed for detection of PP2A and calnexin.
148

PP2A, an intracellular protein (Janssens and Goris, 2001), served as a control
protein to monitor the efficiency of biotinylation of cell surface proteins and was
detected using goat polyclonal PP2A antibody (1:500). Calnexin, an
endoplasmic reticular protein (Hochstenbach et al., 1992; Krijnse-Locker et al.,
1995; Rajagopalan et al., 1994), was detected using rabbit polyclonal calnexin
antibody (1:5000) to monitor biotinylation of intracellular proteins. β-Actin was
quantified to normalize for protein loading across samples.

Immunoreactive bands were quantified by densitometric scanning using
Scion image software (Scion Corp., Frederick, MD). Band density
measurements were used to calculate levels of DAT in total, non-biotinylated and
biotinylated fractions. Specifically, total DAT levels were calculated based on the
density of DAT-immunoreactive bands in an aliquot of synaptosomal extract
multiplied by the total volume of extract and divided by the total volume of
synaptosomal extract subjected to SDS-PAGE. DAT levels in the nonbiotinylated fractions were calculated as density of DAT-immunoreactive bands in
an aliquot of supernatant post-avidin incubation multiplied by the total volume of
the extract and divided by the volume of supernatant subjected to SDS-PAGE.
In preliminary studies, quantification of PP2A revealed a maximum 10%
contamination of intracellular proteins in the plasma membrane biotinylated
fraction. Immunoreactive bands were quantified and were within the linear range
of detection.
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IIf. Subcellular Fractionation. To verify the results using the biotinylation
approach, a subcellular fractionation strategy was adapted from previously
described methods using presynaptic vesicular proteins (Clift-O'Grady et al.,
1990; Huttner et al., 1983). Briefly, rat striata were homogenized in 0.32 M
sucrose buffer containing 5 mM HEPES-NaOH (pH 7.3) using a Wheaton
Instruments Potter Elvejhem homogenizer (10 strokes) and centrifuged (1000 g,
10 min, 4ºC). Supernatants were centrifuged (13,000 g, 17 min, 4ºC) to yield a
crude synaptosomal pellet (P2). Synaptosomes in this P2 fraction (1 mg) were
lysed by homogenization (5 strokes) in ice-cold 5 mM HEPES-NaOH (pH 7.4)
plus protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, 250
µM phenylmethysulfonyl fluoride). Synaptic plasma membranes (LP1) and other
large membranes were separated at 15,000 g for 20 min. The vesicle enriched
LP2 pellet was obtained following centrifugation of the resulting supernatant (LS1
Fraction; 200,000 g, 30 min, 4ºC). Proteins were extracted from each fraction
with 1% SDS, 5 mM HEPES-KOH (pH 7.3), 1 mM EDTA, 1 mM EGTA and
protease inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin, 250 µM
phenylmethysulfonyl fluoride). Protein concentrations were determined using the
bicinchoninic acid method (Pierce, Rockford, IL). Each fraction (50 µg) was
subjected to immunoblot analysis with antibodies against DAT, PP2A, calnexin
and β-actin. DAT-immunoreactive bands were detected using goat polyclonal
anti-DAT antibody (1 µg/ml) in blocking buffer (5% milk in PBS containing 0.05%
Tween 20, pH 7.4) followed by rabbit polyclonal anti-goat antibody (1:2500
dilution in blocking buffer) and goat alkaline phosphatase conjugated polyclonal
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anti-rabbit antibody (1:10,000 dilution). Protein bands present in the transfer
membrane were measured using enhanced chemifluorescence (GE Healthcare,
Piscataway, NJ) with a Typhoon Imaging System (GE Healthcare) and
Imagequant TL software (GE Healthcare). Immunoreactive bands were
quantified and were within the linear range of detection. β-Actin was quantified to
normalize for protein loading across samples. Relative proportion of DAT in the
plasma membrane was expressed by calculating the ratio LP1/LP1+LP2.

III. Results
IIIa. Nicotine administration increases the Vmax for [3H]DA uptake in
rat striatum. Kinetic analysis of [3H]DA uptake was performed in synaptosomes
obtained 5, 10, 40 or 60 min following administration of nicotine (0.8 mg/kg, s.c.)
or saline. Synaptosomal [3H]DA uptake was not different between the saline
control groups across the time points and as such the data were pooled for
statistical analysis and graphical presentation (Figure 21). While the interaction
between treatment and time was not significantly different, a main effect of
nicotine treatment was observed (F1,48 = 4.16; p < 0.05). Compared to the saline
control group, nicotine significantly increased (∼25%) the Vmax for [3H]DA uptake
at 10 and 40 min post-injection (p<0.05). The effect of nicotine on Vmax was not
significant at either the 5 or 60 min time points. There was no change in Kt at any
time point (Table 2).
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IIIb. Nicotine administration does not alter [3H]GBR 12935 binding to
rat striatal membranes. No differences between nicotine (0.8 mg/kg) and saline
groups were observed in either the Bmax or Kd for [3H]GBR 12935 binding at the
5, 10 or 40 min time points (Table 3), suggesting that nicotine pretreatment does
not alter the total amount of DAT protein in striatum.

IIIc. Nicotine administration does not alter the cellular localization of
DAT in striatum. To determine if nicotine pretreatment (0.8 mg/kg) altered cell
surface localization of DAT, rats were administered nicotine or saline and killed
10 or 40 min later. Striatal synaptosomes were prepared and biotinylation and
subfractionation assays were performed. In all of the groups tested, DAT bands
were observed at 80 kDa, as previously reported (Salvatore et al., 2003; Zhu et
al., 2005). In biotinylation assays, DAT-immunoreactive bands were detectable
in all three fractions. DAT band density was not different between nicotine and
saline treated groups at the 10 and 40 min time points (Figure 22). There were
no between-group differences in the levels of control proteins, PP2A (60 kDa),
calnexin (90 kDa) and β-actin (42 kDa). Consistent with the results from the
biotinylation assays, subfractionation experiments also revealed no difference in
DAT levels in total and plasma membrane fractions (LP1). No differences
between the nicotine and saline control groups were observed in the ratio of
LP1/LP1+LP2 at the 10 min and 40 min time points (Figure 23). Also, there was
no difference in the levels of control proteins, β-actin, PP2A and calnexin,
between nicotine and saline control groups.
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IV. Discussion
The current results demonstrate that 10 and 40 min following nicotine (0.8
mg/kg) administration, a significant increase (25%) in the Vmax for [3H]DA uptake
into striatal synaptosomes was observed. These data are consistent with
previous findings from our laboratory showing that systemic nicotine increases
DA clearance in vivo in rat striatum (Middleton et al., 2004). The increase in DA
clearance observed in vivo is likely due to an increase in Vmax for DA. The
nicotine-induced increase in [3H]DA uptake into striatal synaptosomes was not
accompanied by an increase in the total amount of DAT protein, as indicated by
the lack of change in [3H]GBR 12935 binding and in total DAT protein assessed
by immunoblotting methods in comparison with the saline control group.
Furthermore, the biotinylation and subfractionation results revealed no changes
in the cellular distribution of DAT in striatum following nicotine administration.
Taken together, these results suggest that nicotine increases striatal DA uptake
in vitro and DA clearance in vivo via a trafficking-independent mechanism.

Previous research using in vivo voltammetry revealed that nicotine
induced an increase in exogenous DA clearance in striatum in anesthetized rats
(Middleton et al., 2004). The nicotine-induced increase in DA clearance was
dose dependent with the 0.8 mg/kg dose increasing clearance by ~60%.
Nicotine significantly increased DA clearance 15 min following nicotine
administration and the increase persisted for one hour post injection (Middleton
et al., 2004). Consistent with the latter study, results from the current study show
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a 25% increase in Vmax for [3H]DA uptake into striatal synaptosomes. However,
the percent increase in the current study was lower than that observed in the in
vivo voltammetry studies. Furthermore, DAT function in the current in vitro study
was increased at 10 and 40 min post-injection and was back to saline control
levels by 60 min following nicotine injection, whereas the effect of nicotine was
still apparent at 60 min in the in vivo voltammetry studies. Differences in the
magnitude and duration of nicotine effect on DAT function in the two assays may
be due to the fact that DA clearance in the in vivo voltammetry assays is
measured in localized areas of striatum, whereas the in vitro assay utilizes the
entire striatum, potentially diluting localized changes. In this regard, results from
in vivo voltammetry studies show that the striatum is heterogeneous with respect
to DA clearance, which may be related to variations in the density DAT (Ciliax et
al., 1995). Thus, the smaller magnitude of nicotine effect in the synaptosomal
preparation may be due to an averaging of effect across this heterogeneous
brain region. Furthermore, differences between the assays, including use of
anesthetic and repeated exposure to exogenous DA in the in vivo studies, may
have contributed to the observed differences in the magnitude and duration of
the effect of nicotine on DAT function.

Although in vivo nicotine administration results in an increase in striatal
DAT function as demonstrated using in vivo voltammetry and in vitro
synaptosomal [3H]DA uptake, previous results show that when striatum is
exposed to nicotine in vitro, nicotine produces no effect on [3H]DA uptake (Carr
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et al., 1989; Zhu et al., 2003). These contrasting findings may be due to the
effect of nicotine at the dopaminergic cell body or at circuitry which has been
disrupted during the preparation of striatal slice or synaptosomes used in the in
vitro studies.

Several studies have shown that DAT undergoes internalization and
recycling, which may involve dynamin-clathrin mediated pathways and multiple
protein-protein interactions, such as syntaxin-1A, PP2A, PICK1 and synuclein
(Lee et al. 2004; Melikian, 2004; Torres et al., 2003; Zahniser and Doolen, 2001).
Changes in DAT surface expression have been shown to be induced by
psychostimulants or protein kinase C activation, and such changes correlate with
alterations in [3H]DA uptake in striatum (Chi and Reith, 2003; Copeland et al.
1996; Vaughan et al., 1997) and in cell systems expressing DAT (Kahlig et al.,
2004; Little et al., 2002; Pristupa et al. 1998). The previous studies used
biotinylation and subfractionation approaches to show drug-induced changes in
DAT cellular localization. One mechanism by which the nicotine-induced
increase in DAT function may occur is via the trafficking of DAT to the cell
surface. To assess this potential mechanism, cell surface biotinylation and
subfractionation approaches were employed to assess DAT cellular localization
in striatum. Recent studies have used the biotinylation approach for
determination of DAT distribution in total, plasma membrane and intracellular
fractions in rat striatal synaptosomes (Chi and Reith, 2003; Salvatore et al., 2003;
Zhu et al., 2005). In the current study, results were also verified using the
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subfractionation approach for the determination of DAT localization. However,
the biotinylation assay revealed no differences in DAT cellular localization
between the nicotine-treated and saline control groups; and, this finding was
further confirmed using the subfractionation approach. Thus, it appears that the
nicotine-induced increase in DAT function in striatum may occur via a traffickingindependent mechanism.

Alterations in transporter function in the absence of changes in transporter
trafficking have been reported previously (Apparsundaram et al., 2001; Zhu et al.,
2005). Specifically, insulin increases norepinephrine transporter function without
a change in transporter cellular localization (Apparsundaram et al., 2001). The
insulin-induced increase in NET function is likely due to activation of p38 MAP
kinase and PI-3 kinase pathways (Apparsundaram et al., 2001). Similarly, p38
MAP kinase stimulation of the serotonin transporter was also recently shown to
occur via a trafficking-independent mechanism (Zhu et al., 2005), suggesting that
multiple pathways exist to regulate neurotransmitter transporter function.

Nicotine has been shown to activate several different second messenger
pathways. For example, nicotine releases nitric oxide from rat hippocampal
slices (Smith et al., 1998). Nicotine-induced nitric oxide release is inhibited by αbungarotoxin, suggesting the involvement of Ca++ permeable α7 nicotinic
receptors. Also, nicotinic receptor activation induces extracellular signalregulated kinase phosphorylation in PC12 cells (Nakayama et al., 2001), as well
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as alters calmodulin and mitogen-activated protein kinase function (Hu et al.,
2002). Recently, the nitric oxide pathway has been implicated in increasing DAT
function in striatum in studies using rotating disk electrode voltammetry (Volz and
Schenk, 2004). It is possible that such signaling mechanisms may be involved in
the nicotine-induced increase in DAT function without altering cell surface
localization of DAT.
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Figure 21. Nicotine administration increased the Vmax for [3H]DA uptake in
striatal synaptosomes. Rats were injected with nicotine (0.32 mg/kg, s.c.; open
bars) or saline (control, CON; closed bar), and synaptosomes prepared 5, 10, 40
or 60 min post-injection. Specific [3H]DA uptake for the 5, 10, 40 and 60 min
saline control groups was 32.8 ± 1.66, 29.7 ± 1.18, 27.8 ± 1.45, and 33.2 ± 1.72,
respectively. Nicotine increased the Vmax for [3H]DA uptake 10 and 40 min
following nicotine injection. Data are expressed as mean ± SEM percentage of
the mean control group. *indicates significant difference from control, p < 0.05; n
= 6/group.
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Table 2. Nicotine pretreatment does not alter the Kt in striatal
synaptosomes measured by [3H]DA uptake.
Kt (μM)
Time (min)

Saline

Nicotine (0.8 mg/kg)

5

0.09 ± 0.03

0.12 ± 0.03

10

0.09 ± 0.03

0.09 ± 0.03

40

0.08 ± 0.03

0.11 ± 0.03

60

0.10 ± 0.03

0.10 ± 0.02
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Table 3. Nicotine (0.8 mg/kg, s.c.) pretreatment does not alter [3H]GBR
12935 binding to rat striatal membranes.
Bmax (pmol/mg protein)

Kd (μM)

Time (min)

SALINE

NICOTINE

SALINE

NICOTINE

5

183 ± 22

192 ± 33

3.3 ± 0.4

4.6 ± 1.0

10

290 ± 35

195 ± 32

5.3 ± 1.0

4.4 ± 0.5

40

277 ± 69

229 ± 37

4.8 ± 1.0

5.0 ± 0.7

Data are expressed as Mean ± S.E.M, n = 4-9/group.
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Figure 22. Biotinylation assays revealed no change in the distribution of
striatal DAT at 10 or 40 min following nicotine administration.
Representative immunoblots (Top panel) for DAT, PP2A, calnexin and β-actin in
total, biotinylated (BIOT) and nonbiotinylated (NB) fractions of striatal
synaptosomes obtained 10 and 40 min following nicotine (0.32 mg/kg; s.c.) or
saline injection. Group data for DAT in total, biotinylated (BIOT) and
nonbiotinylated (NB) fractions of striatal synaptosomes obtained 10 and 40 min
following nicotine or saline injection are presented as mean ± S.E.M, n = 5/group
(Bottom panel). Immunoreactive bands were within the linear range of detection.
Biotinylation assays used β-actin as a control for protein loading. PP2A and
calnexin were used to monitor biotinylation of proteins located in intracellular
compartments and were found in the nonbiotinylated fractions.
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Figure 23. Subfractionation assays revealed no change in the distribution
of striatal DAT at 10 and 40 min following nicotine administration.
Representative immunoblots of DAT, PP2A, calnexin and β-actin in total, LP1
(synaptic plasma membrane) and LP2 (vesicular) fractions of striatal
synaptosomes from nicotine (0.32 mg/kg; s.c.) or saline injected rats 10 and 40
min post-injection (Top panel). Group data for DAT expressed as the
LP1/LP1+LP2 ratio at 10 and 40 min following nicotine or saline injection (Bottom
panel). LP1/LP1+LP2 ratio represent fraction of DAT in the plasma membrane
fraction as ratio of DAT in plasma membrane and vesicular fraction. Data are
presented as mean ± S.E.M, n = 5/group. The levels of DAT-immunoreactivity (X
105 arbitrary units) in total fractions were 18.0 ± 1.34 (saline, 10 min), 16.8 ± 2.37
(NIC, 10 min), 13.8 ± 1.36 (saline, 40 min) and 15.2 ± 1.92 (NIC, 40 min).
Immunoreactive bands that were quantified were within the linear range of
detection. β-actin was used as a protein loading control.
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Chapter Six
Discussion and Conclusions
I. Review
Tobacco dependence is the most common drug of abuse and the leading
preventable cause of death in the USA (Surgeon General’s Report, 1988; Jaffe,
1990; USDHS, 2001). Nicotine, the most abundant alkaloid in tobacco (Bush et
al., 1993), has intrinsic rewarding properties, which are believed to be
responsible for tobacco dependence (Koob, 1992; Corrigall et al., 1992;
Stolerman and Jarvis, 1995; Di Chiara, 2000; Balfour, 2002; Mathieu-Kia et al.,
2002; Garrett et al., 2003). Volunteers who habitually smoke and are tobacco
deprived will self-administer nicotine (Henningfield and Goldberg, 1983; Harvey
et al., 2004; Johnson et al., 2004). Indicative of its reinforcing properties, nicotine
is self-administered in animal models (Goldberg et al., 1981; Henningfield and
Goldberg, 1983; Cox et al., 1984; Corrigall and Coen, 1989; Corrigall et al., 1992,
1994; Sannerud et al., 1994; Donny et al., 1996, 2003; Rose and Corrigall, 1997;
Shoaib et al., 1997; Valentine et al., 1997; Rasmusen and Swedberg, 1998;
Caggiula et al., 2001, 2002; Suto et al., 2001; LeSage et al., 2002, 2003; Fu et
al., 2003; Paterson et al., 2004). While nicotine and acetylcholine both act at the
nicotinic receptor, the brain responds differently to nicotine than acetylcholine.
Acetylcholine undergoes rapid metabolism by acetylcholinesterase, whereas
nicotine remains in the brain longer with a t1/2 of 52 min (Ghosheh et al., 1999).
Thus, the effects of nicotine on synaptic events are prolonged relative to
acetylcholine. Therefore, the effect of nicotine on the DA system, and specifically
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DAT which is responsible for regulating extracellular DA concentrations, is
important in the overall function of the DA system.

Previous research on the neurobiology of reward and drug addiction has
focused on the mesocorticolimbic and nigrostriatal DA systems, emphasizing the
role of the nucleus accumbens, MPFC and striatum. Recently, focus has been
placed on the involvement of the striatum and MPFC in reward and
reinforcement. The MPFC, which is innervated by dopaminergic projections from
the ventral tegmental area, is believed to encode secondary conditioned stimuli
associated with environmental cues paired with drug, leading to reward
expectancy, which is recognized as important to the process of addiction and
relapse to drug use (Berridge and Robinson, 1998; Shima and Tanji, 1998;
Kelley, 1999; DiChiara, 2000; Kelley and Berridge, 2002; Peoples, 2002; Cohen
et al., 2004; DiChiara et al., 2004; Rose and Behm, 2004; Brody et al., 2004a).
Integration of the motivational information from the MPFC occurs at least in part
in striatal neurons, which are innervated by dopaminergic projections from the
substantia nigra, leading to the initiation and execution of movement in reward
expectancy and detection of reward (Martin-Soelch et al., 2001).

The experiments conducted in this dissertation project have shown that
nicotine administration (s.c.) increases DA clearance in rat striatum and MPFC
and this effect is inhibited by mecamylamine, suggesting nicotinic receptor
involvement. Furthermore, tolerance develops to the nicotine-induced increase
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in DA clearance following repeated nicotine administration in both striatum and
MPFC. The nicotine-induced increase in DA clearance in striatum is due to an
increase in the Vmax of DAT without an increase in trafficking of DAT to the cell
surface. Finally, the nicotine metabolite and tobacco alkaloid, nornicotine, was
shown to have an opposite action of nicotine, i.e., nornicotine administration
decreases DA clearance in striatum. The current studies are the first to examine
the effect of nicotine on DAT function in vivo in both the striatum and MPFC.
Furthermore, these are the first studies examining the mechanism by which
nicotine modulates DAT function.

II. Nicotinic receptor modulation of DAT function in striatum and MPFC
Using in vivo voltammetry, systemic nicotine, in a dose-related manner,
increases DA clearance in both striatum and MPFC. In both brain regions,
nicotine increased DA clearance by 50%. However, across the same nicotine
dose range, differential patterns in the nicotine dose-response curve were
observed in striatum and MPFC. That is, a monophasic dose-response curve
was observed in striatum, whereas a U-shaped curve was found in MPFC.
Maximal effect occurred at a lower dose in MPFC than in striatum (0.4 and 0.8
mg/kg, respectively). With respect to the time course of the nicotine effect, in
both brain regions, the onset of a significant effect on DA clearance occurred 10
to 15 min after nicotine injection. The time to maximal response was more rapid
in MPFC compared with striatum (30 and 45 min, respectively). The time course
of the response to nicotine in both brain regions is in good agreement with
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pharmacokinetic data showing a maximal nicotine concentration in rat brain at 5
min after peripheral nicotine injection and a brain t1/2 of 52 min (Ghosheh et al.,
1999). Nevertheless, the pattern of the nicotine dose-response curve in the
present study was different between MPFC and striatum, with MPFC showing
greater sensitivity to nicotine. α-Conotoxin MII inhibits nicotine-evoked [3H]DA
overflow by only 50%, implicating involvement of at least two different nicotinic
receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh
2005). Nicotine does not evoke DA release in microdialysis experiments using
α4-knockout mice (Marubio et al., 2003), indicating that α4 nicotinic receptors are
critical for DA release, at least in ventral striatum. Previously, it was reported that
nicotine was able to enhance amphetamine-evoked [3H]DA release from rat
MPFC slices, but not from striatal or nucleus accumbens slices via an action at
nicotinic receptors (Drew et al., 2000). Thus, it is possible that striatal nicotinic
receptors modulating DAT function are different between those in MPFC.

The present study also demonstrates that the nicotine-induced
enhancement of DA clearance in both MPFC and striatum was inhibited by
pretreatment of the rats with mecamylamine, a nonselective nicotinic receptor
antagonist (Varanda et al., 1985). The hallmark of an action at nicotinic
receptors is its blockade by mecamylamine. Thus, the current study utilized
mecamylamine as the first approach to determine nicotinic receptor involvement
in the nicotine-induced increase in DA clearance. Further studies are warranted
examining the effects of subtype selective antagonists to determine if different
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subtypes are involved in modulating DAT function between striatum and MPFC.
These results suggest that nicotine stimulates nicotinic receptors to increase
DAT function in these two brain regions. The current results are in agreement
with previous studies showing that peripheral nicotine administration increased
DA clearance in the nucleus accumbens (Hart and Ksir, 1996). In the current
study, mecamylamine had no effect on its own, but inhibited the effect of nicotine
on DA clearance in both striatum and MPFC. While mecamylamine has been
shown to act at NMDA receptors as well as nicotinic receptors (O’Dell and
Christensen, 1988), the hallmark of an action at nicotinic receptors is blockade by
mecamylamine. Thus, mecamylamine was used in the current studies to
determine involvement of nicotinic receptors on the nicotine-induced increase in
DA clearance. Hart and Ksir (1996) also reported no effect of mecamylamine
alone on DAT function in nucleus accumbens. It is possible that the nicotinic
receptors modulating DA release and DAT function are different. Since
acetylcholine is the endogenous ligand for the nicotinic receptor, it is likely that
there is some basal activity of DA release based on nicotinic receptor activation
by acetylcholine. The observation that mecamylamine had no effect alone
suggests that nicotinic receptors, which modulate DAT function in these brain
regions, are not tonically activated. These results support the first hypothesis
that nicotine will increase DA clearance in the striatum and MPFC in a dosedependent manner, and this increase in clearance will be mediated by nicotinic
receptors.
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Following nicotine-induced DA release DA can be taken back up into the
terminal by DAT and can also stimulate presynaptic DA D2 autoreceptors. D2
autorecepetor activation decreases both DA synthesis and DA release from
presynaptic terminals (Starke et al., 1989; Langer, 1997). Importantly stimulation
of D2 autoreceptors also modulates DAT function. Uptake of DA into striatal
minces and synaptosomes is increased following application of a D2 receptor
agonist, quinpirole (Meiergerd et al., 1993; Batchelor and Schenk, 1998;
Thompson et al., 2001). Furthermore, the quinpirole-induced increase in DA
uptake is inhibited by spiperone, a D2 receptor antagonist (Thompson et al.,
2001). Local application of the D2 receptor antagonist raclopride decreased DA
clearance in striatum, nucleus accumbens and prefrontal cortex (Cass and
Gerhardt, 1994). In D2 receptor knockout mice, DA clearance is decreased by
50% compared to wild-type mice (Dickinson et al., 1999). It is possible that the
nicotine-induced increase in DA clearance observed in the current studies may
be influenced by nicotine-induced DA release followed by activation of D2
receptors, as stimulation of D2 receptors would lead to and increase in DA
clearance.

III. Mechanisms Underlying the Different Shaped Dose-Reponse Curves
observed in Striatum and MPFC.
IIIa. Different nicotinic receptors modulating DA clearance in
striatum and MPFC.
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Heteromeric α4β2* nicotinic receptors are most abundant in brain, and
second most abundant are homomeric α7* nicotinic receptors (Whiting and
Lindstrom, 1986; Wada et al., 1989; Morris et al., 1990; Schoepfer et al., 1990;
Anand et al., 1991; Flores et al., 1992; Lukas et al., 1999). The subunits display
different, but overlapping, patterns of expression in brain (e.g., β2 mRNA
expression is prominent in the cerebellum, which exhibits no α4 hybridization;
Wada et al., 1989). mRNA for nine subunits (α2–α7 and β2–β4) of nicotinic
receptors have been identified in SN and VTA dopaminergic neurons (Klink et al.,
2001, Zoli et al., 2002; Azam et al., 2002; Wooltorton et al., 2003), indicating that
potentially a large number of heteromeric nicotinic receptor subtypes of
pentameric structure may be expressed by these neurons.

Nicotinic receptors are localized on presynaptic terminals and cell bodies
of VTA and SN DA neurons (Schwartz et al., 1984; Clarke and Pert, 1985;
McGehee and Role, 1995; Wonnacott, 1997; Quik et al., 2005); and evidence
indicates that nicotinic receptor subtypes at cell body and terminal locations differ
pharmacologically (Reuben et al., 2000; Champtiaux et al., 2003). In striatal
synaptosomes, nicotine has a lower affinity for nicotinic receptors than
acetylcholine, and acetylcholine has equal affinity to epibatidine (a nicotinic
receptor agonist; Reuben et al., 2000). However, in a dendrosomal preparation,
nicotine has equal affinity to epibatidine (Reuben et al., 2000), suggesting that
the nicotinic receptors in the terminal regions differ from those in the cell body
regions. Furthermore, α6β2* receptors have been shown to be located on DA
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terminals, whereas nonα6(α4β2)* receptors represent the majority of functional
receptors on DA cell bodies (Champtiaux et al., 2003; Salminen et al., 2004).
Importantly, α-conotoxin MII inhibits nicotine-evoked [3H]DA overflow by only
50%, implicating involvement of at least two different nicotinic receptor subtypes
(Zoli et al., 2002; Salminen et al., 2004; Azam and McIntosh 2005). It is likely
that the difference in pharmacology between the nicotinic receptors in the cell
body regions and the nerve terminal regions play different physiological roles.

The involvement of distinct nicotinic receptor subtypes in striatum and
MPFC provides a likely explanation for the differential nicotine dose-response
pattern observed in the current study. Recent studies have demonstrated the
presence of multiple mRNAs for nicotinic receptor subunits (α2-α7 and β2-β4)
and their respective proteins in DA cell bodies in both substantia nigra and
ventral tegmental area; however, differences in the relative abundance of these
subunits in substantia nigra and ventral tegmental area have also been reported
(Klink et al., 2001; Azam et al., 2002; Zoli et al., 2002; Wooltorton et al., 2003).
The nicotinic receptors expressed in the nigrostriatal and mesocorticolimbic DA
systems depend on the specific combinations of subunits forming functional
nicotinic receptors. In striatum, the primary subtypes thought to be expressed
are the α6β2* and α4(non α6)β2* nicotinic receptors (Zoli et al., 2002). Pairwise
expression of nicotinic receptor subunits in Xenopus oocytes initially revealed
characteristic pharmacological profiles, i.e., relative sensitivity and
responsiveness to a range of nicotinic ligands (Luetje and Patrick, 1991).
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Inclusion of a third type of subunit (e.g., α5 with β3 and β2 subunits) in similar
expression systems further altered the physiological response, calcium
permeability, and desensitization characteristics of the expressed nicotinic
receptor subtypes (Gerzanich et al., 1998). Characterization of the physiological
response of individual neurons in midbrain slices revealed four different patterns
of nicotinic receptor-mediated currents, revealing the complexity of native
nicotinic receptors, which purportedly contained as many as four different
subunits (Klink et al., 2001). More recently, the selective α6 nicotinic receptor
antagonist, α-conotoxin MII, has been shown to decrease DA release,
suggesting the involvement of the α6 subunit in nicotine-evoked DA release
(Salminen et al., 2004). Importantly, α-conotoxin MII inhibits nicotine-evoked
[3H]DA overflow by only 50%, implicating involvement of at least two different
nicotinic receptor subtypes (Zoli et al., 2002; Salminen et al., 2004; Azam and
McIntosh 2005). Immunoprecipitation of nicotinic receptors from DA terminals as
well as electrophysiological studies in DA neurons from various nicotinic receptor
knockout mice suggest the involvement of α4β2*, α6β2*, α6α4β2* nicotinic
receptors in DA release (Champtiaux et al., 2003).

IIIb. Neuronal circuitry is different between striatum and MPFC.
Another potential explanation for the difference in regional dose-response
is that the local neuronal circuitry is different between these two brain regions,
i.e., different afferents impinge on the dopaminergic terminals in striatum and
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MPFC potentially providing differential regulation of DAT function. In this regard,
the U-shaped function in MPFC may be the result of nicotine-induced stimulation
of an additional neurotransmitter system in the MPFC. The result of activation of
the additional neurotransmitter may have opposed the nicotinic receptormediated enhancement of DAT function. For example, high concentrations of
nicotine have been shown to activate α7 nicotinic receptors, resulting in
glutamate release in the frontal cortex (Schilstrom et al., 2000; Marchi et al.,
2002). Stimulation of metabotropic glutamate receptors has been reported to
decrease DAT function (Page et al., 2001). Thus, activation of α7 receptors
indirectly through glutamate neurotransmission could result in the inhibition of
DAT function, counteracting activation of the high affinity heteromeric nicotinic
receptors, which enhance DAT function.

Alternatively, nicotinic receptors may modulate DAT function through
activation of neural circuitry at the cell body level. Local administration of nicotine
into the substantia nigra and ventral tegmental area has been shown to evoke
DA release in striatum and nucleus accumbens, respectively, via stimulation of
nicotinic receptors in the cell body region (Blaha and Winn, 1993; Sziraki et al.,
2002). Additionally, the effect of peripheral administration of nicotine to increase
DA release in the nucleus accumbens determined using microdialysis was
inhibited by local administration of mecamylamine into the ventral tegmental area
(Sziraki et al., 2002). Thus, it seems plausible that in the current study,
peripherally administered nicotine may be acting at nicotinic receptors at the level
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of the cell body to modulate DAT function at the terminal. Furthermore, different
nicotinic receptor subtypes expressed at the cell body may be responsible for the
different dose-response patterns observed in MPFC and striatum with respect to
DA clearance.

Due to the lower DAT density and decreased number of DAT per terminal
in MPFC compared with striatum, metabolism and diffusion likely play a larger
role in clearing DA from the extracellular space in MPFC under physiological
conditions. However, following pharmacological treatment with nicotine,
enhanced DAT function in MPFC would be predicted to have a large impact on
dopaminergic transmission. Nicotine enhancement of DAT function would result
in more efficient DA clearance from the extracellular space.

IV. Data Analysis
Initially the voltammetry data was presented and analyzed as described in
the literature. The results of the analysis were problematic and confusing
because the clearance data were showing a decrease in clearance when actually
the results showed an increase in clearance (Figure 8). Further examination of
the data presented in the literature revealed that previous investigators were not
using a correct or most appropriate measure of clearance. Exogenous DA
clearance has been defined previously as Amax/T80, a parameter with units of
concentration/time (Zahniser et al., 1999). In more recent assessments of DAT
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function by this group of investigators (Sabeti et al., 2002), another parameter for
DA clearance has been elaborated and referred to as DA clearance efficiency.
DA clearance efficiency has been defined as a rate constant k, with units of sec−1
and is determined by fitting the DA signal to a first-order exponential decay
function (A(t)=Amax*e-k(t-t0); where A is the signal amplitude (µM) at any time t
(sec) following peak signal amplitude (Amax), and k is the first-order rate constant
of decay of the DA signal). However, exogenous DA clearance defined by either
Amax/T80 or k do not represent the classical physiological measure of clearance.
In the current studies, the classical pharmacokinetic approach has been utilized
to assess exogenous DA clearance (Ito et al., 1998; Shargel et al., 2005). Thus,
the parameter determined in the current study, CLDA, was calculated as the
amount of DA pressure ejected divided by the AUC for each DA signal, with units
of volume/time. CLDA can be directly equated to the physiological process of DA
elimination from the ejection site, and represents DA transport via DAT.
Importantly, CLDA is independent of the concentration of DA that is pressure
ejected and is independent of the volume into which DA distributes under linear
conditions. The current work used a more classical approach for the analysis of
the clearance parameter, which allowed for a more accurate measurement of DA
clearance. Thus, the current analysis directly measures the efficiency of DA
removal after its exogenous application, i.e., the transport process via DAT.

V. Tolerance Develops to the nicotine-induced increase in DAT function
following repeated nicotine administration.
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Following repeated nicotine administration tolerance develops to the
nicotine-induced increase in DAT function in MPFC and striatum. Following
repeated injection with saline, an acute challenge with nicotine resulted in an
increase in DA clearance in MPFC and striatum consistent with the findings
presented in Chapter Two (Middleton et al., 2004). Moreover, following repeated
treatment with nicotine, DA clearance after nicotine challenge was not different
from that in the control group repeatedly administered saline and challenged with
saline. However, in both MPFC and striatum, DA clearance in the group
repeatedly injected with nicotine and challenged with nicotine on the experiment
day was decreased compared to the group of rats injected repeatedly with saline
and challenged with nicotine on the experiment day. These results demonstrate
that tolerance develops to the nicotine-induced increase in DA clearance
following repeated nicotine injection. The current results extend previous
findings showing that systemically administered nicotine increases DA clearance,
via a nicotinic receptor-mediated mechanism, in several dopaminergic terminal
regions, including MPFC, striatum, and nucleus accumbens (Hart and Ksir, 1996;
Middleton et al., 2004). The current results did not support the third hypothesis
that repeated nicotine administration will further enhance the nicotine-induced
increase in DA clearance in striatum and MPFC.

Va. Acute vs. Repeated Nicotine Administration
It is possible that initially nicotinic receptor activation causes release of DA
and subsequently increases the clearance of DA from the synapse. The
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increase in DA clearance may cause a sharpening of the DA kinetics. Following
nicotine pretreatment, using in vitro superfusion and in vivo microdialysis,
nicotine-evoked DA release was higher than nicotine-evoked DA release from
rats injected with saline (Yu and Wecker, 1994; Marshall et al., 1997). A study
examining the chronic use of tobacco in humans determined that DA levels were
elevated in the striatum of smokers compared to nonsmokers (Court et al., 1998),
which would lead to an increase in DA activity. Acutely, the increase in DA
clearance coupled with the immediate increase in DA release may sharpen the
kinetics of the nicotine-mediated increase in extracellular DA concentration. By
sharpening the kinetics, the extracellular DA is removed from the synapse more
rapidly. In the current study, tolerance that occurs following repeated nicotine
administration may cause a flattening of the DA kinetics, thus increasing the
amount of DA in the extracellular space.

Tolerance to chronic nicotine administration has been shown in various
animal models, i.e., locomotor activity, striatal dopamine metabolism and of
nicotine-induced antinociception (Stolerman et al., 1973; Marks et al., 1983;
Marks et al., 1991; McCallum et al., 2000; Pietila and Ahtee, 2000). Another
potential explanation for the tolerance of DA clearance to repeated nicotine
administration may be due to nicotinic receptor desensitization. Following longterm stimulation of nicotinic receptor by agonists, nicotinic receptors are no
longer able to produce an effect, even in the presence of agonist, i.e.
desensitization. Furthermore, the EC50 for nicotine to produce desensitization
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was the same as that required for upregulation, suggesting that upregulation
occurs as a result of desensitization (Fenster et al., 1999). Using various doses
of nicotine and different dosing regimens, Rowell and Li (1997) showed that
nicotinic receptors were upregulated and that the degree of desensitization was
dependent on dose and regimen of administration. Concentrations of nicotine
that are achieved by smokers desensitize nicotinic receptors located on the
mesolimbic DA neurons (Pidoplichko et al., 1997). Tolerance following chronic
nicotine has been shown in the absence of upregulation of nicotinic receptors
(Pauly et al., 1992; McCallum et al., 2000). However, it is also possible that the
observed tolerance is due to nicotinic receptor upregulation. Mice chronically
treated with nicotine have shown and increase in nicotine binding sites in brain
(Marks et al., 1983; Schwartz and Kellar 1983; Collins et al., 1988; Kassiou et al.,
2001; Nuutinen et al., 2005). Recently, in β2 knockout mice, following chronic
nicotine treatment, upregulation of nicotine binding sites is no longer observed
(McCallum et al., 2005). Thus, while acute nicotine increases DAT function,
repeated nicotine decreases DAT function back to control levels.

Tolerance to the nicotine-induced increase in DA clearance may also be
due to desensitization of DA D2 autoreceptors. Following repeated nicotine
injection, dopamine release is enhanced compared to acute nicotine injection (Yu
and Wecker, 1994; Marshall et al., 1997). As mentioned above, D2 receptors
can modulate DAT function. Thus, it is possible that following repeated nicotine
injection the increased amount of extracellular DA results in desensitization of D2
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autoreceptors and therefore DAT function is no longer increased. This would
then result in tolerance to the nicotine-induced increase in DAT function.

Previously, it was reported that nicotine was able to enhance
amphetamine-evoked [3H]DA release from rat MPFC slices, but not from striatal
or nucleus accumbens slices via an action at nicotinic receptors (Drew et al.,
2000). More recently, the same group examined the effect of chronic nicotine on
amphetamine evoked DA release (Drew and Werling, 2003). Following chronic
nicotine treatment, nicotine was still able to enhance amphetamine-stimulated
DA release, suggesting that even after chronic nicotine; nicotinic receptors may
not be desensitized. In contrast, the current studies determined that following
repeated nicotine administration, tolerance develops to the nicotine-induced
increase in DA clearance. It is possible that the nicotinic receptors modulating
DA release and DA transport are different. Thus, one subtype may desensitize
(nicotine can still release DA) and one may not (nicotine can no longer modulate
DAT function).

Tolerance to the nicotine-induced increase in DA clearance may be due to
an increase in nornicotine production. Nornicotine decreases DAT function
(Chapter Three). Following systemic nicotine injection, nicotine reaches maximal
brain concentration within 5 min and has a brain t1/2 of 52 min. However, nicotine
metabolism results in production of nornicotine (Ghosheh et al., 1999). Following
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nicotine injection nornicotine reaches maximal brain concentrations 60 min
following nicotine injection and has a brain t1/2 of 166 min (Ghosheh et al., 1999).
Furthermore, following repeated nicotine treatment, nornicotine accumulates in
brain (Ghosheh et al., 2001). Therefore, it is possible the nicotine is no longer
able to increase DAT function following repeated nicotine treatment because
nornicotine is inhibiting DAT function. Following repeated nicotine administration
it is possible that changes in nicotine metabolism also may occur. Cytochrome
P450 (CYP) 2B1 is a nicotine metabolizing enzyme found in the brain. Following
7 days of nicotine treatment, CYP 2B1 protein was increased in brain, specifically
in the brain stem, frontal cortex, striatum and olfactory tubercle (Miksys et al.,
2000). Increases in the CYP 2B1 protein could lead to an increase in nicotine
metabolism. Thus, the difference observed between acute and repeated nicotine
in striatum and MPFC may be due to differences in nicotine metabolism.

VI. Nornicotine inhibits DA clearance.
Attention has focused on the N-demethylated nicotine metabolite and
minor tobacco alkaloid, nornicotine, as contributing to the neuropharmacological
effects of nicotine exposure and tobacco use (Crooks and Dwoskin, 1997).
Nornicotine inhibits [3H]nicotine binding to rat brain membranes with a 50-fold
lower affinity compared with nicotine (Reavill et al., 1988; Copeland et al., 1991;
Zhang and Nordberg, 1993; Xu et al., 2001). In contrast, nicotine and nornicotine
exhibit similar affinities for the [3H]methyllycaconitine binding site in brain. These
results indicate interaction of these alkaloids with both α4β2* and α7* nicotinic
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receptors. Similar to nicotine, nornicotine evokes a concentration-dependent,
Ca2+-dependent and mecamylamine-sensitive increase in DA release from rat
striatal and nucleus accumbens slices (Dwoskin et al., 1993; Teng et al., 1997;
Green et al., 2001), indicating that nornicotine acts as an agonist at nicotinic
receptor subtypes modulating DA release. In the latter studies, whereas nicotine
and nornicotine were equipotent in releasing DA from striatal slices, nicotine was
more potent than nornicotine in releasing DA from nucleus accumbens slices.
Furthermore, nornicotine is a partial agonist whereas nicotine is a full agonist
(Green et al., 2001). It is interesting to note that nornicotine has a longer half-life
than nicotine in plasma and brain (Kyerematen et al., 1990; Crooks et al., 1995,
1997; Ghosheh et al., 2001); and following chronic treatment with nicotine,
nornicotine accumulates in brain reaching pharmacologically relevant
concentrations (Ghosheh et al., 2001). The current experiments examined the
ability of nornicotine to modulate striatal DAT function. Using in vivo
voltammetry, systemic administration of nornicotine decreased DA clearance in
striatum in a dose-related manner, demonstrating that nornicotine inhibits striatal
DAT function. The nornicotine-induced decrease in DA clearance was inhibited
completely by mecamylamine, a noncompetitive and nonselective nicotinic
receptor antagonist, indicating that this effect of nornicotine on DAT function is
mediated by nicotinic receptors. In contrast, nornicotine did not inhibit [3H]DA
uptake into striatal synaptosomes when nornicotine was incubated with
synaptosomes obtained from drug-naïve rats. Similar to nornicotine, incubation
of synaptosomes from drug-naïve rats with nicotine did not inhibit [3H]DA uptake.
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Taken together, these results suggest that nornicotine and nicotine activate
nicotinic receptors which are located at sites other than on DA nerve terminals in
striatum to inhibit DAT function in vivo. The current results did not support the
hypothesis that nornicotine would increase DAT function in striatum, however,
the effect of nornicotine was mediated by nicotinic receptors.

VII. Potential Mechanism for the Differences Observed between Nicotine
and Nornicotine.
VIIa. Nicotinic receptor subtypes.
More than one nicotinic receptor subtype has been suggested to mediate
nicotine-evoked DA release in striatum (Kaiser et al., 1998; Dwoskin et al., 2004).
α-Conotoxin MII as well as other small molecules is a nicotinic receptor
antagonist that partially inhibits DA release, i.e., only inhibits DA release by 50%
(Wilkins et al., 2002; Grinevich et al., 2003; Wei et al., 2005). This has led to the
idea that there are more that one nicotinic receptor subtype that modulate DA
release, α-conotoxin MII sensitive and α-conotoxin MII resistant subtypes
(Luetje, 2004). A recent study examined the subunit composition of nicotinic
receptors modulating α-conotoxin MII sensitive and resistant DA release in
striatal synaptosomes and slices using knockout mice for various nicotinic
receptor subunits (Salminen et al., 2004). Both the α-conotoxin MII sensitive and
resistant subtypes required the β2 subunit, however only the α-conotoxin MII
sensitive subtype required the β3; whereas the α-conotoxin MII resistant
subtypes required α4. These data suggest that the primary subtypes involved in
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DA release are the α6β3β2* and α4β2* subtypes (Salminen et al., 2004). High
concentrations of nicotine have been shown to activate α7* nicotinic receptors,
which results in glutamate release in the frontal cortex (Schilstrom et al., 2000;
Marchi et al., 2002). Stimulation of metabotropic glutamate receptors has been
reported to decrease DAT function (Page et al., 2001). Thus, multiple nicotinic
receptor subtypes could be involved in modulation of DAT function. The current
evidence provides the first report that more than one nicotinic receptor subtype
may mediate DAT function, since nicotine and nornicotine both mediate DAT
function but in a different manner.

VIIb. Neuronal Circuitry
The current study also shows that incubation of synaptosomes from drugnaïve rats with both nornicotine and nicotine does not alter [3H]DA uptake into
striatal synaptosomes, which is consistent with previous reports determining the
effect of nicotine in vitro (Carr et al., 1989; Zhu et al., 2003). Taken together with
the results from the in vivo voltammetry studies, these findings suggest that the
nicotinic receptors mediating DAT function in vivo are located on dopaminergic
cell bodies in the substantia nigra or in brain regions other than striatum.
However, procedural differences between the in vivo and in vitro preparations,
such as the use of the urethane anesthetic in vivo, may also contribute to the
differential results obtained. The anesthetic used in the current in vivo
voltammetry experiments, urethane, has been shown to not alter striatal DAT
function (Sabeti et al., 2003).
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Evidence supporting a critical role for nicotinic receptors at the level of the
dopaminergic cell body is provided from studies in which local administration of
nicotine into the substantia nigra or ventral tegmental area evokes DA release in
striatum and nucleus accumbens, respectively (Blaha and Winn, 1993; Nisell et
al., 1994; Sziraki et al., 2002). Additionally, local administration of
mecamylamine into the ventral tegmental area was shown to inhibit DA release
in the nucleus accumbens following peripheral administration of nicotine (Sziraki
et al., 2002). Thus, as has been suggested for nicotine, nicotinic receptors at the
level of the substantia nigra may be involved in modulating DAT function in
striatum following peripheral nornicotine administration.

VIII. Trafficking Independent modulation of DAT function.
The current project as well as others have examined the effect of nicotine
on DA uptake/transport by exposing synaptosomes to nicotine in vitro (Carr et al.,
1989; Zhu et al., 2003). The results of those studies showed that nicotine did not
alter DA transport. In the current studies the effect of nicotine administered in
vivo on DAT function in vitro were examined. Furthermore, previous studies
examined the ability to inhibit DAT function. In the current study, a saturation
analysis was performed to determine the kinetic parameters of in vivo nicotine
administration on DAT function measured in vitro. In rats pretreated with nicotine
(0.8 mg/kg, s.c.) and killed 10 and 40 min later, a significant 20-25% increase in
the Vmax for [3H]DA uptake was observed in striatal synaptosomes. The dose of
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nicotine was chosen based on previous results showing that nicotine (0.8 mg/kg)
increased DA clearance in vivo in rats striatum. Rats killed at 5 min following
nicotine injection showed a slight but nonsignificant increase in [3H]DA uptake.
This effect was diminished to control levels by 60 min following nicotine injection.
This increase in DA uptake was not accompanied by an increase in the total
amount of DAT protein as measured by [3H]GBR 12935 binding. Furthermore,
nicotine pretreatment did not increase the density of DAT on the cell surface
membrane as measured using biotinylation and subcellular fractionation
experiments. These data support and extend previous findings showing that
systemic nicotine increases DA clearance in vivo in rat striatum (Middleton et al.,
2004). The increase in DA clearance in striatum observed in vivo is likely due to
an increase in the Vmax of DAT. Taken together, these data suggest that nicotine
increases DA uptake in striatum in vitro through a trafficking-independent
mechanism. These data support the hypothesis that nicotine increases DAT
function by increasing the Vmax for DA uptake, however, the results did not
validate the hypothesis that the nicotine-induced increase in DAT function was
due to an increase in the number of transporters on the cell surface.

VIIIa. DAT Modulation by different proteins/phosphorylation
DAT localized at the presynaptic membrane reflects functional DAT that is
involved in the clearance of extracellular DA. The mechanism by which nicotine
modulates DAT function may involve regulation of intracellular signaling
cascades. Changes in DAT surface expression have been shown to be induced
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by activation of protein kinase C or exposure to psychostimulants, and such
changes correlate with alterations in DA uptake in striatum (Copeland et al. 1996;
Chi and Reith, 2003; Vaughan et al., 1997) and in cell systems expressing DAT
(Pristupa et al. 1998). In cells expressing hDAT, application of amphetamine
results in a decrease in the cell surface expression of DAT (Kahlig et al., 2004).
Whereas amphetamine decreases cell surface DAT, cocaine has been shown to
increase trafficking of DAT to the cell surface (Little et al., 2002).

In the current study, nicotine increases DAT function without a change in
the cell surface localization of DAT, thus acting differently than other
psychostimulants. Nitric oxide may play a role in the nicotine-induced increase in
DAT function. Nicotine releases nitric oxide from rat hippocampal slices (Smith
et al., 1998). Nicotine also activates voltage gated Ca++ channels which increase
intracellular Ca++ levels and can lead to an increase in the production of reactive
oxygen species. Recently, L-arginine has been shown to increase DAT activity
using rotating disk electrode voltammetry in striatum by a nitric oxide synthase
pathway (Volz and Schenk, 2004). Nicotine activates many different second
messenger pathways that may be involved in modulating DAT. For example,
nicotinic receptor activation induces ERK phosphorylation mediated by CaM
kinase and MAP kinase in PC12 cells (Nakayama et al., 2001). ERK
phophorylation then induces CREB phsophorylation. In hippocampal neurons,
nicotine has been shown to activate the transcription factor CREB which is
dependent on calmodulin and MAP kinase (Zhang et al., 2001; Hu et al., 2002).
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PI-3 kinase and p38 MAP kinase activate a trafficking-independent pathway for
NET regulation (Apparsundaram et al., 2001), suggesting that neurons likely
have multiple pathways to modulate NE clearance capacity intrinsically. Similar
to insulin regulation of NET, p38 MAP kinase has been shown to have similar
effects on the serotonin transporter, i.e., an increase in serotonin uptake without
a change in trafficking of the serotonin transporter (Zhu et al., 2005). A
schematic representation of the multiple pathways that may be involved in
nicotinic receptor modulation of DAT function is shown in Figure 24. Taken
together, these results suggest the possibility that nicotine activates neural
systems in the striatum that subsequently augment the activity of signaling
cascades leading to an increase in DAT function without altering cell surface
localization.

One potential explanation could involve the activation of second
messenger signaling cascades. A study in hippocampal neurons revealed that
nicotinic receptor activation resulted in an increase in intracellular calcium (Hu et
al., 2002). The calcium then activated MAP kinase and calcium/calmodulindependent protein kinase pathways to activate the cyclic AMP response element
binding protein producing transcriptional effects (Hu et al., 2002). Furthermore,
inhibition of the MAP kinase pathway results in downregulation of DAT from the
plasma membrane to intracellular pools as measured by biotinylation in human
embryonic kidney 293 cells (Morón et al., 2003). Taken together, these data
suggest a potential role of the MAP kinase pathway to increase DAT levels on
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the plasma membrane, and thus, increasing DA clearance following acute
administration of nicotine. Repeated nicotine may result in an inhibition of the
MAP kinase pathway resulting in down regulation of DAT, and therefore, a loss in
the nicotine-induced increase in DA clearance. Furthermore, it is possible that
nicotinic receptor activation could lead to phosphorylation of DAT, which would
decrease DAT function (Copeland et al., 1996; Vrindavanam et al., 1996; Huff et
al., 1997; Vaughan et al., 1997; Melikian and Buckley, 1999; Chang et al., 2001).
Therefore, changes in DAT function can be regulated not only by trafficking but
by modulating the phosphorylation status of DAT.

IX. Implications:
Nicotinic receptor agonists have been shown to increase learning and
memory in both rats and humans (Levin, 1992; Warburton, 1992; Levin and
Simon, 1998; Levin et al., 1999; Ernst et al., 2001; Houlihan et al., 2001; Uzum et
al., 2004). Due to the lower DAT density and decreased number of DAT per
terminal in MPFC compared with striatum, metabolism and diffusion likely play a
larger role in clearing DA from the extracellular space in MPFC under
physiological conditions. However, following pharmacological treatment with
nicotine, enhanced DAT function in MPFC would be predicted to have a large
impact on dopaminergic transmission. Nicotine enhancement of DAT function
would result in more efficient DA clearance from the extracellular space, and
cortical function would be disinhibited. Thus, the ability of nicotinic receptors to
modulate DAT function, and thereby extracellular DA concentration, may have
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physiological importance with respect to nicotine enhancement of cognitive
processes such as attention, learning, and memory, as well as important clinical
relevance with respect to schizophrenia and drug abuse.

Nicotine is an effective pharmacotherapy for the cessation of tobacco
smoking when used alone or in combination with other drugs or clinical programs
(Po, 1993; Rose et al., 1994; Balfour and Fagerstrom, 1996; Glover and Glover,
2001; Karnath, 2002). However, despite efficacy with nicotine replacement, the
majority of smokers continue to relapse, suggesting that more efficacious
therapeutic agents are needed. Nornicotine may offer a beneficial alternative to
nicotine as a tobacco use cessation agent. The pharmacokinetic profile of
nornicotine, with its longer half-life and slower clearance compared to nicotine
(Kyerematen et al., 1990; Crooks and Dwoskin, 1997; Ghosheh et al., 1999),
may afford additional advantages over nicotine. Furthermore, since nornicotine
is significantly less potent than nicotine in increasing blood pressure and heart
rate (Mattila, 1963; Risner et al., 1988; Stairs et al., submitted 2005), the safety
index for nornicotine may be greater than that for nicotine, especially among
smokers with advanced cardiovascular disease.

The ability of nornicotine to decrease DAT function in vivo, as shown in
the present study, may afford another advantage over nicotine as a tobacco use
cessation agent. In this respect, the antidepressant agent, bupropion, which
inhibits both DAT and norepinephrine transporter function (Ascher et al., 1995),
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has been shown to be efficacious as a tobacco smoking cessation agent (Hurt et
al., 1997; Jorenby et al., 1999; Shiffman et al., 2000). Thus, nornicotine
incorporates both inhibition of DAT function and promotion of DA release
properties into one molecule, and these pharmacological effects have been
associated with the clinical efficacy of the currently available tobacco cessation
products, nicotine and bupropion.

Behavioral studies using animal models also provide support for the use of
nornicotine as a tobacco use cessation agent. Nornicotine produces nicotine-like
discriminative stimulus effects (Rosecrans and Meltzer, 1981; Goldberg, et al.,
1989; Bardo et al., 1997; Desai et al., 1999), as well as nicotine-like effects on
schedule-controlled operant responding (Risner et al., 1985; 1988). Recent
results indicate that nornicotine functions as a positive reinforcer (Bardo et al.,
1999); however, under similar experimental conditions, nornicotine is associated
with a lower rate of responding in comparison with nicotine (Corrigall and Coen,
1989; Donny et al., 1995; Bardo et al., 1999), suggesting that nornicotine has a
lower reinforcing efficacy. Moreover, nornicotine has been shown to decrease
self-administration of nicotine in rats (Green et al., 2000). Furthermore, across
repeated nornicotine pretreatments, tolerance did not develop to nornicotineinduced decrease in nicotine self-administration. Thus, a simple structural
change, i.e., removal of the N-methyl group from the pyrrolidine ring nitrogen of
nicotine which affords nornicotine, causes a profound change in its effect on DAT
function, which may be beneficial with respect to its pharmacological profile. In
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summary, the current preclinical results suggest that nornicotine could be a
promising candidate for development as a smoking cessation agent.

X. Future Directions
The current series of experiments demonstrate that nicotine, via a nicotinic
receptor-mediated mechanism, increased DA clearance in striatum and MPFC.
It is possible that the difference in the response to nicotine between these brain
regions is due to the involvement of different nicotinic receptor subtypes. Thus,
future studies using various subtype selective antagonists to inhibit the effect of
nicotine on DAT function would help determine which subtypes are involved in
modulating DAT.

In the current experiments, nicotine was administered systemically.
Incubation of synaptosomes from drug naïve animals in vitro with nicotine did not
result in an increase in the Vmax for [3H]DA uptake. Because systemic
administration of nicotine increased both the Vmax for DA uptake in vitro and
increased DA clearance in vivo, to determine if the effect of nicotine is occurring
in the striatum, nicotine could be locally applied into the striatum and DA
clearance determined. Therefore, the effect of nicotine could be localized to the
striatum. Conversely, if local application of nicotine did not increase DA
clearance, it would suggest the role of circuitry in the effect of nicotine. Another
potential way to determine if the effect of nicotine is occurring locally, slices from
the brain region could be removed and voltammetry performed in the slices. Use
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of slices would allow determination of the localization of nicotinic receptors either
on the DA nerve terminals or if other neurotransmitter systems that may alter
DAT function.

The increase in the Vmax for [3H]DA uptake was observed in the absence
of an increase in trafficking of DAT to the cell surface membrane. The increase
in Vmax was approximately 25%, which is at the limit of detection for biotinylation
experiments. It is possible that increasing the dose of nicotine would lead to a
further increase in the Vmax. If the Vmax further increases, it is possible that there
will be a change in DAT trafficking. If no change in DAT trafficking persists, it is
likely that the increase in DAT function is due to the involvement of another
neurotransmitter system or specific second messenger systems. Use of slices in
voltammetric experiments would allow determination of the different mechanisms
involved in nicotine modulation of DAT function.

One major difference between the in vivo and in vitro experiments is the
use of anesthetic. While the anesthetic used in the current experiments,
urethane, does not appear to affect DAT function (Sabeti et al., 2003), it is
possible that it is altering other systems that could impact the effect of nicotine or
the DA system. To rule out the caveat of using an anesthetic, the effect of
nicotine on DAT function could be measured using voltammetry in awake
animals.
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Finally, the effect of nicotine to increase DAT function by increasing the
Vmax for DA uptake is important to determine in MPFC. If there is an increase in
Vmax, then the ability of nicotine to modulate trafficking of DAT would be important
to determine. The limiting factor for using MPFC for the in vitro and trafficking
experiments is that it requires the use of a large number of animals to obtain
enough protein to see any effects.

XI. Final Comments
The results of the current experiments in this dissertation project are the
first to examine the effects of nicotine alone on DAT function in striatum and
MPFC. Furthermore, this is the first report examining the mechanism by which
nicotine does modulate DAT. Nicotine action on the DA system has been well
studied with regards to DA release. However the impact of nicotine action on
DAT will be an important mechanism that has to be considered not only in how
nicotine acts but in the treatment of nicotine addiction.
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Figure 24. Schematic representation of second messenger pathways
involved in nicotinic receptor modulation of DAT function.
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